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ABSTRACT 
 
Heart failure (HF) causes high mortality and morbidity of whom at least 50% die 
suddenly, termed sudden cardiac death (SCD). HF is an independent risk factor of 
SCD and its incidence are comparable to the total incidence of common cancers (i.e., 
lung, prostate, breast, colon). Current preventive strategies are suboptimal and there 
is a growing need to optimize treatment to further improve the actual poor survival. In 
fact, HF patients are usually put under a polydrug regimen (e.g., beta-blockers (BB), 
angiotensin-converting enzyme inhibitors (ACE-i), angiotensin receptor blockers 
(ARBs), aldosterone antagonists, diuretics, hydralazine/isorbide di-nitrate, ivabradine, 
digoxin, amiodarone and anti-arrhythmic agents (AADs), omega-3 polyunsaturated 
fatty acids (PUFA)…etc.) in addition to non-drug devices (e.g., cardiac 
resynchronization therapy (CRT) and implantable cardioverter defibrillators (ICD)). 
Importantly, it is known that not all HF evidence-based drugs reduce SCDs or all-cause 
mortality. Therefore, we reviewed the current evidence on SCD prevention for 
commonly prescribed drug interventions; and our findings showed three evidence 
categories: 
 
- effective interventions as BB, anti-aldosterone agents or mineralocorticoid-receptor 
antagonists, and combined ARB/neprilysin inhibitors.  
- ineffective interventions as ACE-i, ARBs, and statins. 
- uncertain evidence (conflicting or inconclusive evidence) as amiodarone & AADs, 
PUFA or fish oil supplementation.   
We used a variety of evidence-based medicine methodology: systematic reviews and 
meta-analysis, overviews, survival analysis, statistical models such as Cox 
proportional hazards model, Kaplan-Meier survival curves, propensity score analysis 
and instrumental variables approaches. Through adopting effective drugs, our work 
allowed paving the way toward an optimization of SCD prevention strategies in HF 
that would finally lead to a better survival and quality of life and a potential reduction 
of public health expenditure.  
 
Keywords: sudden cardiac death, heart failure, evidence-based medicine, drugs, 
prevention 
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RÉSUMÉ  
L'insuffisance cardiaque (IC) entraîne une morbidité et une mortalité élevées dont au 
moins 50% de décès surviennent subitement, appelée mort subite cardiaque (MSC). 
L’IC est un facteur de risque indépendant de MSC ; son incidence est comparable à 
l'incidence totale de cancers courants (c'est-à-dire poumon, prostate, sein, côlon). Les 
stratégies préventives actuelles sont sous optimales ; il est ainsi de plus en plus 
nécessaire d'optimiser le traitement pour améliorer la mauvaise survie actuelle. En 
effet, les patients souffrants d’IC sont généralement soumis à un traitement 
polyconsommateur (par exemple, bêtabloquants (BB), inhibiteurs de l'enzyme de 
conversion de l'angiotensine (IEC), antagonistes des récepteurs de l'angiotensine 
(ARA), antialdostérone (AA), diurétiques, hydralazine/ dinitrate d’isorbide, ivabradine, 
digoxine, amiodarone et autres antiarythmique, acides gras poly-insaturés oméga-3 
(AGPI), etc.) en plus des dispositifs non médicamenteux (par exemple la thérapie de 
resynchronisation cardiaque et les défibrillateurs implantables). Il est important de 
savoir que les médicaments prescrits chez l’IC ne sont pas tous efficaces contre la 
mort subite ou la mortalité totale. Par conséquent, nous avons examiné les preuves 
actuelles sur la prévention de MSC par les interventions médicamenteuses 
couramment prescrites; nos résultats ont montré trois catégories de preuves : 
- interventions efficaces comme BB, AA, et inhibiteurs combinés ARB/ néprilysine. 
- interventions inefficaces comme l’IEC, les ARA et les statines. 
- preuves incertaines (preuves contradictoires ou non concluantes) comme 
l'amiodarone et autres antiarythmique, les AGPI ou les suppléments en huile de 
poisson. 
 
Nous avons utilisé diverses méthodologies de médecine factuelle : revues 
systématiques et méta-analyses, analyse de survie, modèles statistiques tels que le 
modèle de Cox, les courbes de survie de Kaplan-Meier, l'analyse par score de 
propension et la méthode de variables instrumentales. Grâce à l'adoption de 
médicaments efficaces, nos travaux pourraient permettre d'optimiser les stratégies de 
prévention des MSC chez les patients atteints d’IC, ce qui mènerait finalement à une 
meilleure survie et qualité de vie, et à une réduction potentielle des dépenses de santé.  
Mots-clés: mort subite cardiaque, insuffisance cardiaque, médecine factuelle, 
médicaments, prévention  
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1. GENERAL INTRODUCTION 
Heart failure (HF) contributes to a high a public health burden [1]. HF causes a high 
morbidity and substantial mortality [2].  In addition, HF is a very costly disease [3]. The 
incidence of HF is reported to be as high as the incidence of the four common cancers 
combined (i.e., lung, prostate, breast and colon) [4]. HF patients are frequently 
hospitalized, have reduced quality of life and highly prevalent pain, have often 
comorbidities, and consume healthcare constantly [5-7]. Consequently, the prognosis 
of HF is extremely bad and reported to be comparable to cancer with a 5-year survival 
rate of about 60% [8]. Moreover, it has been extensively reported that at least 50% of 
HF mortality is attributed to sudden cardiac death (SCD). SCD is defined as a death 
that occurs within 1 or 2 hours from the onset of symptoms [9] not associated with the 
severity of HF prognosis; indeed SCD may occur in HF patients who are clinically 
stable. Despite advances in therapy and management, there is still an unfilled gap and 
unmet needs in HF related to SCD prevention or all-cause mortality in general. A 
justified thought - that comes to mind - focuses on evidence-based HF therapies. In 
practice, the so-called evidence-based drugs and non-drug interventions are 
underused as observed in the Euro Heart Survey [10] (e.g., beta-blockers were 
prescribed only 37% and 49% for HF population and HFrEF, respectively) and - in 
some cases- wrongly indicated in HF patients in contrary to current guidelines [11]. In 
fact, clinical decisions and current practice should be based on the best available 
evidence and guided by the most updated guidelines. That is why it is important to 
distinguish effective interventions from ineffective ones. Therefore, an evaluation of 
the effectiveness of drug and non-drug interventions on SCD prevention is warranted 
(Figure 1), which would play a key role on the final target to optimize HF therapy to 
further improve the quality of life of patients and their survival.  
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Figure 1: Effectiveness of drug interventions in heart failure with reduced ejection 
fraction (HFrEF).   
SCD: sudden cardiac death.  ?: uncertain effectiveness. : reduce or decrease  
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1.1.1. Definitions of heart failure and sudden cardiac death 
The definition of heart failure (HF) in the current European Society of Cardiology (ESC) 
guideline [11] is that:  
 
 
 
 
The American College of Cardiology and American Heart Association HF have 
introduced a staging system.  (Stage A) and (Stage B) are asymptomatic patients with 
clinical risk factors for HF without or with an evidence of cardiac structural and 
functional abnormalities, respectively. Patients with current or previous symptoms of 
HF are defined as (Stage C) while (Stage D) patients are those with refractory 
symptoms despite optimal medical therapy or specialized cardiac support [12]. 
Moreover, the patient’s true functional capacity is estimated by the New York Heart 
Association (NYHA) functional class (see Table 1) [13] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HF is a clinical syndrome characterized by typical symptoms (e.g. 
breathlessness, ankle swelling and fatigue) that may be accompanied 
by signs (e.g. elevated jugular venous pressure, pulmonary crackles 
and peripheral oedema) caused by a structural and/or functional 
cardiac abnormality, resulting in a reduced cardiac output and/or 
elevated intracardiac pressures at rest or during stress. 
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 Mortality in HF are mainly due to two types of causes:  
1. progressive HF (pump failure) 
2. unexpected death termed sudden cardiac death (SCD).  
The former occurs more likely in IV-stage HF while the latter occurs in II-III stage HF 
whose life expectancy is relatively longer. 
The definition of SCD varies from one source to another. SCD has been defined as 
“natural death due to cardiac causes, heralded by abrupt loss of consciousness within 
one hour of the onset of acute symptoms; pre-existing heart disease may have been 
known to be present, but the time and mode of death are unexpected” [14]. The time 
interval between sudden death occurrence and the onset of symptoms lies preferably 
within 1 hour instead of “6 or 24 hours” period [15]. This definition variation has an 
impact not only on the prevalence and incidence of SCD but also on the evaluation of 
medical interventions that estimate survival. Of note, sudden death occurring in 
infancy is a different issue and is neither presented, nor studied here.  
1.1.2. Epidemiology and risk factors 
The prevalence of heart or circulation problems in fourteen European countries is 
reported around 9.2% overall [16]. For instance, 7.6 % in France, 7.0 % in Switzerland, 
12.8% in Germany, 10% in Austria. However, heart failure (HF) prevalence varies 
Class New York Heart Association functional classification 
I Patients have no limitations of physical activity. Ordinary physical activity does 
not cause undue fatigue, palpitation, dyspnea (shortnesss of breath) or anginal 
pain. 
II Patients have slight limitation of physical activity. They are comfortable at rest. 
Ordinary physical activity results in fatigue, palpitation, dyspnea or anginal pain. 
III Patients have a marked limitation of physical activity. They are comfortable at 
rest. Less than ordinary physical activity causes fatigue, palpitation, dyspnea or 
anginal pain. 
IV Patients are unable to carry on any physical activity without discomfort. 
Symptoms of HF may be present even at rest. If any physical activity is 
undertaken, discomfort increases. 
Table 1: The New York Heart Association functional classification (NYHA) 
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depending on the definition of the denominator, whether it is a certain population, 
region or community [17, 18]. Meanwhile, the prevalence of HF in the US is estimated 
as 1.9% [19] and an estimated annual incidence of SCD in the US (total population 
approx. 300,000,000), would range between 180,000 – 250,000 cases per year [20].  
Risk factors of SCD were reported to be similar to cardiovascular diseases. However, 
the most studied and proven predictor of SCD in HF patients is left ventricular ejection 
fraction (LVEF) [21]. Indeed, individuals with depressed ejection fraction and better 
functional class have the highest SCD risk [21, 22]. Nevertheless, SCD accounted for 
up to 40% of cardiovascular-related deaths in HF patients with preserved ejection 
fraction (HFpEF) [23]. HF is, therefore, a risk factor of SCD and of out-of-hospital 
cardiac arrest [24]. 
1.1.3. Treatment of heart failure & current strategies 
Heart failure (HF) patients are currently managed and treated regardless of their risk 
to present an SCD outcome. This is true because SCD is a mode of death that is 
difficult to identify and so challenging. On the contrary, if we hypothesize that risk score 
models to predict SCD have been externally validated with good discriminatory power, 
we would need an optimal preventive strategy. The evaluation of drug effectiveness 
of clinical outcomes - such as SCD or total mortality – would eventually contribute to 
optimize treatment for HF patients with reduced ejection fraction (HFrEF). The 
European Society of Cardiology (ESC) guideline [11] categorizes pharmacological 
treatment of HFrEF according the level of recommendation and stages of HF (table 
2). 
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Recommendation for HFrEF Drug/non-drug Intervention 
All symptomatic patients Beta-blockers 
Angiotensin-converting enzyme inhibitors 
Mineralocorticoid/aldosterone receptor antagonists  
Selected symptomatic patients Diuretics 
Angiotensin receptor neprilysin inhibitors 
If –channel inhibitor (e.g., ivabradine) 
Angiotensin receptor blockers 
Hydralazine/isosorbide dinitrate 
Less certain benefits in 
symptomatic patients   
Digoxin and other digitalis glycosides 
n-3 polyunsaturated fatty acids 
Not recommended (Unproven 
benefit) in symptomatic 
patients 
Statins (3-Hydroxy-3-methylglutaryl-coenzyme A 
reductase inhibitors) 
Oral anticoagulants and anti-platelet therapy   
Renin inhibitors   
Not recommended (believed to 
cause harm) in symptomatic 
patients 
 
Calcium-channel blockers   
Non-surgical device treatment 
 
Implantable cardioverter defibrillators 
Cardiac resynchronization therapy 
Other implantable electrical devices 
      Adapted from ref. [11].  
 
Table 2: Therapeutic strategies in heart failure patients  
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We hypothesize that a good preventative strategy of SCD involves identifying and 
predicting high-risk patients and the availability of effective interventions. 
It is noteworthy that HF patients are currently categorized according to left ventricular 
ejection fraction (LVEF) into: HF with reduced ejection fraction (HFrEF, <40%), HF 
with mid-range ejection fraction (HFmrEF, 40–50%) and HF with preserved ejection 
fraction (HFpEF, >50%) [11]. Of note, our work evaluated drug interventions on HFrEF 
as most randomized clinical trials (RCTs) excluded the other two types of HF. It is also 
important to mention that we did not evaluate non-drug devices in HF, which we 
acknowledge later as a limitation.     
2. OUTLINE OF THE THESIS 
In this work, we reviewed and updated the evidence for beta-blockers (BBs), 
angiotensin-converting enzyme inhibitors (ACE-i), angiontensin receptor blockers 
(ARBs), combined angiotensin receptor blockers (ARB)/neprilysin inhibitors, 
aldosterone antagonists, omega-3 fatty acids, statins, amiodarone and anti-arrhythmic 
drugs. We used standard reporting methods and a variety of evidence-based medicine 
methodology: systematic reviews and meta-analysis (cf. chapter 1&4 and appendix 
I&V), overviews (cf. chapter 2 and appendix III), survival analysis, statistical models 
such Cox proportional hazards model, Kaplan-Meier survival curves, propensity score 
analysis and instrumental variables approaches (cf. chapter 3 and appendix IV). 
Separating this work into four chapters, we provided a summary of findings for each 
chapter. Thereafter, we wrote an overall discussion and highlighted the limitations, 
clinical implications and perspectives for future work.  
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Statins in Heart Failure with Reduced Ejection Fraction 
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1.1. Article title and statement of permission 
“No benefits of statins for sudden cardiac death prevention in patients with heart failure 
and reduced ejection fraction: A meta-analysis of randomized controlled trials” 
Al-Gobari M, Le HH, Fall M, Gueyffier F, Burnand B. PLoS One. 2017 Feb 6;12(2):e0171168. doi: 
10.1371/journal.pone.0171168. eCollection 2017. 
 
Enclosed in appendix I, the above-cited manuscript has been published as an open 
access article in a peer-reviewed journal. Use of this manuscript is distributed under 
the terms of the Creative Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, provided the original author and 
source are credited (Copyright: © 2017 Al-Gobari et al.).  
 
1.2. Contribution of authors and co-authors  
As stated in the original work [25], conceptualization: MA. Data curation: MA HHL MF. 
Formal analysis: MA BB FG. Investigation: MA HHL MF. Methodology: MA BB FG. 
Project administration: BB. Software: MA. Supervision: MA BB FG. Writing – original 
draft: MA. Writing – review & editing: MA BB FG HHL MF. 
 
1.3. Introduction and objectives 
Patients with heart failure (HF) often take multi-drug therapy, including 3-
methylglutaryl coenzyme A (HMG-Co A) reductase inhibitor or simply statins, over 
which efficacy is debated in the literature [26-28]. In fact, randomized clinical trials and 
observational studies showed mixed results related to clinical outcomes such as all-
cause mortality, sudden cardiac death (SCD), and hospitalization for worsening HF 
[26-30]. The European society of cardiology (ESC) guidelines do not recommend 
statins use in patients with merely a diagnosis of HF [11], but the current practice is 
often not in line with such recommendations [31]. This might be related to discordant 
and multiple available evidence or simply due to the complexity of clinical benefits in 
primary prevention, as often coronary artery syndrome and myocardial infarction or 
other comorbidities are coexisting with HF. Such situation generated biases, serious 
limitations and/or indirectness of evidence. Therefore, it is noteworthy that such 
potential biases in the current literature related to statin benefits in HF merit to be 
16 
 
explored and explained in detail. Hence, our objective was to systematically evaluate 
and update the current evidence. 
2.1. Methods of chapter 1 
Apart from refining the research question, we started to design a search strategy to 
retrieve related evidence published in the literature. Searched databases were 
Medline, Embase, Cochrane central library and www.clinicaltrials.gov and hand 
searched references of included studies. After that, we abstracted data in pre-defined 
forms after selection of relevant studies. Then, we analyzed the data according to the 
following steps: 
- build statistical models (fixed-effects and random-effects models) according to 
Mantel-Haenzel methods 
- determine the effect size for the pooled data: risk ratio (RR) and used odds 
ratios (OR) in sensitivity analyses.   
- calculate the absolute effect or the absolute risk reduction (ARR) for measured 
outcomes (all-cause mortality, SCD, and hospitalization for worsening HF). 
- create a prediction interval whenever a random-effects model is used; a 
prediction interval is an interval that estimate a treatment effect of a new or 
future trial within which we are confident it lies. By definition, it helps to predict 
the effects - of adding new data from a future trial- upon our current effect size 
estimation. 
- sample size computation  
- meta-regression and heterogeneity measurement as well as subgroup and 
sensitivity analysis 
- risk of bias assessment and quality of studies  
- GRADE assessment of the quality of the evidence per outcome. Five key 
elements: risk of any bias, inconsistency, indirectness, imprecision or 
publication bias.  
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3.1. Main findings of chapter 1 (cf. Appendix I) 
Summary 
The pooled studies resulted into no added benefits for HF patients with reduced 
ejection fraction concerning SCD prevention or all-cause mortality. A slight significant 
decrease in the occurrence of hospitalizations due to HF was, however, observed. A 
further investigation to the trend the lower lipoprotein cholesterol (LDL-c), the lower 
mortality showed insignificant output (figure 1.1).   
 
  
 
 
 
 
 
Conclusion  
This article provides a clear message to the existed debate and to the discordant or 
inconsistent results and multiple systematic reviews. Statins do not show significant 
benefits on SCD or all-cause mortality prevention. The study offered a plausible 
explanation by observed publication bias and small-study effects in the current 
literature.  
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Figure 1.1: LDL-c: low-density lipoprotein cholesterol; RRR: relative risk reduction. (cf. table 1 in Appendix I). 
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CHAPTER 2 
Overview of Effectiveness of Drug Interventions 
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2.1. Article title and statement of permission 
“Effectiveness of drug interventions to prevent sudden cardiac death in patients with 
heart failure and reduced ejection fraction: an overview of systematic reviews” 
Al-Gobari M, Alaqeel S, Gueyffier F, Burnand B. http://dx.doi.org/10.1136/bmjopen-
2017-021108 
 
Enclosed in appendix III, the above-cited manuscript has been published as an open 
access article in a peer-reviewed journal. Use of this manuscript is expected to be 
distributed under the terms of the Creative Commons Attribution License (CC-BY), 
which permits unrestricted use, distribution, and reproduction in any medium, provided 
the original author and source are credited (Copyright: © 2018 Al-Gobari et al.).  
 
2.2. Contribution of authors and co-authors  
As stated in the original work (appendix III), design and conception: MA, FG, BB. (MA 
is the guarantor). Project administration: BB. Writing original draft: MA. Critical 
analysis: MA, SA, FG, BB. Data curation: MA, SA. Statistical analysis: MA. Proofread 
and approved the final draft: MA, SA, FG, and BB.  
 
2.3. Introduction and objectives 
One important target of heart failure (HF) therapy is to alleviate symptoms, improve 
the quality of life and reduce the mortality of the disease. It is noteworthy that 50% of 
HF patients die within 5 years of initial diagnosis and at least half of them die suddenly, 
termed “sudden cardiac death” (SCD). Since HF with reduced ejection fraction patients 
adopt a multi-regimen therapy (Figure 2.1) and the necessity, not only from economic 
viewpoint but also clinically, to determine whether a particular drug intervention is 
effective or not in all-cause mortality and SCD prevention, we aimed to summarize and 
update the current evidence in the literature. We categorized the evidence into 
effective, ineffective, and unclear evidence of effectiveness.   
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2.2. Methods of Chapter 2 
We developed an a priori protocol (cf. Appendix II) for this study and registered it on 
the international prospective register of systematic reviews (PROSPERO). The 
protocol included a search strategy, data sources, inclusion and exclusion criteria, and 
data abstraction forms. We looked on the literature on methods of quality assessment 
of included reviews and selected AMSTAR measurement tool. To assess the quality 
of evidence in included reviews, we used the GRADE (Grading of Recommendations, 
Assessment, Development and Evaluation) approach. GRADE categorizes the quality 
of evidence into four levels: high, moderate, low and very low.  
- After data collection, we statistically analyzed it and provided a narrative 
synthesis of the evidence.  
- We also meta-analyzed one intervention (i.e. angiotensin receptor blockers 
(ARBs)) in order to update the existed evidence using random-effects and fixed-
effects models with Mantel-Haenszel methods [32]. Odds ratios (OR) or relative 
risk (RR) was used as a summary statistic with confidence intervals(CIs) and a 
significance level at two-sided alpha < 0.5.  
- Other than scrutinizing the heterogeneity and inconsistencies between 
retrieved reviews, we categorized the resulted synthesis into:  
1- effective interventions;  
2- ineffective interventions;  
3- uncertain evidence (conflicting or inconclusive evidence).  
         
3.2. Main findings of chapter 2 (cf. Appendix III) 
Summary  
The published protocol [33] was followed and all outcomes were reported, namely 
SCD and all-cause mortality. Measuring quality by AMSTAR and GRADE, the study 
resulted into three categories of evidence (see Table 2.1)  
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Table 2.1: Result of drug evaluation on SCD prevention for HFrEF patients 
SCD: sudden cardiac death; RR: risk ratio; OR: odds ratio  
 
 
We reported the risk ratio (RR) or odds ratio (OR) of the effective interventions (i.e., 
BBs, AAs, combined ARB/neprilysin inhibitor). It is possible to compute the association 
of the three drug interventions by multiplying the effect size, assuming that there is no 
interaction. The resulted effect size estimation suggested an SCD reduction of almost 
50%.         
 
 
 
 
 
 
 
 
 
 
 
 
 
Evidence for SCD 
outcome  
Drugs RR/OR 
Effective interventions - beta-blockers (BB) 
- anti-aldosterone (AAs) 
- combined ARB/neprilysin inhibitor 
- 0,69 
- 0,81 
- 0,81 
Ineffective 
interventions 
- angiotensin-converting enzyme inhibitors (ACE-i) 
- angiotensin receptor blockers (ARBs) 
- statins 
-  
Uncertain evidence - amiodarone & anti-arrhythmic drugs (AADs) 
- omega-3 polyunsaturated fatty acids (PUFA) 
- fish oil supplementation 
-  
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Conclusion  
This overview contributes to enhance the understanding of the current evidence of 
effectiveness of the strategies used to prevent SCD and all-cause mortality in HF 
patients with reduced ejection fraction. It helps to adopt an optimal strategy in patients 
with high risk of SCD.    
 
 
 
Figure 2.1: Drug and non-drug interventions in heart failure with reduced ejection fraction (HFrEF). 
SCD: sudden cardiac death. Thumb up= reduce SCD. Thumb down: failed to significantly reduce SCD.  
Question mark (?): uncertain evidence. 
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CHAPTER 3 
Statins in real-world Clinical Cohort (EPICAL2) 
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3.1. Article title and statement of permission 
 
“Effects of statins to reduce all-cause mortality in heart failure patients: findings from 
the EPICAL2 cohort study” 
Al-Gobari M, Agrinier N, Burnand B. Thilly N.  
 
Enclosed in appendix IV, the above-cited manuscript has been drafted or prepared 
for submission to a peer-reviewed journal.  
 
3.2. Contribution of authors and co-authors  
 
Drafted the manuscript: MA. Original data possession: NT. Data Analysis: MA. 
Supervision: NA BB NT. Writing- review & editing: MA NA BB NT 
 
3.3. Introduction and objective 
 
Heart failure (HF) patients have poor survival despite current advances in therapy and 
management. Statins showed contradictory results in observational data and 
randomized clinical trials (RCTs) [29, 30, 34, 35]. Unlike RCTs, observational studies 
are prone to selection and allocation bias. Advanced statistical techniques, such as 
propensity score analysis and instrumental variables methods, have been developed 
to reduce bias and mimic some aspects of experimental studies [36, 37]. Using these 
statistical techniques, we aimed to evaluate the effects of statins on all-cause mortality 
prevention in HF. In our analysis, we used data from an observational study of 2,254 
subjects hospitalized for acute heart failure and recruited between October 2011 and 
October 2012 from 20 hospitals located in the Lorraine region of northeast France.  
 
2.2. Methods of Chapter 3 
2.3.1 Participants 
This clinical cohort (EPICAL2, NCT 02880358) has included 2,254 patients. We 
excluded patients who were lost to follow-up, were dead before discharge or 
discharged with unknown treatment status for statins. After exclusion, the study cohort 
finally consisted of 2,032 patients, 919 (45 %) of whom received statins (treated group) 
versus 1,113 (55 %) not treated with statins as a (control group)  
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2.3.3.1. Propensity score analysis 
We calculated the propensity scores (i.e., the probability of being treated with statins) 
using multivariable logistic regression, without including the outcome (all-cause 
mortality) and performed balance assessment tests to compare the distribution of 
covariates between treated and control patients [38]. We used one-to-many matching 
with replacement as it produced better balance between treated and control groups 
than one-to-one matching without replacement. Then we estimated treatment effects 
and their standard errors using propensity score matching methods within a caliper 
distance of 0.2 [39, 40]. 
 
2.3.3.2. Instrumental variable analysis 
Propensity scores balance for measured covariates but not necessarily for 
unmeasured covariates [40]. However, instrumental variables approach takes into 
account unmeasured variables that are associated with the treatment but not directly 
with the outcome. We used “the prevalence or the percentage of statin prescription” in 
participating health centers as an instrumental variable. Using a two-stage least 
square method, we regressed the instrumental variable, the prevalence of statin 
treatment in the participating hospitals (dichotomized as above or below the median 
of 47%), on other covariates previously used for the propensity score analysis. 
Thereafter, we tested the endogeneity (Durbin (score) and Wu-Hausman) and 
weakness of our instrument.    
 
2.3.3.3. Kaplan-Meier survival curves and Cox proportional-hazards model 
We used a log-rank test to determine the equality of survivor functions, used a stratified 
log-rank test (on propensity scores), and stratified Wilcoxon (Breslow) test to compare 
survival curves. To illustrate the increased rate of having an event, we regressed all-
cause mortality (the outcome) on independent variables - previously adjusted for in 
Kaplan-Meier survivor curves- in a multivariable Cox proportional-hazard model with 
Breslow methods for ties. We verified the proportional-hazards assumption by a global 
test for all covariates included in the model and based on Schoenfeld residuals for all 
covariates individually. 
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3.2. Main findings of chapter 3 (cf. Appendix III) 
3.3.2. Propensity score matching  
The overlap of the propensity scores between treated and control groups appeared 
subjectively satisfying (Figure 3.2). 
 
 
The 
estimated satin-treatment effects (the average treatment effects on the treated, ATT) 
for all-cause mortality in HF resulted into negative result [Coefficient: - 0.055, AI robust 
standard errors: 0.032, Z: -1.73; 95% CI: (-0.11 to 0.007), p-value: 0.083]. 
 
3.3.3. Instrumental variable analysis 
 The hypotheses related to the correlation of our instrument with the treatment and 
indirectly with the outcome (all-cause mortality) via the treatment were satisfied. In 
addition, the test of endogeneity (Durbin (score) and Wu-Hausman) failed to reject our 
null hypothesis that the variables are exogenous (p-value = 0.3). The treatment 
estimation, using the two-stage least squares regression, did not show a significant 
0 .2 .4 .6 .8 1
Propensity Score
Untreated Treated
Figure 3.2: Distribution and degree of overlap of the propensity score 
between statin-treated and control groups in the included HF patients. 
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decrease of death in the statin group versus the control group [Coefficient: -0.43, 
standard errors: 0.46, Z: -0.95; 95% CI: (-1.34 to 0.46), p-value: 0.34].  
 
3.3.4. Kaplan-Meier curves and cox-proportional hazards model 
 
The number of deaths in our sample was 539 (26.53%). Of those, 195 (21.22%) 
occurred in the treated group versus 344 (30.91%) in the control group. Unadjusted 
Kaplan-Meier survivor curves (Figure 3.3) and log-rank test showed significant result 
(P-value < 0.0000). However, the adjusted Kaplan-Meier survivor curves and the 
stratified log-rank test failed to show a significant result (P-value: 0.317) (Figure 3.4). 
We adjusted using the same covariates as in the propensity score analysis. 
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Conclusion  
Statins were not associated with a decrease in all-cause mortality in statin-treated 
group in heart failure patients after one-year hospital discharge compared to those not 
treated with statins. 
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CHAPTER 4 
 
Other Scientific Contributions 
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4.1. Article title and statement of permission 
“Impact of Aldosterone Antagonists on Sudden Cardiac Death Prevention in Heart 
Failure and Post-Myocardial Infarction Patients: A Systematic Review and Meta-
Analysis of Randomized Controlled Trials” 
Le HH, El-Khatib C, Mombled M, Guitarian F,  Al-Gobari M, Fall M, Janiaud P, Marchant I, Cucherat 
M, Bejan-Angoulvant T, Gueyffier F. PLoS One. 2016 Feb 18;11(2):e0145958. doi: 
10.1371/journal.pone.0145958. eCollection 2016 
 
Enclosed in appendix V, the above-cited manuscript has been published as an open 
access article in a peer-reviewed journal. Use of this manuscript is distributed under 
the terms of the Creative Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, provided the original author and 
source are credited (Copyright: © 2016 Hai-Ha LE et al.).  
 
4.1.1. Contribution of authors and co-authors  
As stated in the original work [41], conceived and designed the experiments: HHL F. 
Guitarian TBA F. Gueyffier. Performed the experiments: HHL MMF. Guitarian CE MC 
TBA F. Gueyffier. Analyzed the data: HHL F. Guitarian CE MM MC F. Gueyffier. Wrote 
the paper: HHL CE F. Guitarian MM MA MF MC TBA F. Gueyffier. Literature and data 
extraction: HHL MMF. Guitarian CE TBA F. Gueyffier. Proofreading: HHL MA MM CE 
MF F. Guitarian PJ IM MC TBA F. Gueyffier. Editing: HHL. 
 
4.1.2. Summary 
In a subgroup analysis, anti-aldosterone antagonists reduced SCD in heart failure (HF) 
patients ([Risk Ratio (RR) 0.79; 95% Confidence interval (CI), 0.68 to 0.91, P = 0.002]. 
However, a particular attention and risk/benefits evaluation should be ensured 
because of adverse effects such as hyperkalemia, degradation of renal function, and 
gynecomastia.     
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4.2. Article title and statement of permission 
“A sudden death risk score specifically for hypertension: based on 25 648 individual 
patient data from six randomized controlled trials”  
Le HH, Subtil F, Cerou M, Marchant I,  Al-Gobari M, Fall M, Mimouni Y, Kassaï B, Lindholm L, Thijis L, 
Gueyffier F. Journal of hypertension. 2017;35:2178-84 
 
Enclosed in appendix VI as author version, the above-cited manuscript has been 
published in a peer-reviewed journal. Use of this manuscript is governed by the 
publisher (Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved).  
4.2.1. Contribution of authors and co-authors  
As stated in the original work [42], F.G. proposed the idea of the study. F.S., L.T. made 
substantial contributions to study conception and design. H.H.L. and M.C. performed 
the analyses. H.H.L. wrote the article. F.S., M.C., M.A., I.M., L.L., L.T., and F.G. have 
been involved in revising the manuscript critically for important intellectual content.  
4.2.2. Summary 
We have developed a risk score model to predict SCD in hypertensive patients with 
or without cardiovascular disease. To calculate a five-year risk of SCD, seven risk 
factors are needed (i.e. age, sex, systolic blood pressure, serum total cholesterol, 
cigarette smoking, diabetes, and history of myocardial infarction). This tool might 
help identify those at high risk of SCD in hypertensive patients and hence optimize 
the therapeutic strategy accordingly.  
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4.3. Article title and statement of permission 
“Beta-blockers for the prevention of sudden cardiac death in heart failure patients: a 
meta-analysis of randomized controlled trials” 
Al-Gobari M, El Khatib C, Pillon F, Gueyffier F. BMC Cardiovascular Disorders 2013, 13:52  
 
Enclosed in appendix VI, the above-cited manuscript has been published as an open 
access by a peer-reviewed journal. Use of this manuscript is distributed under the 
terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source 
are credited (Copyright: © 2013 Al-Gobari et al.).  
 
4.3.1. Contribution of authors and co-authors  
As stated in the original work [43], MA and FG participated in the conception and 
design of the study. MA, FP and CK extracted the data. MA drafted the study. MA, FP 
and FG had critically analyzed and interpreted the data. All authors read and approved 
the final manuscript. 
 
4.3.2. Summary 
Beta-blockers (BB) reduce SCD and all-cause mortality in heart failure (HF) patients 
[OR 0.69; 95% CI, 0.62-0.77, P<0.00001], and [OR 0.67; 95% CI, 0.59-0.76, 
P<0.00001], respectively. BBs should be given to all eligible patients for mortality 
benefits.  
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5. GENERAL SUMMARY AND DISCUSSION 
 
5.1. Synthesis 
Overall, heart failure (HF) patients use a combination of drugs and non-drug 
interventions to alleviate symptoms and impede the mortality and morbidity of the 
disease. Currently, there is no an established strategy to deal with patients at high risk 
of SCD. In such patients, a particular attention should be considered and a careful 
selection of available therapeutic options is needed. We appraised the effectiveness 
of evidence-based HF drugs and updated the evidence of the most commonly 
prescribed ones. Namely, we reviewed beta-blockers (BBs), angiotensin-converting 
enzyme inhibitors (ACE-i), angiotensin receptor blockers (ARBs), combined 
angiotensin receptor blockers (ARB)/neprilysin inhibitors, aldosterone antagonists, 
omega-3 fatty acids, statins, amiodarone and anti-arrhythmic drugs.  
In chapter 1, our findings showed that statins add no more benefits in solely HF 
patients. Thus, our systematic review supports the current ESC guideline [11]. It 
concurs with the two large-scale RCTs in HF [29, 30] and thus represents a convincing 
evidence to recent controversial results [27, 28].    
In chapter 2, ARBs, a recommended HF drugs, failed to significantly reduce SCD and 
all-cause mortality. ACE-i tended to reduce all-cause mortality but not SCD. Only one 
trial [44] suggested beneficial effects of ACE-i on SCD prevention in non-MI HF 
patients [45] but failed in the pooled data. This is perhaps due to small study effects.  
Oppositely, BBs reduced SCD significantly. Hence, BBs remain the mainstay of 
therapeutic strategies in HF. Similarly, both aldosterone antagonists and combined 
ARB/neprilysin inhibitors significantly reduced SCD events, whereas omega-3 fatty 
acids or fish oil supplementation as well as amiodarone and anti-arrhythmic drugs had 
uncertain evidence of effectiveness.  
In chapter 3, we evaluated the effectiveness of statins in a real-world setting to prevent 
all-cause mortality. The data came from a French cohort of hospitalized acute HF 
patients (n= 2254). Advanced statistical methods were used, namely, propensity score 
analysis and instrumental variable approach that help to mimic controlled experiments 
such as RCTs. In our study, statins remained ineffective in HF patients in consistency 
with large RCTs, which confirmed our previous findings in the updated meta-analysis 
(cf. chapter 1). 
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In chapter 4, aldosterone antagonists showed to reduce SCD in HF subgroup 
analysis. However, there were more adverse events (e.g., hyperkalemia, degradation 
of renal function, and gynecomastia) in the treated group compared to the control 
group.  
Of note, it has been reported that antihypertensive treatment failed to reduce SCD 
[46].  In chapter 4, we also developed a risk score model to predict SCD in 
hypertensive patients.   
Acknowledging the high potentially avoidable HF mortality, there is an urgent need to 
improve clinical outcomes, to optimize therapy, to identify compliance issues and to 
adopt evidence-based clinical decisions. Nevertheless, current strategies and 
management plans in HF do not fully address the needs of patients with high risk of 
SCD.   
Importantly, a commonly known intervention in HF to prevent SCD is an implantable 
cardioverter defibrillator (ICD) implantation. However, studies showed that only a small 
proportion of patients are potential candidates for an ICD [11, 47]. In addition, despite 
reducing SCD, ICD therapy does not preclude the progression of HF [48], which might 
be explained by an increase in deaths from pump failure [49]. ICDs implantation comes 
with high financial costs and periprocedural and long-term risks [50-52]. In fact, the 
2016 ESC guideline recommends ICD implantation only after an optimal medical 
therapy has failed to increase the left ventricular ejection fraction (LVEF) to > 35%. 
That is why it is of importance to optimize therapy beforehand. Nevertheless, we 
acknowledge that our work did not fully review ICDs or other non-drug devices such 
as cardiac resynchronization therapy (CRT), which we consider important for future 
research  
The patients’ characteristics in our study (cf. chapter 3) also revealed that the use of 
life-saving drugs is still suboptimal. One can raise the question of the 
representativeness of the EPICAL 2 cohort but we found that it was comparable to 
findings from other countries [53, 54]. 
By advocating the most effective interventions, this might not only result in a much 
less number of deaths and a better quality of life but also in a reduction of public health 
expenditure. 
 
 
35 
 
It is noteworthy that before introducing those interventions in the intent to reduce SCD 
events, it is important that a patient’s risk is properly stratified and predicted and that 
warning signs are timely detected [55]. To this end, a number of prediction risk models 
were developed [22, 56]. However, their external validity and clinical applicability may 
not be well established. In the athletic community, most SCDs occur without prodromal 
warning symptoms [55] but obligatory screening decreased events rate up to 90% in 
Italy, for instance [57]. It is important to emphasize that the public access to automated 
external defibrillators (i.e. in libraries, museums, sport clubs, concert/theater, 
government buildings, and hotels) has substantially improved survival rate of victims 
of SCDs [55, 58].  
 
5.2. Limitations and Strengths  
We acknowledge several limitations in our work. First, we evaluated (cf. chapter 1-4) 
only drug interventions in HF excluding non-drug interventions or devices. In addition, 
our work did not cover all drug interventions but the most widely prescribed ones. 
Although devices such as implantable cardioverter defibrillators are considered an 
important intervention in SCD prevention strategies, they are recommended only after 
optimal medical therapy failed to increase LVEF >35%.  
Second, we were not able to update the evidence at primary-study level for some 
interventions like angiotensin-converting enzyme blockers (ACE-i).  
Third, we used grouped published data and did not have individual patient data that 
would allow us to stratify patients according to their ischaemic and non-ischaemic 
status, for instance.  
Fourth, we adjusted for selected variables - in the propensity score analysis - to which 
we believe that both treatment assignment and the outcome are related (cf. chapter 
3). Even if the assumption of treatment assignment ingorability is satisfied, because 
of adjustment on selected observable covariates, a selection bias still potentially exists 
[59].  
Fifth, the variables (left ventricular ejection fraction (LVEF), body mass index (BMI), 
hospital stay duration, and hemoglobin level), used in the propensity score model, had 
missing values and the way to deal with this missingness involved another methods 
[60, 61] to be considered in further research.  
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Finally, most of aforementioned limitations and others have been mentioned in the 
original related published work (cf. Appendix I – V). It is noteworthy that before 
conducting our overview (cf. chapter 2), we wrote a protocol to help avoiding biases 
such as reporting bias (cf. Appendix III). According to our knowledge, our work is a 
valuable contribution to an original high-demand research that used a standard 
methodology in agreement with current guidelines, the Equator’s (http://www.equator-
network.org/) recommendations and the GRADE approach, as well.   
 
5.3. Clinical implications and perspectives  
Our work paved the way toward optimization of therapeutic strategies in patients at 
high risk of SCD. A suggested design for a good therapeutic strategy in SCD 
prevention might be to identify, treat, monitor and evaluate (ITME) high-risk individuals 
in HF population. This implies that we should correctly stratify and predict those at risk 
and then select the most effective therapeutic regimen, taking into account net clinical 
benefits, patient preference and quality of life and in light of our findings. Those 
patients should also be closely monitored as HF prognosis is extremely bad, 
particularly in individuals with existing comorbidities. Thereafter, we would need to 
evaluate whatever adopted strategy in a regular basis.  
In line with limitations of our work, it would be interesting to investigate the overall 
evidence altogether (i.e., drug and non-drug interventions). A suggested methodology 
would be to use network meta-analyses. This might highlight which intervention is the 
most effective and which intervention is perhaps preferred to another. Other 
approaches are under development that involve the use of GRADE to evaluate 
complex interventions.  
It is noteworthy that our study evaluated pharmacological interventions on HFrEF 
patients and our result may not extend to other patients groups (i.e., HFmrEF or 
HFpEF). This highlights the importance of launching new clinical trials and research 
on those patients [62] because they are also concerned with the incidence of SCD 
outcome as HFrEF patients.  
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6. CONCLUSION 
In our work, we reviewed most drug interventions in heart failure (HF) patients in the 
context of a potentially alternative strategy to optimize medical therapy for SCD 
prevention in HF patients. Using published data from randomized trials of HF with 
reduced ejection fraction and a cohort of hospitalized acute HF patients (one-year 
follow-up), statins added no benefits in SCD prevention or all-cause mortality. 
Moreover, angiotensin receptor blockers (ARB) and angiotensin-converting enzyme 
inhibitors (ACE-i) failed to significantly reduce SCD events. The latter reduced all-
cause mortality. By contrast, beta-blockers (BB), combined ARB/neprilysin inhibitors 
and anti-aldosterones decrease SCD and all-cause mortality events. The possibility to 
distinguish whether a particular HF drug prevents SCD (or not) might contribute toward 
an optimal strategy in patients with high risk of SCD. If only the most effective 
interventions were adopted, we would expect not only a much less number of deaths 
and a better quality of life but also a reduction of public health expenditure.  
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Abstract
Background and objectives
Statins showed mixed results in heart failure (HF) patients. The benefits in major HF out-
comes, including all-cause mortality and sudden cardiac death (SCD), have always been
discordant across systematic reviews and meta-analyses. We intended to systematically
identify and appraise the available evidence that evaluated the effectiveness of statins in
clinical outcomes for HF patients.
Design
Systematic review and meta-analysis
Data sources
We searched, until April 28, 2016: Medline, Embase, ISI Web of Science and EBM reviews
(Cochrane DSR, ACP journal club, DARE, CCTR, CMR, HTA, and NHSEED), checked clini-
caltrials.gov for ongoing trials and manually searched references of included studies.
Eligibility criteria for selecting studies
We identified 24 randomized clinical trials that evaluated the efficacy of statins for HF patients.
All randomized clinical trials were assessed for risk of bias and pooled together in a meta-anal-
ysis. Pre-specified outcomes were sudden cardiac death, all-cause mortality, and hospitaliza-
tion for worsening heart failure.
Results
Statins did not reduce sudden cardiac death (SCD) events in HF patients [relative risk (RR)
0.92, 95% confidence interval (CI) 0.70 to 1.21], all-cause mortality [RR 0.88, 95% CI 0.75
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to 1.02] but significantly reduced hospitalization for worsening heart failure (HWHF) although
modestly [RR 0.79, 95% CI 0.66 to 0.94]. Nevertheless, estimated predictive intervals were
insignificant in SCD, all-cause mortality and HWHF [RR, 0.54 to 1.63, 0.64 to 1.19, and 0.54
to 1.15], respectively. An important finding was the possible presence of publication bias,
small-study effects and heterogeneity of the trials conducted in HF patients.
Conclusions
Statins do not reduce sudden cardiac death, all-cause mortality, but may slightly decrease
hospitalization for worsening heart failure in HF patients. The evaluation of the risk of biases
suggested moderate quality of the published results. Until new evidence is available, this
study supports the 2013 ACCF/AHA guidelines to not systematically prescribe statins in
“only” HF patients, which should help avoid unnecessary polypharmacy.
Introduction
Heart failure (HF) patients are likely to take more than one drug and tend toward polypharmacy.
Guideline-directed medical therapy includes angiotensin converting enzyme inhibitors, beta-
blockers, aldosterone antagonists as well as implantable cardioverter defibrillators, which all have
reported a reduction in mortality and morbidity in heart failure patients [1–4]. Though, such
benefits are still insufficient to the current management need as almost half of HF patients die
within 5 years after initial diagnosis and half of the mortality is attributed to sudden cardiac death
(SCD) [5,6]. More potential benefits are hypothesized with statin treatment but current ACCF/
AHA guidelines do not recommend statins for only HF diagnosis [7]. However, 3-hydroxy-
3-methylglutaryl coenzyme A (HMG-Co A) reductase inhibitors or simply statins are still widely
prescribed for HF patients [8].
Several studies [9–11] evaluated the effects of statin on sudden cardiac death prevention but
with a variety of population characteristics which made the result difficult to apply for HF patients.
Oppositely, two large randomized clinical trials (RCTs) [12,13] in heart failure reported no reduc-
tion of all-cause mortality and SCD events by statins. Moreover, studies often evaluated surrogate
endpoints or biomarkers other than important clinical endpoints such as mortality and that might
have exaggerated the expected benefits of statins[14].
A systematic review [15], published in 2006, stressed on the importance of this research
question and pointed out the conflicting and unclear evidence. CORONA [13] and GISSI-HF
[12] (unpublished at that time) was expected to resolve the issue. In the contrary, both studies,
after publication, raised controversial statements and debates. The morbidity and mortality
rate among HF patients is considerably high and an emphasis on effective prevention strategies
would lead to a significant reduction of such events. Similarly, HF patients have a reduced lon-
gevity thus the need for providing clinicians and health care actors an optimal evidence-based
strategy is of vital importance.
Nevertheless, current trials, systematic reviews and meta-analyses [16–24] for statins have
shown mixed results for major HF outcomes. Positive studies were not immune to bias, serious
limitations or indirectness. Therefore, we intended to evaluate and update the quality of evi-
dence of statins efficacy to reduce SCD, mortality or hospitalization for worsening heart failure
(HWHF) by means of a systematic review and a meta-analysis with a careful consideration of
potential biases in published studies.
Statins for sudden cardiac death prevention in heart failure
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Methods
Study search strategy
We searched Medline (1946 to April 28, 2016), Embase (1974 to April 28, 2016), EBM reviews
(Cochrane DSR, ACP journal club, DARE, CCTR, CMR, HTA, and NHSEED) (to April 28,
2016), and ISI web of science (‘‘All years” to April 28, 2016) via an Ovid online interface and iden-
tified systematic reviews and meta-analyses via a search strategy accessible on S1 File. In a first
step, we used a filter [25,26] to search for systematic reviews and meta-analyses and initially
excluded individual clinical trials for the purpose of our study. In a second step, we searched for
primary studies and included randomized clinical trials evaluating statins in heart failure patients.
In Medline and Embase, we combined medical subject heading terms (MeSH and EMTREE
respectively), text words as well as a truncation when appropriate. The method included a combi-
nation of a disease (i.e., heart failure), an intervention (i.e., statins) as well as the aforementioned
filter. Also, we added an outcome (i.e., sudden cardiac death and/or mortality) to limit the research
output. No language restrictions were applied and a bimonthly alert was set up for an automatic
update during the study. We also checked the references of included studies for potential addi-
tional studies, searched clinicaltrials.gov and tried to contact authors for additional or missing
data. Fig 1 shows the search strategy results according to the PRISMA guidelines (see also S2 File).
Selection criteria and data abstraction
We included randomized clinical trials (RCTs) that evaluated statins efficacy in heart failure
patients and contained at least one outcome of interest. No exclusion was based on treatment
duration or follow-up period, language or intention-to-treat analysis. Risk of bias was deter-
mined by the Cochrane risk bias assessment tool [27]. Two reviewers (MA&HHL) indepen-
dently collected data and were checked by a third reviewer (MF) while discrepancies were
resolved via discussion and consensus. Abstracted data included eligibility criteria, baseline
characteristics, study design (including treatment and control arms), follow-up duration, and
Fig 1. Flow chart for search result.
doi:10.1371/journal.pone.0171168.g001
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outcomes. Pre-specified outcomes of interest included sudden cardiac death (SCD), all-cause
mortality and hospitalization for worsening heart failure (HWHF) and were analyzed accord-
ing to an intention-to-treat principle when possible.
Statistical analysis
We pooled the data in a meta-analysis, using random-effects and fixed-effects model with Man-
tel-Haenszel methods that are preferable to inverse variance methods in case of few events [27].
Sensitivity and subgroup analyses were done to verify the extent to which different hypotheses
might change our confidence in the result. The effect size was relative risk or risk ratio (RR),
confidence intervals (CIs) of 95% was given when applicable and a significance level was deter-
mined at two-sided alpha less than 5%. We reported both fixed-effect and random-effects mod-
els for the meta-analysis and used risk ratios (RR) as the summary effect estimate that may give
better interpretation as the outcome is hospitalization or death events, termed bad outcome.
We calculated the absolute effect or the absolute risk reduction (ARR) for SCD, all-cause mor-
tality and HWHF with an assumed control risk (ACR) of 0.11, 0.27 and 0.38 respectively. To
check the validity of choosing the summary statistic, odds ratio (OR) was used instead of RR in
a sensitivity analysis. The 95% prediction interval, an interval that estimate a treatment effect of
a new or future trial within which we are confident it lies, was given when a random-effects
model is used. Also, we rated the quality of the evidence using a summary of findings table from
the GRADE approach [28]. We computed the sample size required to reach a statistical signifi-
cance according to the observed differences between the groups of statin and placebo or control
for all outcomes [α = 5% and power (1- β) = 0.80] and intended to stratify the studies according
to follow-up and sample size in subgroup and sensitivity analyses. Heterogeneity was measured
by I-squared (I2, variation in RR/OR attributable to heterogeneity) and Tau-squared (Tau2, esti-
mate of between-study variance). We noticed that the follow-up period differed largely from
one study to another from one month [29,30] to more than 30 months [12,13,31]. Therefore,
studies were grouped according to follow-up as a potential determinant of any heterogeneity
among studies. Data was analyzed with STATA version 14.1 (StataCorp LP, Texas), RevMan
(version 5.3) and GradePro (version 3.6.1).
Results
Study selection
Electronic databases and manual searches resulted in 1335 studies after removal of duplicates.
After screening of titles and abstracts and examination of selected full-texts, we ended up with
17 systematic reviews/meta-analyses [9,11,18–24,32–39] and 24 randomized controlled trials
(RCTs) [12,13,40–51] [29,31,52] [30,53–58] (Fig 1).
Study and baseline patient characteristics
As shown in Tables 1 and 2, we identified 24 RCTs of statins in heart failure (HF) patients for
inclusion in this meta-analysis, which enrolled a total of 11,463 patients. The mean and the
median of follow-up duration were 11.5 and 6 months respectively. The studies included in
majority male participants (ratio ranged from 54% to 100%) with an average age of 60 years.
The mean age of the three biggest studies (CORONA [13], GISSI-HF [12] and Takano H. et al.
(PEARL) [31]) was 68 years. All studies included HF patients with New York Heart Association
classification (NYHA) ranging from I-IV and at least 9 studies included stable HF patients.
Seven studies included non-ischaemic HF patients, 4 studies exclusively ischaemic, 12 included
both types and one unknown. All patients in included studies had an ejection fraction less than
Statins for sudden cardiac death prevention in heart failure
PLOS ONE | DOI:10.1371/journal.pone.0171168 February 6, 2017 4 / 24
45% and no one included HF with a preserved ejection fraction (HFpEF). Baseline mean lipid
levels were relatively similar from one study to another with mean low-density lipoprotein
Table 1. Randomized trials of statins in heart failure patients.
Trial [Reference] Publication
Year
Number of patients
(statin/comparator)
Name of
drug
Comparator Mean baseline
Lipids
Primary Endpoint Dosage (mg/
day)
Follow-up
(months)
AbdulHul E. et al.
[40]
2012 56(28/28) Atorvastatin No statin LDL-c = 2.73
mmol/L
Biomarkers, BNP 40 6
Bielecka-D. et al.
[41]
2009 68(41/27) Atorvastatin No statin LDL-c = 3.15
mmol/L
Factors affect
HWHF/mortality
10–40 6
Bleske BE. et al.
[42]
2006 18(9/9)* Atorvastatin Placebo LDL-c = 2.84
mmol/L
Surrogate markers in
NICM
80 3
CORONA [13] 2007 5011(2514/2497) Rosuvastatin Placebo LDL-c = 3.55
mmol/L
HWHF/SCD/mortality 10 32.8
Erbs S.et al. [43] 2011 42(22/20) Rosuvastatin Placebo LDL-c  3.78
mmol/L
Pleiotropic effects 40 24
Gissi-HF
Investigators [12]
2008 4574(2285/2289) Rosuvastatin Placebo NR HWHF/SCD/mortality 10 46.8
Hammad A. et al.
[44]
2005 23(13/10) Atorvastatin Placebo TC  3.5
mmol/L
Autonomic nervous
system
40 3
Hong et al.[58] 2005 202(106/96) Simvastatin No statin LDL-c  3.62
mmol/L
PCI rate, restenosis,
mortality
40 12
Horwich TB. et al.
[45]
2011 26(14/12) Atorvastatin Placebo LDL-c  2.79
mmol/L
Sympathetic nervous
system
10 3
Krum et al. [46] 2007 86(40/45) Rosuvastatin Placebo NR Ventricular
remodeling
10–40 6
Laufs U. et al.[47] 2004 15(8/7) Cerivastatin Placebo LDL-c  3.46
mmol/L
Pleiotropic effects 0.4 5
Liu M. et al. [48] 2009 64(32/32) Atorvastatin Placebo LDL-c 
3.03mmol/L
Inflammation 10 3
Mozaffarian D.et al.
[49]
2005 22(12/10) Atorvastain Placebo LDL-c = 3.33
mmol/L
Inflammation 10 2
Node K. et al. [50] 2003 51(23/25) Simvastatin Placebo LDL-c  3.85
mmol/L
Cardiac function 5–10 3.5
Sola S. et al. [51] 2006 108(46/43) Atorvastatin Placebo LDL-c  3.12
mmol/L
Inflammation 20 12
Strey CH. et al. [52] 2006 23(11/12)* Atorvastatin Placebo LDL-c  3.56
mmol/L
Endothelial function 40 1.5
Takano H. et al.[31] 2013 577(288/286) Pitavastatin No statin LDL-c  3.24
mmol/L
Mortality /HWHF/
stroke
2 35.5
Tousoulis D.et al.
[29]
2005 38(19/19) Atorvastatin No statin TC  4.83
mmol/L
Inflammation 10 1
Tousoulis D.et al.
[30]
2004 38(14/12) Atorvastatin No statin TC  5.04
mmol/L
Inflammation 10 1
Vrtovec B. et al.
[53]
2005 80(40/40) Atorvastatin No statin TC  5.07
mmol/L
HRV/ QTV/ QTc 10 3
Vrtovec B. et al.
[54]
2008 110(55/55) Atorvastatin No statin LDL-c = 2.45
mmol/L
SCD 10 12
Wojnicz R. et al.
[55]
2006 74(36/38) Atorvastatin No statin LDL-c  4.18
mmol/L
Inflammation 40 6
Xie RQ. et al.[56] 2008 119(78/41) Atorvastatin Statin/no
statin
LDL-c  3.64
mmol/L
Cardiac function 10–20 12
Yamada T. et al.
[57]
2007 38(19/19) Atorvastatin No statin LDL-c  3.02
mmol/L
Cardiac function 10 31
BNP: B-type natriuretic peptide; HRV: heart rate variability; QTV: QT variability; QTc: QTc interval; HWHF: Hospitalization for worsening heart failure; LDL-
c: lowdensity lipoprotein cholesterol; NICM: Non-Ischaemic Cardiomyopathy; PCI: percutaneous coronary intervention; SCD: sudden cardiac death; TC:
total cholesterol; NR: not reported;: approximately.
* Estimated values
doi:10.1371/journal.pone.0171168.t001
Statins for sudden cardiac death prevention in heart failure
PLOS ONE | DOI:10.1371/journal.pone.0171168 February 6, 2017 5 / 24
cholesterol (LDL-c) of 3.3 for 19 studies and mean total cholesterol (TC) of 5.19 for 3 studies
and unknown for 2 studies. Only 5 studies[13] [12] [31] [58] [54] had a mortality endpoint
while others evaluated surrogate endpoints and biomarkers. Statins were compared to placebo
in 13 studies and to no statin in 10 studies; one study compared two different doses of statins to
a no statin group[56].
Risk of bias and quality of studies
We assessed studies’ risk of bias by means of the Cochrane bias tool[27]. We noticed that the
intention-to-treat principle was not followed in all trials, among which 10 had either high or
unclear risk (Fig 2(B)). Most of the included trials had unclear risk towards blinding of investiga-
tors or outcome assessors. Overall, the studies fluctuated from high to moderate/low level of qual-
ity. Fig 2 (A) shows the summary of bias risk assessment in percentages and for each included
trial. We also rated each outcome (SCD, All-cause mortality and hospitalization for worsening
heart failure (HWHF)) according to the GRADE approach (Fig 3). Studies were evaluated per
outcome for any bias, inconsistency, indirectness, imprecision or publication bias. The latter was
Table 2. Patient characteristics in randomized trials of statins in heart failure patients.
Trial [Reference] Mean age
(Years)
Male
(%)
Inclusion criteria Population (Ischaemic or non-
ischaemic, %)
Mean LVEF
(%)
NYHA
AbdulHul E. et al.[40] 72 68 Mild-moderate HF, LVEF 45% Ischaemic, 64 35 II-III
Bielecka-D. et al.[41] 57 85 Stable HF with DC NR 29 I-III
Bleske BE. et al.[42] 56 60 CHF due to NICM, LVEF<40% Non-ischaemic 25 I-III
CORONA [13] 73 76 Ischaemic HF, age 60,
LVEF < 40%
Ischaemic,100 31 II-IV
Erbs S.et al. [43] 62 76 CHF—Ischaemic HF or DC Ischaemic,28 30 II-III
Gissi-HF Investigators
[12]
68 77 CHF, No LVEF restriction Ischaemic,40 33 II-IV
Hammad A. et al. [44] 67 86 Stable systolic HF Ischaemic, 57 31 II-III
Hong et al.[58] 61 72 Patients underwent PCI for AMI Ischaemic, 100 31 II-IV
Horwich TB. et al. [45] 48 62 Symptomatic HF, LVEF 35% Non-ischaemic 26 I-III
Krum et al. [46] 62 80 NYHA II-IV, LVEF 35%
or 40%
Ischaemic,12 29 II-IV
Laufs U. et al.[47] 51 NR CHF with NICM Non-ischaemic 42 II-III
Liu M. et al. [48] 67 94 NYHA II-III, CHF with IDCM Ischaemic/ Non-ischaemic 20 II-IV
Mozaffarian D.et al. [49] 51 86 Ambulatory HF, LVEF < 40% Ischaemic, 9 31 II-III
Node K. et al. [50] 54 69 HF with IDCM Non-ischaemic 33 II-III
Sola S. et al. [51] 54 63 Stable non-ischaemic HF Non-ischaemic 33 II-IV
Strey CH. et al. [52] 61 70 Symptomatic HF, LVEF < 40% Non-ischaemic 30 II-III
Takano H. et al.[31] 63 81 CHF, LVEF 45% Ischaemic, 27 34 II-III
Tousoulis D.et al.[29] 69 100 Ischaemic HF, LVEF 35% Ischaemic 25 III-IV
Tousoulis D.et al.[30] 58 NR Stable HF. LVEF 35% Ischaemic, 65.7 25 II-IV
Vrtovec B. et al. [53] 67 54 Stable HF, LVEF < 30% Ischaemic, 62 25 III
Vrtovec B. et al. [54] 62 61 Stable HF, LVEF < 30% Ischaemic, 59 25 III
Wojnicz R. et al. [55] 38 81 Stable HF with DC Non-Ischaemic 28 II-III
Xie RQ. et al.[56] NR NR Ischaemic HF, LVEF<45% Ischaemic,100 38 II-IV
Yamada T. et al.[57] 64 79 Stable HF, NYHA I-III Ischaemic, 53 34 I-III
AMI: acute myocardial infarction; CHF: Chronic Heart Failure; DC: dilated cardiomyopathy; DCM: dilated cardiomyopathy; HF: heart failure; IDCM:
idiopathic dilated cardiomyopathy; LVEF: Left Ventricular Ejection Fraction; NICM: Non-Ischaemic Cardiomyopathy; NR: not reported; NYHA: New York
Heart Association; PCI: percutaneous coronary intervention.
doi:10.1371/journal.pone.0171168.t002
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a concern for all outcomes and this resulted in moderate evidence. Due to missing data or
absence of events, only 8 studies for SCD, 13 studies for all-cause mortality and 12 studies for
HWHF were analyzed.
Efficacy of statins and synthesis of results
We pooled the studies to evaluate effects of statins on the reduction of sudden cardiac death
(SCD), all-cause mortality, and hospitalization due to worsening heart failure (HWHF). The
forest plots in Fig 4 shows insignificant reduction in SCD [Risk Ratio (RR) 0.92; 95% CI, 0.70
to 1.21, P = 0.554] and all-cause mortality [RR 0.88; 95% CI, 0.75 to 1.02, P = 0.092] and a sta-
tistically significant difference in HWHF [RR 0.79; 95% CI, 0.66 to 0.84, P = 0.008]. Random-
effects and fixed-effect models were used to quantify the summary statistic by RR. The effect
Fig 2. Risk of bias for included studies. A) Risk of bias graph for statin trials in heart failure patients: review
authors’ judgments about each risk of bias item presented as percentages across all included studies. B) Risk
of bias summary for statins in heart failure patients: review authors’ judgments about each risk of bias item for
each included study.
doi:10.1371/journal.pone.0171168.g002
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size of fixed-effects models was quite similar to CORONA [13] which weighted 59.9%, 50.8%,
and 63.7% for the respective outcomes of the study population.
In Grade output (Fig 3), the SCD rate was 10.7% (n = 540/5057) in those treated with statins
compared with 10.8% (n = 544/5020) in those treated with placebo/control with an absolute effect
of 9 fewer per 1000 (from 33 fewer to 23 more). All-cause mortality rate was 25.9% (n = 1436/
5549) in those treated with statins compared with 27.3% (n = 1494/5475) in those treated with
placebo/control with an absolute effect of 33 fewer per 1000 (from 68 fewer to 5 more). Also, hos-
pitalization rate was 33.33% (n = 1804/5412) in those treated with statins compared with 38%
(n = 2033/5349) in those treated with an absolute effect of 80 fewer per 1000 (from 23 fewer to
129 fewer) (see also S1 Table). The estimated sample size needed to detect a statistically significant
difference, given the effect size found, were 599506, 15394 and 1642 respectively for SCD, all-
cause mortality and HWHF [59]. Moreover, the estimated predictive intervals (PIs) were statisti-
cally insignificant [0.52 to 1.63, 0.54 to 1.15, and 0.64 to 1.19] in SCD, all-cause mortality and
HWHF, respectively, as shown in Fig 4.
The retrieved published systematic reviews and meta-analyses were evaluated against
potential biases and are compared with the results of our systematic review in the discussion
section.
Meta-regression and heterogeneity of combined studies
For SCD, all-cause mortality and HWHF, heterogeneity estimators were, respectively: I2 =
(42.8%, 37.9%, and 58%) and Tau2 = (0.0353, 0.0135, and 0.0215). We intended to explain the
heterogeneity by a meta-regression analysis for cholesterol levels changes for each outcome
but this was not statistically feasible because of zero events in the intervention or control group
in some trials [log (OR) or log (RR) became undefined]. Also, at least because the number of
studies left for any outcome assessment decreased and the risk of type error may have proba-
bly increased.
However, we tried to explain the heterogeneity observed for assessed outcomes by stratifica-
tion according to follow-up duration. As shown in Fig 5, studies were classified into three cate-
gories: 6 months or less, more than 6 months and less than 12, and more than 12 months.
Negative result was maintained in this analysis except for studies of less than 12 months of fol-
low-up which was likely due to small-study effects, revealed by insignificant reduction for
studies more than 12 months which represented between 85–92% of the studied population.
Fig 3. GRADE summary of findings table.
doi:10.1371/journal.pone.0171168.g003
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Sensitivity and subgroup analyses
Both CORONA [13] and GISSI-HF [12] comprised at least 70% of the study population irrespec-
tive of the outcome or the model used. Therefore, we conducted a sensitivity analysis to assess
the impact of these trials on the results by excluding them from the random-effect estimate. This
resulted into significant difference: RR for SCD [0.27 (95% CI, 0.11 to 0.66), P = 0.004], RR for
all-cause mortality [0.55 (95% CI, 0.40 to 0.77), P = 0.0001], and RR for HWHF [0.54 (95% CI,
0.39 to 0.76), P = 0.0001] (see Fig 6).
Fig 4. Efficacy of statins compared with control in heart failure for the prevention of (A) sudden
cardiac death (SCD) (B) all-cause mortality, and (C) hospitalization for worsening heart failure (HWHF).
doi:10.1371/journal.pone.0171168.g004
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On the other hand, after deleting less powered studies, i.e., those with less than 100 patients
in each group, this resulted into insignificant increase in SCD [RR 1.03 (95% CI, 0.88 to 1.20),
P = 0.725], RR for all-cause mortality [0.98 (95% CI, 0.90 to 1.06), P = 0.566], and RR for
HWHF [0.90 (95% CI, 0.79 to 1.04), P = 0.149]. The remaining studies were (CORONA [13],
GISSI-HF [12] for SCD plus Takano H. et al. (PEARL) [31] for all-cause mortality and HWHF
outcomes) (see Figs 7 and 8).
Fig 5. Efficacy of statins compared with control in heart failure stratified by follow-up duration for the
prevention of (A) sudden cardiac death (SCD) (B) all-cause mortality, and (C) hospitalization for worsening
heart failure (HWHF).
doi:10.1371/journal.pone.0171168.g005
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To test our choice of the summary statistic, we shifted to OR instead of RR, the result
changed slightly: OR for SCD [0.89 (95% CI, 0.65–1.23), P = 0.49], OR for all-cause mortality
[0.81 (95% CI, 0.65–1.00), P = 0.05] and OR for HWHF [0.66 (95% CI, 0.50 to 0.87), P = 0.008].
Also, we stratified studies according to being ischaemic, non-ischaemic or both (see Fig 9). This
resulted into statistically insignificant difference for all outcomes: SCD, all-cause mortality and
HWHF. The effect size for ischaemic group, non-ischaemic and ischaemic/non-ischaemic
were, respectively: SCD [RR 0.42 (95% CI, 0.12–1.47), 0.33 (95% CI, 0.02–7.24), and 0.85 (95%
Fig 6. Sensitivity analysis without corona and GISSI-HF.
doi:10.1371/journal.pone.0171168.g006
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CI, 0.36–1.99), overall P = 0.49]; all-cause mortality [RR 0.68 (95% CI, 0.44–1.05), 0.80 (95% CI,
0.24–2.68), and 0.57 (95% CI, 0.24–1.34), overall P = 0.087]; HWHF [RR 0.97 (95% CI, 0.86–
1.09), 0.53 (95% CI, 0.19–1.49), and 0.57 (95% CI, 0.28–1.17), overall P = 0.015]. We noticed
that only five studies had our outcome of interest as a primary endpoint. When studies were
stratified according to their respective endpoints, this resulted into significant differences and a
considerable heterogeneity among studies with mortality and/or hospitalization endpoints (Fig
10).
Fig 7. Sensitivity analysis without less powered studies.
doi:10.1371/journal.pone.0171168.g007
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Publication bias
According to the funnel plots, we estimated that publication bias was likely for the three out-
comes (SCD, all-cause mortality, and HWHF); asymmetry appeared bigger for all-cause mor-
tality (Fig 11). Funnel plot analyses were reinforced [60] for all-cause mortality and HWHF
(for which the number of trials was above 10) by Egger and Harbord tests which showed sig-
nificant small-study effects for all-cause mortality (P = 0.001) but insignificant result for
Fig 8. Efficacy of statins compared with control in heart failure stratified by sample size (more than
100 or less than 100) for the prevention of (A) sudden cardiac death (SCD) (B) all-cause mortality, and (C)
hospitalization for worsening heart failure (HWHF).
doi:10.1371/journal.pone.0171168.g008
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HWHF (P = 0.088 and P = 0.062). Overall, publication bias was taken into account in the
GRADE evaluation and the synthesis of the study results.
Discussion
Our systematic review and meta-analysis showed no clinical benefits of adding statins to the
treatment of HF patients with reduced left ventricular ejection fraction. Statins are ineffective
Fig 9. Efficacy of statins compared with control in heart failure stratified by population type
(ischaemic or non-ischaemic) for the prevention of (A) sudden cardiac death (SCD) (B) all-cause
mortality, and (C) hospitalization for worsening heart failure (HWHF).
doi:10.1371/journal.pone.0171168.g009
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for the prevention of sudden cardiac death (SCD), all-cause mortality but may slightly decrease
hospitalization for worsening heart failure (HWHF). However, the apparent reduction of HWHF
might result from small-study effects. Actually the studies with a longer follow-up (more than
one year), represented almost 85% of the population in this analysis, showed insignificant reduc-
tion. The little reduction in the number of hospitalization is not supported by the estimated pre-
dictive intervals [0.64 to 1.19] derived from random effects models.
Fig 10. Efficacy of statins compared with control in heart failure stratified by endpoint (those with
against without mortality and/or HWHF) for the prevention of (A) sudden cardiac death (SCD) (B) all-
cause mortality, and (C) hospitalization for worsening heart failure (HWHF). [Random-effects model].
doi:10.1371/journal.pone.0171168.g010
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Several previously published meta-analyses [9,11,18,38] evaluated the effects of statins in
SCD prevention and reported a decrease but all studies were limited by indirectness as they
included different populations, i.e. patient with coronary heart disease (CHD), recent and his-
tory of myocardial infarction (MI), or diabetes, and even primary-and-secondary prevention
statin trials [18].
Another meta-analysis [24] claimed that statins reduce all-cause mortality in chronic heart
failure. The study had a biased result as authors lumped together randomized clinical trials
(RCTs) with non-causal observational studies [61] with a high heterogeneity (I2 = 90%).
Our sensitivity and subgroup analyses suggested a potential publication bias, as indicated by
the unbalanced presence of small studies which showed beneficial effects and heterogeneity
Fig 11. Funnel plots of SE (log odds ratio) by odds ratio to evaluate publication bias for the effect of
treatment for prevention of (A) sudden cardiac death (SCD) (B) all-cause mortality, and (C) hospitalization
for worsening heart failure (HWHF). (Fixed-effects model).
doi:10.1371/journal.pone.0171168.g011
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among included studies. The two large clinical trials CORONA [13] and GISSI-HF [12] showed
no benefit of statins and thus different results than the small studies. Many argued that CORONA
[13] and GISSI-HF [12] used a hydrophilic statin (rosuvastatin) that may have a different effec-
tiveness than the predominantly lipophilic statins (atorvastatin, simvastatin, lovastatin, fluvasta-
tin, cerivastatin and pitavastatin)—pravastatin and rosuvastatin are relatively hydrophilic[62].
Fig 12. Efficacy of statins compared with control in heart failure stratified by statin type (lipophilic
versus hydrophilic) for the prevention of (A) sudden cardiac death (SCD) (B) all-cause mortality, and (C)
hospitalization for worsening heart failure (HWHF).
doi:10.1371/journal.pone.0171168.g012
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Based on statin type, two meta-analyses [17,21] included lipophilic statins and stated that
they decreased all-cause mortality, cardiovascular death and HWHF. Both studies included
only 13 RCTs, compared to 24 in this analysis, and the latter mistakenly reported death events
in Hammad A. et al. [44] and Node K. et al [50] whereas the authors of those small trials stated
that no death occurred during the study period. This limitation created more small-scale trials
that exaggerated the benefits of lipophilic statins In addition, those meta-analyses included
Takano H. et al. [31], representing at least 48% of the population in the analysis, which used a
lipophilic statin (pitavastatin) and reported no overall significant decrease in all-cause death or
HWHF.
Moreover, a meta-analysis [63] pooled 10 trials (out of the 24 in our analysis) and showed no
benefits for overall non stratified population and concluded for trend toward benefits for ator-
vastatin at subgroup analysis. However, given the influence of small, poor quality RCTs on the
overall pooled results and only 5% of the studied population for atorvastatin, the authors’ con-
clusion seemed overstated [64]. Such result was quite similar to a study [22] which excluded
both CORONA [13] and GISSI-HF [12] for no apparent reason.
Although one cannot exclude that different statins would have different effects on HF out-
comes, the hypothesis of differences among statins does not seem to be biologically plausible
[16]. According to our sensitivity analysis, the inclusion or exclusion of CORONA [13] and
GISSI-HF [12] impacted the result and changed it significantly. Also, since both studies repre-
sented 80% of the population in the analysis, we believe that only large RCTs with head-to-
head comparison would give us reliable evidence (see Fig 12). Of note, two studies [36,39]
directly compared atorvastatin (lipophilic statin) to rosuvastatin (hydrophilic statin) but for
surrogate endpoints like C-reactive protein and hence did not evaluate any clinical outcomes
with a similar output to Lei Zhang et al. [35,37].
On the other hand, a meta-analysis [33] evaluated statins’ effect in mortality prevention in
heart failure with preserved ejection fraction (HFpEF) but included only cohorts and other
observational studies. Our study, restricted to RCTs, did not include these patients. Similarly, a
study [34] reported statin benefits in non-ischaemic cardiomyopathy and included two obser-
vational studies and ad-hoc analysis of 4 RCTs of which 2 were beta-blockers’ trials and so are
not immune to bias. Although our analysis included 7 non-ischaemic HF trials, we could not
pool them all together because of the limited data on mortality events.
A recent systematic review [19] concluded that statins did not decrease mortality, and
might lead to little or no decrease in HWHF which is consistent with our findings. Likewise, a
meta-analysis [20], included 13 trials, among the 24 trials in our analysis, concluded that stat-
ins might have no beneficial effects on all-cause death, cardiovascular death or pump failure
and rehospitalization for heart failure in the overall (non-stratified) CHF populations. The
authors stratified CHF patients according to age but since individual data were not used, the
possible benefits for younger patients (< 65 years) might be unreliable as this could also be
related to the stage and severity of CHF.
Of note, we think that the inability to prove the benefits of statins may be outweighed by a
negative impact of cholesterol lowering in chronic heart failure (CHF) patients, as some evi-
dence suggests that low levels of total cholesterol are associated with worse outcomes and a
marked increase in mortality in CHF.[22,65–67]. Also any harm for statins in HF might also
be masked, given the potential publication bias.
Overall, our updated review supports the current guidelines and do not recommend statins
in patients with diagnosis of heart failure as this will avoid unnecessary prescriptions, overuse
of care, and might help reluctant or hesitating physicians to make an evidence-based decision
based on updated knowledge.
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Limitations and strength of this study
One principle of a meta-analysis is that included studies should be as much as similar to each
other as possible. However, it is almost impossible to find identical studies with the same
patient characteristics. This limitation is common and particularly in heart failure (HF)
patients who usually have various characteristics and co-morbidities.
Our study revealed a potential for publication bias as shown from funnel plots for clinical
outcomes. Although, this might be a serious limitation, we tried to take it into account in the
study synthesis. As a consequence, this limitation had also downgraded the quality of the evi-
dence from high to moderate within GRADE approach.
Our study had no access to individual data and unpublished studies and no data received
by correspondence, though we have contacted studies’ corresponding authors.
For SCD outcome, for instance, due to the limited number of studies in ischaemic and non-
ischaemic groups and potential heterogeneity, we could not investigate if statins have the same
effects on ischaemic and non-ischaemic heart failure.
For blinding of investigators or outcome assessors in included trials, most studies had
unclear risk but we believe this might have little impact due to weak subjectivity at least for
all-cause mortality outcome in double blind trials.
The studies, in our analysis, had not recruited HF patients with preserved ejection fraction
(HFpEF) and so this result might not be applicable to them.
Our study could contribute to the understanding of the existing discordant evidence in
the evaluation of statins efficacy in clinical outcomes in heart failure with reduced ejection
fraction which is revealed by heterogeneity, publication bias and small-study effects within
clinical trials.
To our knowledge, this is the first analysis that evaluates the efficacy of statins for SCD pre-
vention in HF patients; it helps bridge the gap of controversy towards statin benefits in impor-
tant clinical outcomes rather than surrogate endpoints.
Ongoing studies and perspectives
An ongoing study [https://clinicaltrials.gov/ct2/show/NCT01554592] is expected to resolve the
issue of statin withdrawal in CHF patients. Future RCTs are still needed to: (i) compare lipo-
philic statins with hydrophilic statins. (ii) verify any class effect for statins and (iii) if any sub-
population of heart failure might benefit from statins in order to improve survival and reduce
morbidity.
Conclusion
Limited by a potential publication bias, and heterogeneity between studies, our systematic
review and meta-analysis showed that statins do not decrease SCD or all-cause mortality. The
benefits of statins regarding a possible decrease in hospitalization for worsening heart failure
was not supported by estimated predictive intervals which means the expected treatment
effects for a new brand trial. Physicians should follow the current guidelines of ACCF/AHA
and not systematically prescribe statins for heart failure patients with left ventricular ejection
fraction less than 45%. Ongoing and future trials should shed more light if any subpopulation
might benefit from a particular statin.
Summary for current knowledge
Heart failure has a high morbidity and mortality rate despite significant advances in therapy,
diagnosis and management.
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There is some evidence that low total cholesterol is associated with worse outcomes in
(advanced) chronic heart failure, contrary to the general population.
Statin effects in sudden cardiac death prevention in heart failure is unknown and current
discordant studies for other clinical outcomes like all-cause mortality are unresolved.
Summary for this study outcome
This study delivers a clear message of no benefits of statins in HF patients in response to an
existing controversy.
Publication bias and small-study effects offer a possible explanation to the observed discrep-
ancies between trials, and between previous and our meta-analyses.
Within available data and potential publication bias, statins are ineffective in sudden car-
diac death prevention and all-cause mortality reduction and may or may not slightly reduce
hospitalization for worsening heart failure.
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AbstrACt
Objectives To summarise and synthesise the current 
evidence regarding the effectiveness of drug interventions 
to prevent sudden cardiac death (SCD) and all-cause 
mortality in patients with heart failure with reduced 
ejection fraction (HFrEF).
Design Overview of systematic reviews.
Data sources MEDLINE, Embase, ISI Web of Science and 
Cochrane Library from inception to May 2017; manual 
search of references of included studies for potentially 
relevant reviews.
Eligibility criteria for study selection We reviewed the 
effectiveness of drug interventions for SCD and all-cause 
mortality prevention in patients with HFrEF. We included 
overviews, systematic reviews and meta-analyses of 
randomised controlled trials of beta-blockers, angiotensin-
converting enzyme inhibitors (ACE-i), angiotensin receptor 
blockers (ARBs), antialdosterones or mineralocorticoid-
receptor antagonists, amiodarone, other antiarrhythmic 
drugs, combined ARB/neprilysin inhibitors, statins and fish 
oil supplementation.
review methods Two independent reviewers extracted 
data and assessed the methodological quality of the 
reviews and the quality of evidence for the primary 
studies for each drug intervention, using Assessing 
the Methodological Quality of Systematic Reviews 
(AMSTAR) and Grading of Recommendations, Assessment, 
Development and Evaluation(GRADE), respectively.
results We identified 41 reviews. Beta-blockers, 
antialdosterones and combined ARB/neprilysin inhibitors 
appeared effective to prevent SCD and all-cause mortality. 
ACE-i significantly reduced all-cause mortality but not 
SCD events. ARBs and statins were ineffective where 
antiarrhythmic drugs and omega-3 fatty acids had unclear 
evidence of effectiveness for prevention of SCD and all-
cause mortality.
Conclusions This comprehensive overview of systematic 
reviews confirms that beta-blockers, antialdosterone 
agents and combined ARB/neprilysin inhibitors are 
effective on SCD prevention but not ACE-i or ARBs. In 
patients with high risk of SCD, an alternative therapeutic 
strategy should be explored in future research.
systematic review registration PROSPERO 2017: 
CRD42017067442.
IntrODuCtIOn  
Heart failure (HF) morbidity and mortality 
constitute an important burden for patients 
and for the healthcare systems in both devel-
oped and developing countries.1 Patients 
with HF are frequently hospitalised and have 
a high mortality risk because of a poor prog-
nosis or an unexpected death, termed sudden 
cardiac death (SCD). In people diagnosed 
with HF, SCD occurs at 6–9 times the rate of 
the general population. Almost 20% and 80% 
of patients die within one year and eight years 
of initial diagnosis, respectively.1 2 Risk factors 
of SCD were reported to be similar to cardio-
vascular diseases. However, the most studied 
and proven predictor of SCD in patients 
with HF is left ventricular ejection fraction.3 
Potential drug interventions in patients with 
heart failure with reduced ejection fraction 
(HFrEF) include beta-blockers (BBs), angio-
tensin-converting enzyme inhibitors (ACE-
i), angiotensin receptor blockers (ARBs), 
antialdosterones or mineralocorticoid 
receptor antagonists, amiodarone, other 
strengths and limitations of this study
 ► A major strength of our study is that it summaris-
es and synthesises the effectiveness of most evi-
dence-based drug interventions in heart failure 
patients with reduced ejection fraction for sudden 
cardiac death (SCD) prevention and classified drug 
interventions according to the current evidence of 
their effectiveness.
 ► Our study used data from published studies and no 
data from unpublished studies.
 ► Our study reviews most heart failure drugs on the 
prevention of SCD and all-cause mortality but lim-
ited in scope for not including some drugs such as 
digoxin, ivabradine and non-drug interventions/de-
vices such as implantable cardioverter defibrillators.
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antiarrhythmic agents, combined ARB/neprilysin inhib-
itors, statins and fish oil supplementation.4 Some of these 
interventions aimed at improving survival and reducing 
total mortality and SCD in HF. For instance, a newly 
licensed drug (sacubitril/valsartan) in PARADIGM-HF 
trial (Prospective Comparison of angiotensin neprilysin 
inhibitor (ARNI) with ACE-i to Determine Impact on 
Global Morbidity and Mortality in Heart Failure) showed 
around 20% SCD reduction compared with enalapril.5 
Nevertheless, optimal strategies for SCD prevention 
in HF are warranted if we take into account the high 
portion of mortality that still occurs in this population. 
Had a practitioner identified a patient with high risk of 
SCD, it would be important to know which drug is effec-
tive or not in SCD prevention other than non-drug inter-
ventions such as implantable cardioverter defibrillators 
(ICDs). However, the large amount of information and 
the multiple and sometimes discordant systematic reviews 
on drug interventions could be misleading.6
Therefore, it is vital to identify the pharmacological 
agents that confer the greatest benefit in SCD risk reduc-
tion particularly in high-risk patients and if any optimisa-
tion of therapeutic strategies to those patients is possible 
accordingly. Thus, we decided to conduct an overview 
of systematic reviews to summarise and synthesise the 
available evidence about the effectiveness of drug inter-
ventions in the prevention of SCD in HFrEF and catego-
rised the evidence into effective, ineffective and unclear 
evidence of effectiveness.
MEthODs
We developed an a priori protocol for this review 
according to the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses statement (online supple-
mentary file S1) and registered it in the PROSPERO 
International prospective register of systematic reviews 
(CRD42017067442).
Data sources and search strategy
Using the Ovid online interface, we searched MEDLINE 
(up to 24 May 2017), Embase (up to 23 May 2017), ISI 
Web of Science and the Cochrane Library (up to 24 May 
2017). We identified overviews, systematic reviews and 
meta-analyses of randomised clinical trials by means of 
a search strategy (available on online supplementary 
file S2). The search strategy was composed of a filter,7 8 
a mixture of Medical Subject Heading terms (MeSH and 
EMTREE in MEDLINE and Embase, respectively), text 
words as well as a truncation when possible without any 
language or publication date restriction. We did not 
search conference proceedings nor the grey literature. 
Reference lists of the included reviews were manually 
checked for any additional eligible studies. We contacted 
corresponding reviews’ and primary studies’ authors to 
seek for relevant unreported data. If judged necessary, 
we intended to update the included reviews by searching 
primary studies published after the systematic review 
publication date. Apart from authors’ expertise in the 
field, we decided to update if the most up-to-date review 
of a drug intervention was published more than 5 years 
ago and/or new clinical trials are not integrated into the 
evidence.
selection criteria and data abstraction
Studies were eligible if they were overviews, systematic 
reviews and meta-analyses of randomised clinical trials 
that evaluated the effectiveness of drug interventions in 
patients with HFrEF. Reviews were included if they exam-
ined the effectiveness of the following drugs: BBs, ACE-i, 
ARBs, antialdosterones or mineralocorticoid receptor 
antagonists, amiodarone, antiarrhythmics, combined 
ARB/neprilysin inhibitors, statins and fish oil supple-
mentation. The selected reviews should have contained 
at least one of the aforementioned HF therapy and had 
evaluated SCD and/or all-cause mortality prevention as 
outcomes. We used Endnote and Rayyan9 to remove dupli-
cates during the selection based on titles and abstracts, 
and full-text screening.
The abstracted data included eligibility criteria, popula-
tion type, ejection fraction, study design (including inter-
vention and comparator arms), follow-up duration and 
authors’ evaluation of outcomes. Two reviewers (MA and 
SA) independently abstracted data. We resolved discrep-
ancies by consensus or by adding a third reviewer’s judge-
ment when necessary.
Quality assessment of the included reviews
Methodological quality of the included reviews
Two authors (MA and SA) independently used the 
AMSTAR (Assessing the Methodological Quality of 
Systematic Reviews) measurement tool to assess systematic 
reviews included in our overview. The AMSTAR checklist 
comprises 11 questions (online supplementary S3 table) 
and each question accounted for one score point.10 The 
answer of ‘yes’ gave a score of 1 and zero otherwise. This 
increasingly adopted tool was used at the data collection 
step as stipulated in the overview protocol.11 If the authors 
of included reviews failed to publish their protocol, we 
deducted a score of one. In addition, we scored ‘yes’ if 
the authors mentioned that two reviewers were involved 
in the study screening, selection or data extraction.
Quality of evidence in the included reviews
Two authors (MA and SA) independently used the 
Grading of Recommendations, Assessment, Develop-
ment and Evaluation (GRADE) approach12 to assess the 
quality of evidence of each intervention. GRADE is a 
widely accepted tool that allows the assessment of five key 
elements: risk of bias, inconsistency, indirectness, impreci-
sion and publication bias. GRADE categorises the quality 
of evidence into four levels: high, moderate, low and very 
low. In the presence of a high risk of bias, the quality of 
the evidence is downgraded from high to moderate and 
so on. We also reported the GRADE assessments reported 
by the authors of the included reviews, or assessed them 
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otherwise. Moreover, we did not reassess the risk of bias 
at primary study level if authors of included reviews 
had sufficiently assessed their quality. In the case of the 
updated review of ARBs, however, we assessed the quality 
of newly added randomised clinical trials and integrated 
it into the evidence synthesis.
statistical analysis and data synthesis
We provided a narrative synthesis of the findings of the 
included reviews and if multiple reviews existed for the 
same intervention. However, in the case of ARBs, we 
updated the evidence and meta-analysed the data using 
random effects and fixed effects model with Mantel-
Haenszel methods13 and reported random effects model 
to account for heterogeneity. Meanwhile, we evaluated 
each intervention against our outcomes of interest and 
synthesised the evidence taking into account heteroge-
neity and inconsistencies between reviews. As a rule of 
thumb, I2 (I-square) values of 25%, 50% and 75% corre-
spond to low, moderate and high levels of heterogeneity, 
respectively.14
For the purpose of our overview, we categorised 
the evidence of the included interventions into three 
categories: (1) effective interventions; (2) ineffective 
interventions; and (3) uncertain evidence (conflicting 
or inconclusive evidence). We used odds ratios (OR) 
and relative effect or risk ratio (RR) as a summary statistic 
from the most recent or largest published systematic 
reviews, and confidence intervals (CIs) of 95% with a 
significance level determined at two-sided alpha less than 
5%.
Patient and public involvement
Our study did not involve direct contact with patients or 
the public.
rEsults
search result
According to our predefined eligibility criteria, our 
search strategy in electronic databases and manual 
searches resulted in 41 studies.6 15–54 Figure 1 shows 
the search strategy results. At full-text level, we 
excluded studies that did not assess our outcome of 
interest (n=129), were narrative reviews (n=4), did 
Figure 1 Flow chart for search result.
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not include HF patients (n=8), included preserved 
patients with HF (n=3), were duplicate or had no full 
text (n=2).
Characteristics of the included reviews
As shown in table 1, the population of the included 
reviews consisted of HF patients with an ejection frac-
tion ≤45% in most studies and a corresponding New 
York Heart Association classification ranging from I 
to IV. The effectiveness of each drug intervention has 
been assessed in at least one review. All reviews were 
systematic, except two reviews for antiarrhythmic 
drugs (AADs). At the time of their publication, 15 out 
of 41 reviews (37%) had corresponding authors based 
in the USA, 7 (17%) in Canada, 6 (15%) in China, 3 in 
Chile, 2 in France, 2 in the UK and the 6 remaining in 
other countries.
The disclosure and reporting of financial resources or 
funding varied from one study to another. Twenty-one 
reviews (51%) did not report the source of funding. Ten 
reviews (24%) reported financial supports that included 
governments, academic institutions and device industry. 
Six reviews declared financial resources as none or no 
external funds. Three reviews reported industry spon-
sorship for at least one author. One review53 stated that 
one author obtained funds for the review without clar-
ifying the source (online supplementary S4 table). We 
also reported findings summary of each review as stated 
by their respective authors (table 1).
risk of bias and quality of reviews
As shown in table 1, the AMSTAR scores for quality 
assessment of the included reviews widely ranged 
from 2 to 10 (out of 11). All reviews had one score 
less because of non-listing of excluded primary studies 
except Cochrane reviews,27 41 which scored 10 because 
of non-inclusion of grey literature in the search strategy 
in one review and missing information for funding 
resources of included primary studies in another, cited 
respectively (online supplementary S3 table). We did 
not assess the AMSTAR score for six studies, of which 
two46 47 were narrative reviews, two25 44 were individual 
participant or patient data meta-analyses and the other 
two26 32 were overviews of reviews.
The risk of bias of the included primary studies 
within reviews remained as judged by the original 
reviews’ authors with the exception of the newly added 
randomised trials in the update of the ARBs review that 
we assessed (GRADE) (table 2). The quality of evidence 
for BBs and antialdosterone agents obtained a high 
quality on the GRADE scale, while ACE-i, amiodarone 
and statins obtained a moderate quality. However, 
combined ARB/neprilysin inhibitors had a moderate 
and high quality for SCD and all-cause mortality 
outcomes, respectively, whereas ARBs had a low quality 
of evidence (table 2).
Up-to-dateness of included reviews
Most retrieved evidence was published within the last 
10 years (2008 and on), and seven (out of nine) drug 
interventions with updated systematic reviews were 
within the last 5 years (2012 and on). Moreover, we 
updated the pooled results for ARBs, which resulted 
in slightly different results compared with the original 
Cochrane review.27
Effectiveness of interventions
We report below the summaries of our evaluation on 
the effectiveness of the drug interventions considered 
that we have categorised into effective, ineffective and 
uncertain effectiveness (inconclusive or conflicting 
evidence).
EffECtIvE IntErvEntIOns
beta-blockers
Meta-analyses and systematic reviews of randomised 
controlled trials15–20 provided overwhelming evidence 
that BBs decrease the risk of SCD and all-cause mortality 
in patients with HFrEF. The quality of the evidence was 
rated high with a relative effect of 0.69 for SCD (OR, 
95% CI (0.62 to 0.77)) and of 0.67 for all-cause mortality 
(OR, 95% CI (0.59 to 0.76)) (table 2).
Antialdosterone agents
Published studies about mineralocorticoid receptor 
antagonists (antimineralocorticoids) or (so-called) 
antialdosterones appeared effective in SCD and all-cause 
mortality prevention.21 22 54 However, in a recent system-
atic review,21 adverse effects (hyperkalaemia, degra-
dation of renal function and gynaecomastia) were 
significantly higher in the antialdosterone-treated group 
compared with placebo. The quality of the evidence was 
rated high with relative effect for SCD (RR 0.81, 95% CI 
(0.67 to 0.98)) and all-cause mortality (RR 0.81, 95% CI 
(0.74 to 0.88)) (table 2).
Arb/neprilysin inhibitor
One meta-analysis23 estimated the effects of combined 
neprilysin renin-aldosterone system inhibition and 
reported a reduction in SCD and all-cause mortality. 
The finding was principally derived from one RCT 
(PARADIGM-HF)5 that showed about 16% reduction 
of all-cause mortality in favour of sacubitril/valsartan 
(LCZ696 previously) compared with enalapril (an 
ACE-i). This mortality reduction was attributed to a 
decline on both SCD (20%) and pump failure deaths.55 
Table 2 shows the relative effect for SCD (RR 0.81, 95% 
CI (0.69 to 0.95)) and all-cause mortality (RR 0.86, 
95% CI (0.79 to 0.94)). The moderate quality of the 
evidence for SCD outcome was due to the estimation 
from one single clinical trial and the absence of data 
from other included studies. All-cause mortality was, 
however, rated as high with a possibility of downgrading 
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in case of a detectable publication bias or unestablished 
class effect.
InEffECtIvE IntErvEntIOns
ACE inhibitors
 Although two systematic reviews,24 25 with an AMSTAR 
score of 2/11 and 3/11, respectively, reported a decline 
in total mortality and less progressive HF deaths, SCD 
events did not significantly decrease (OR 0.91, 95% CI 
(0.73 to 1.12)). The quality of the evidence was rated as 
moderate because of the unclear or high risk of bias in 
included primary studies (table 2).
Angiotensin receptor blockers
As shown in figures 2 and 3, we updated a Cochrane 
review27 by including more eligible primary studies such 
as SUPPORT trial.56 Comparing ARBs with controls 
resulted in a slightly different effect size estimation. 
Eventually, we did not combine the different control 
groups to account for heterogeneity. In stratified anal-
yses, ARBs compared with placebo remained ineffective 
for all-cause mortality (RR 0.79, 95% CI (0.55 to 1.13)). 
Similarly, ARBs, compared with ACE-i or in combina-
tion versus ACE-i alone, were not superior in all-cause 
mortality reduction (RR 0.87, 95% CI (0.56 to 1.36); RR 
0.99, 95% CI (0.90 to 1.09), respectively) (figure 2). The 
quality of the evidence is rated as low because of risk of 
bias, imprecision and inconsistency (I2≈78, p=0.010 for 
SCD outcome) (table 2). Data were limited for studies 
reporting SCD, in particular those comparing ARBs 
versus placebo, or versus ACE-i (figure 2). In addition, 
the funnel plot for all-cause mortality outcome showed 
no evidence of publication bias (figure 4). No estima-
tion of publication bias and no funnel plot was drawn 
for SCD as only five studies reported this outcome.
statins
Published systematic reviews and meta-analyses about 
statins in HF were inconsistent6 32–40 with a recent 
tendency towards inefficacy in total mortality and SCD 
prevention. The quality of the evidence was rated as 
moderate because of a likelihood of publication bias 
revealed on the most up-to-date systematic review6 
(table 2).
unClEAr EvIDEnCE Of EffECtIvEnEss
The evidence of effectiveness of the drug interventions 
reported below was considered uncertain due either to 
conflicting or inconclusive evidence.
Amiodarone and AADs
Recently published systematic reviews41 43 for 
amiodarone showed a significant reduction for SCD 
but not for all-cause mortality with less favourable net 
clinical benefits.42 Other older reviews44 45 of minor 
quality (AMSTAR of 3/11 and 5/11 cited respectively) 
reported a decline of both SCD and all-cause mortality. A
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The quality of evidence for amiodarone was rated as low 
because of the unclear or high risk of bias and poten-
tial publication bias in primary studies (table 2). No 
systematic review for AADs of other classes or drugs 
(other than amiodarone) were retrieved. Nevertheless, 
two narrative reviews46 47 reported that class I antiar-
rhythmics increased SCD and all-cause mortality. These 
narrative reviews called for caution regarding the mixed 
results of amiodarone and its adverse effects.
Omega-3 polyunsaturated fatty acids (PufAs) and fish oil 
supplementation
No systematic review was exclusively conducted in 
patients with HF for this intervention. One primary 
study,57 known as GISSI-Prevenzione HF, recruited 
patients with chronic HF and reported a lower mortality 
events in the n-3 PUFAs group compared with the 
placebo group. The authors reported an adjusted HR 
of 0.91 (95.5% CI 0.833 to 0.998), p=0.041). However, 
Table 2 Summary of findings and GRADE evaluation for sudden cardiac death (SCD) and all-cause mortality prevention 
Drug interventions for SCD and all-cause mortality prevention in heart failure patients
Outcome Intervention/comparison
Assumed 
risk with 
comparator
Corresponding risk 
with intervention
Relative effect
(95% CI)
Number of 
participants
(no. of studies)
Quality of the 
evidence
(GRADE) Comments
SCD
Beta-blockers/placebo 77 per 1000 54 per 1000
(49–60)
OR 0.69
(0.62 to 0.77)
24 779
(26 RCTs)
⊕⊕⊕⊕ High* I2=0% (p=0.57)
Antialdosterone inhibitor/
placebo; ‘usual care’
61 per 1000 49 per 1000
(41–60)
RR 0.81
(0.67 to 0.98)
8301
(5 RCTs)
⊕⊕⊕⊕ High* I2=8% (p=0.36)
ARB; neprilysin inhibitor/ACE-i 74 per 1000 60 per 1000
(51–70)
RR 0.81
(0.69 to 0.95)
8399 (1 RCsT) ⊕⊕⊕⊝ 
Moderate†
ACE-i/placebo 59 per 1000 54 per 1000
(43–65)
OR 0.91
(0.73 to 1.11)
6988 (30 RCTs) ⊕⊕⊕⊝ 
Moderate‡
I2=0% (p=0.94)
ARB (or ARB+ACE i)/Placebo; 
ACE-i
See comment See comment Not estimable 13 884 (5 RCTs) ⊕⊕⊝⊝
Low‡§
I2=78% (p=0.010). 
Overall, we did 
not pool the 
studies because of 
heterogeneity
Statins/placebo; ‘usual care’ 108 per 1000 100 per 1000
(76–131) (99 per 
1000
(72–131))
RR 0.92
(0.7 to 1.21)
(OR 0.90
(0.64 to 1.24))
10 077 (8 RCTs) ⊕⊕⊕⊝ 
Moderate¶
I2=42.6% (p=0.094)
Amiodarone/placebo; ‘usual 
care’
118 per 1000 93 per 1000
(79–110)
RR 0.79
(0.67 to 0.93)
5006 (11 RCTs) ⊕⊕⊝⊝
Low¶‡
Omega 3 fatty acids/placebo; 
‘usual care’
93 per 1000 88 per 1000
(77–102)
RR 0.94
(0.82 to 1.09)
6975 (1 RCT) ⊕⊕⊕⊝ 
Moderate†
All-cause mortality
Beta-blockers/placebo 178 per 1000 127 per 1000
(113–141)
OR 0.67
(0.59 to 0.76)
24 779
(26 RCTs)
⊕⊕⊕⊕ High* I2=40 % (p = 0.02) 
Antialdosterone inhibitor /
placebo; ‘ usual care’ 
200 per 1000 162 per 1000
(148–176)
RR 0.81
(0.74 to 0.88)
9019 (10 RCTs) ⊕⊕⊕⊕ High I2= 0% (p= 0.56) 
ARB; neprilysin inhibitor /ACE -i 183 per 1000 158 per 1000
(145–172)
RR 0.86
(0.79 to 0.94)
14 742 (3 RCTs) ⊕⊕⊕⊕ High I2= 0% (p = 0.42) 
ACE-i/placebo 219 per 1000 178 per 1000
(158–198)
OR 0.77
(0.67 to 0.88)
7105 (32 RCTs) ⊕⊕⊕⊝ 
Moderate
I2=0% (p= 0.95) 
ARB (or ARB+ACE -i)/ placebo; 
ACE-i.
183 per 1000 177 per 1000 
(161–197)
RR 0.97 (0.88 to 
1.08)
19 510 (27 RCTs) ⊕⊕⊝⊝
Low‡**
I2= 24% (p = 0.14) 
Statins/placebo; ‘usual care’ 273 per 1000 240 per 1000 (205–
278) (233 per 1000
(199–273))
RR 0.88 (0.75 to 
1.02) OR 0.81
(0.66 to 1)
11 024 (13 RCTs) ⊕⊕⊕⊝ 
Moderate¶
I2= 37.7% (p =0.083) 
Amiodarone/placebo; ‘usual 
care’ 
264 per 1000 237 per 1000
(211–266)
RR 0.90
(0.80 to 1.01)
5006 (11 RCTs) ⊕⊕⊝⊝
Low¶‡
Omega 3 fatty acids/ placebo; 
‘usual care’ 
291 per 1000 274 per 1000
(253–294)
RR 0.94
(0.87 to 1.01)
6975 (1 RCT) ⊕⊕⊕⊝ 
Moderate
*Although graded high, this might be downgraded into moderate if we strictly consider the risk of bias of primary studies other than an overall estimation.
†Estimation comes from one single clinical trial. No data obtained from other relevant studies for this outcome.
‡The studies reported to generally have a moderate to high risk of bias due to allocation concealment and blinding reporting.
¶Likelihood of publication bias presence with an asymmetric funnel plot.
§Inconsistent results ranged from no effect to insignificant increase of events (I2≈  71%).
**Most studies have small sample and wide CIs including no effect with appreciable harm or benefit.
ACE-i, ACE inhibitors; ARBs, angiotensin receptor blockers; GRADE, Grading of Recommendations, Assessment, Development and Evaluation; I2, between-study 
variance due to heterogeneity; RR, risk ratio.
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relative risk in our analysis remained statistically insig-
nificant (RR 0.94, 95% CI (0.87 to 1.01), p=0.10) and 
(RR 0.94, 95% CI (0.81 to 1.09), p=0.42) for all-cause 
mortality and SCD, respectively. Our assessment of the 
quality of the evidence involving GISSI-Prevenzione 
HF was moderate because of an absence of data of 
any other relevant studies (table 2). In addition, some 
recent systematic reviews48–51 included patients regard-
less of their cardiovascular disease and concluded of 
no clear effect, insufficient evidence or no reduction 
on SCD and all-cause mortality outcomes. Meanwhile, 
some older studies52 53 reported that omega-3 fatty acids 
and fish oil supplements (other than α-linolenic acid53) 
reduced SCD and all-cause mortality.
DIsCussIOn
Our assessment of the effectiveness of drug interven-
tions to prevent SCD in patients with HFrEF indicated 
that BBs, antialdosterone agents, as well as combined 
ARB/neprilysin inhibitors were effective.
Previously reported meta-analyses and systematic 
reviews of RCTs15–20 indicated that BBs are effective in 
the prevention of SCD and all-cause mortality in HFrEF. 
Figure 2 Efficacy of angiotensin receptor blockers (ARBs) compared with placebo, angiotensin-converting enzyme inhibitor 
(ACE-i) or combined in heart failure with reduced ejection fraction (HFrEF) for the prevention of all-cause mortality.
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However, although they were increasingly used as a 
usual ‘routine’ care in the compared arms of the more 
recently published clinical trials,58 BBs stayed underused 
for long time and may still be.59 Mineralocorticoid 
receptor antagonists or antialdosterone drugs have 
been reported effective in HFrEF by reducing SCD and 
all-cause mortality.21 22 54 60 Our summary of the findings 
and the consistency of the results support this claim 
Figure 3 Efficacy of angiotensin receptor blockers (ARBs) compared with placebo, angiotensin-converting enzyme inhibitor 
(ACE-i) or combined in heart failure with reduced ejection fraction (HFrEF) for the prevention of sudden cardiac death (SCD).
Figure 4 Funnel plot of SE (log OR) by OR to evaluate publication bias for the efficacy of angiotensin receptor blockers (ARBs) 
compared with control in heart failure and reduced ejection fraction (HFrEF) for the prevention of all-cause mortality.
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with a high quality of evidence. Only one retrieved 
meta-analysis23 supported the effectiveness of combined 
ARB/neprilysin inhibitor. The authors acknowledged 
the limitation of their meta-analysis, which was not 
based on a systematic review, but merely pooling three 
well-known trials published in high impact journals (ie, 
IMPRESS,61 OVERTURE62 and PARADIGM-HF).5 The 
quality of the evidence is, however, moderate for SCD 
and high for all-cause mortality, although our inability 
to assess any presence of a class effect or a potential 
publication bias.
We found that ACE-i showed a total mortality reduc-
tion in clinical trials and systematic reviews of patients 
with HF.24 25 However, our overview showed that ACE-i, 
surprisingly, did not significantly decrease SCD with a 
moderate quality of evidence.
In addition, we found that neither ARBs nor 
statins reduced SCD and/or all-cause mortality. Our 
findings for ARBs were in agreement with Jong and 
colleagues,31 Shibata et al28 and Dimopoulos et al,30 
but in contradiction to Lee et al29 and Rain and Rada’s 
conclusions.26 Our up-to-date meta-analysis for ARBs 
included only five primary studies, but large-scale 
trials, that reported SCD events. Eventually, we did 
not pool all the different comparators together but 
separately estimated the effect size for each group to 
account for the heterogeneity. Moreover, the addi-
tion of current trials such as SUPPORT56 improved 
the statistical power of detecting an effect if existed 
and the summary statistic remained statistically insig-
nificant (figure 2). Of note, Jong and colleagues31 
attributed this inefficacy of ARBs in HF to the back-
ground treatment with ACE-i.
Within the current evidence, ARBs should not be seen 
as interchangeable with ACE-i, which also showed a 
neutral effect on SCD, without a proper reason. There-
fore, in a high-risk SCD patient, another therapeutic 
strategy should be sought, and an ARB/neprilysin 
inhibitor might be an alternative in patients similar to 
those of the PARADIGM-HF trial.5
The addition of statins to the therapy regimen of 
patients with HF had no survival benefits. Actually, a 
recent systematic review and meta-analysis indicated 
that statins did not reduce SCD nor all-cause mortality.6 
Our current study reached the same conclusion with 
similar quality of evidence.
Our overview showed unclear evidence of effective-
ness of omega-3 PUFAs, fish oil supplementation and 
AADs. The latter intervention had an evidence origi-
nated from only narrative reviews, as we did not identify 
any systematic reviews. Also, only one n-3 PUFA clinical 
trial57 was conducted in patients with HF and reported 
a statistically significant mortality reduction; this result 
was not supported by other trials and recent systematic 
reviews,48–51 a finding that justified our conclusion of 
unclear evidence. Moreover, no other data or system-
atic reviews conducted in HF were retrieved by our elec-
tronic and manual searches.
AADs are classified into four categories46: sodium 
channel blocking drugs (class I), BBs (class II), potas-
sium channel blockers (class III) and calcium channel 
blockers (class IV). We found inconclusive evidence 
of effectiveness of all categories, with the exception of 
BBs. The evidence of effectiveness of class I, III and IV is 
inconclusive, neutral or even detrimental to patients as 
for class I AADs.46 47 Amiodarones, which present class I, 
II, III and IV effects, reported mixed results with poten-
tial SCD prevention with adverse effects43 and poten-
tially, but rare,63 life-threatening proarrhythmias.46
Our overview has some limitations. First, we limited 
the scope of our study to drug treatment, thus excluding 
devices like ICDs. We believe that non-drug devices should 
be tackled in future research. European Society of Cardi-
ology (ESC) Guideline (2016)64 and others (eg, www. 
uptodate. com) recommend the use of ICDs for only ≤35% 
of patients with HF and only after optimisation of drug 
therapy. In fact, SCDs occur in both reduced and preserved 
HF. Our overview might help to optimise therapy as a first 
step before introducing ICDs, which applies to a limited HF 
subpopulation, regardless of costs. Second, we may have 
failed to include other drug interventions used in HFrEF. 
Such drug candidates include digoxin, If-channel blockers 
(ivabradine), hydralazine/isosorbide dinitrate, nitroglyc-
erin and phosphodiesterase 3 or 5 inhibitors. However, 
our overview included most commonly prescribed and 
evidence-based pharmacological therapy in HF as prespec-
ified in our published protocol.11 Third, we did not use 
specific drug names in our literature search strategy, in 
order to avoid omitting a therapy that evaluated SCD 
and/or all-cause mortality prevention in patients with HF. 
Fourth, we based our analyses on existing systematic reviews 
and meta-analyses, and we updated only one meta-analysis. 
Consequently, we were unable to update the evidence for 
ACE-i. Furthermore, as indicated by the AMSTAR score, the 
methodological quality of some of the existing reviews was 
suboptimal. Fifth, we did not assess the safety of the evalu-
ated drug interventions, nor the contraindications for their 
prescription, drug–drug interactions, as well as treatment 
adherence. Indeed, we considered that these important 
aspects were out of the scope of our analysis. Sixth, we were 
unable to do a sensitivity analysis, initially suggested in our 
protocol, for ischaemic versus non-ischaemic HF due to 
limited data availability. Finally, a potential source of bias 
relates to authors of this overview being the authors of three 
of the included reviews.16 21 65 However, the adopted meth-
odology is in line with systematic reviews guidelines and 
ensured a double check of data and methodological eval-
uation by at least two reviewers and a published protocol.11
It is noteworthy that high-quality evidence does not 
necessarily imply strong recommendations, and strong 
recommendations can arise from low-quality evidence.66 
Therefore, when one intervention is graded high, it is not 
our intention to say that it is highly recommended, as we 
did not assess the level of recommendation in our study. In 
fact, a level of recommendation depends on the strength of 
evidence and (among others) on values and preferences of 
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patients, net benefits and cost-effectiveness of a particular 
intervention.
Implications for practice
Our study summarises and synthesises the effectiveness of 
most evidence-based drug interventions in patients with 
HFrEF for SCD prevention. It classified drug interven-
tions according to the current evidence of their effective-
ness. This categorisation could help health professionals 
and patients making evidence-based decisions based on 
updated knowledge, particularly whenever a high-risk SCD 
patient is identified. Currently, there is no an established 
strategy to deal with patients at high risk of SCD. In such 
patients, a particular attention should be considered, and a 
careful selection of available therapeutic options is needed. 
Furthermore, there might be a shift towards an alternative 
therapeutic strategy based on SCD prevention-effective 
drugs in light of our findings.
COnClusIOn
Our overview indicates that only three drug interventions 
(BBs, antialdosterones, combined ARB/neprilysin inhibi-
tors) significantly reduce SCD and improve overall survival 
among individuals with HF and reduced ejection fraction. 
However, there is no evidence of effectiveness of ARBs to 
reduce neither all-cause mortality nor SCD (with a low 
quality of evidence), and ACE-i do not significantly reduce 
SCD events. When the goal of drug therapy is to reduce 
SCD, especially in high-risk patients, our synthesis supports 
the use of the most effective regimen.
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Abstract 
Introduction 
The addition of statins to standard care in heart failure (HF) patients remains 
controversial in clinical practice. Large-scale clinical trials failed to show mortality 
benefits but uncertainty persists in real-world settings. 
Objective  
We evaluated whether the prescription of statins at hospital discharge is associated with 
a reduction in all-cause mortality up to one year of follow-up in HF patients.  
Methods 
Analysis of EPICAL2 patients who were admitted to 21 hospitals located in northeast 
France for acute HF between October 2011 and October 2012 and who received statins 
at discharge compared to patients who did not. We used a propensity score matching 
and instrumental variable analyses to estimate the treatment effects of statins, and a 
multivariable Cox proportional hazards model to examine survival with statin use, 
adjusting for patient demographics, HF characteristics, medical history, comorbidities, 
drug treatment and other known potential confounders. We plotted Kaplan-Meier survivor 
curves and used log-rank test to determine the equality of survivor functions.  
Results 
We included 2032 patients in this investigation: 919 (45%) in the statin-treated group and 
1,113 (55%) in the control group. The estimated average statin-treatment effects for all-
cause mortality in HF failed to demonstrate a significant effect on mortality [Z: -1.73; 95% 
CI: (-0.11 to 0.007), p-value: 0.083] and [Z: -0.95; 95% CI: (-1.34 to 0.46), p-value: 0.34] 
for propensity score matching and instrumental variable analyses, respectively. 
Moreover, the Cox proportional-hazard model showed that statins prescription was not 
significantly associated with the rate of death [Hazard ratio: 0.85, (95% CI 0.66 to 1.11), 
p-value: 0.26], adjusted for all confounders.  
Conclusion 
In patients with heart failure (HF), the prescription of statins was not associated with better 
survival after one year of follow-up in the EPICAL2 cohort. We cannot exclude that a 
subpopulation of HF patients may have some benefits compared to the whole HF 
population or that there might be a lack of power to show such effect. 
Keywords 
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 KEY POINTS 
There is moderate evidence from large-scale clinical trials and meta-analyses that 
statins failed to reduce mortality in heart failure (HF) patients, including ischemic 
cardiomyopathy.  
Scarce real-world data exist in the literature to encourage or discourage the use of 
statins in clinical practice. 
The EPICAL2 observational cohort study failed to show mortality benefits for statins use 
post-discharge in line with large-scale clinical trials but we do not exclude potential 
benefits in a particular HF subpopulation.  
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1. Introduction    
Despite progress and current advances in heart failure (HF) therapies, 50% of patients 
die within five-years of initial diagnosis [1]. Therefore, there is a growing need to prevent 
all-cause mortality and to optimize therapeutic strategies. 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-Co A) reductase inhibitors or simply statins, in addition to drugs 
recommended in HF (angiotensin converting enzyme inhibitors, β blockers, 
mineralocorticoid inhibitors), have been hypothesized to further reduce mortality 
compared to usual care. However, HF patients were systematically excluded from most 
clinical trials with statins, leaving us with limited data and moderate evidence [2]. Unlike 
large-scale clinical trials [3, 4], some observational studies reported that statins were 
effective in all-cause mortality reduction [5, 6] raising discrepancies and debates. 
Therefore, it appeared important to find out if a further analysis of a well-conducted 
observational study could add a new evidence to the current literature. In our analysis, 
we used data from the Epidemiologie et Pronostic de l'Insuffisance Cardiaque Aiguë en 
Lorraine (EPICAL2) cohort study of 2,254 hospitalized acute HF patients, recruited 
between October 2011 and October 2012 from 21 hospitals located in the Lorraine region 
of northeast France to examine if the prescription of statins at hospital discharge for an 
HF-related hospitalization was associated with better 1-year survival.  
 
2. Methods  
 
2.1 Participants 
The methods of recruitment and patient characteristics were already published elsewhere 
[7, 8]. In brief, this cohort (EPICAL2, NCT 02880358) included 2,254 patients who were 
hospitalized in the Lorraine region of northeast France (2,350,000 inhabitants, according 
to the 2012 census) for acute HF between October 2011 and October 2012, and followed 
during one year after hospital discharge. In the present analysis, we excluded patients 
who died before discharge from the index hospitalization, who had unknown prescription 
status for statins or those who were lost to follow-up or had an unknown vital status after 
one year of follow-up from the index hospitalization (Figure 1).  
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The EPICAL2 cohort study was conducted according to the principles of the Declaration of 
Helsinki and approved by national ethics committees (Comité Consultatif sur le Traitement de 
l'Information en Matière de Recherche, Comission Nationale de l’Informatique et des Libertés). 
All eligible patients were informed about the study protocol and were free to refuse to be included 
in the cohort. 
2.2. Variables selection 
Independent variables used for the present analysis were those known to influence 
mortality and those that might be related to initiating or maintaining statin treatment. 
These variables were age, gender, hypertension, body mass index (BMI), left ventricular 
ejection fraction, NYHA class III or IV, increased BNP or NT pro-BNP, hemoglobin level, 
alcohol abuse, smoking status, previous history of HF, hospital stay duration,  angina, 
history of stroke/ transient ischemic attack (TIA),  arrhythmias, dyslipidemia,  history of 
acute coronary syndrome, chronic obstructive pulmonary disease (COPD)/Asthma,  
diabetes, chronic kidney disease, malignant hemopathies or any cancer, current 
treatment with beta-blockers, angiotensin-converting enzyme inhibitors, and 
spironolactone. We included the prescription of beta-blockers, angiotensin-converting 
enzyme inhibitors, and spironolactone among selected variables because they are known 
to be associated with a better prognosis [7, 9]. We defined the variable “increased BNP 
or NT-proBNP (pg/mL)” based on the literature [8, 10] at the time of EPICAL2 recruitment 
phase: BNP >400 pg/ml or NT-proBNP >450 pg/ml in patients <50 years, NT-proBNP 
>900 pg/ml in patients 50-75 years, NT-proBNP >1800 pg/ml in patients >75 years.  
2.3. Statistical analysis  
For bivariate analyses, we used Pearson chi-square for dichotomous categorical 
variables and two-sample unpaired t-test for continuous variables. We assumed that the 
data were normally distributed and used the Shapiro-Wilk and the Shapiro-Francia test 
statistics to verify normality in addition to plotting histograms. We reported the baseline 
characteristics between compared groups. In our study, patients with missing data were 
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deleted from the analyses. We considered a two-sided alpha value of <5% as statistically 
significant. We analyzed data with STATA version 14.2 (StataCorp LP, Texas).  
2.3.1. Propensity score analysis 
Propensity score has been defined as the conditional probability of assignment to a 
particular treatment (here statins) given a vector of observed covariates [11]. Propensity 
scores allow reducing bias and increasing precision of treatment effects estimation [12, 
13]. We calculated the propensity scores (i.e., the probability of being treated with statins) 
using multivariable logistic regression, without including the outcome (all-cause mortality) 
and performed balance assessment tests to compare the distribution of covariates 
between treated and control patients [14]. We used one-to-many matching with 
replacement as it produced better balance between treated and control groups than one-
to-one matching without replacement. Then we estimated treatment effects and their 
standard errors using propensity score matching methods within a caliper distance of 0.2 
[15, 16]. On the propensity score step calculation, we included variables associated with 
both the outcome and the treatment assignment.The selected independent variables 
were age, gender, hypertension, BMI, left ventricular ejection fraction (LVEF), NYHA 
class III or IV, increased BNP or NT pro-BNP, hemoglobin level, alcohol abuse, smoking 
status, hospital stay duration,  angina, history of stroke/TIA, arrhythmias, dyslipidemia, 
history of acute coronary syndrome, COPD/asthma,  diabetes, chronic kidney disease, 
malignant hemopathies or any cancer, atrial fibrillation and prescription of beta-blockers, 
angiotensin-converting enzyme inhibitors and spironolactone. We included all 
aforementioned variables in our models except the variable “History of heart failure” 
because of collinearity. We tested beforehand the overlap of the propensity score 
between the treated and control groups. Thereafter, we checked the balance of the mean 
of the propensity score throughout the blocks where 8 blocks was created in the 
propensity scores calculation. We intended to re-specify the selected covariates (by 
categorizing or dichotomizing, for instance) if imbalance appeared. To avoid imbalance 
between groups, we deleted the “atrial fibrillation” variable from propensity score 
calculation as it caused an unsatisfied balance. This is perhaps attributed to the 
potentially perfect prediction by the variable “arrhythmia”. Nonetheless, we re-entered this 
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variable in the propensity score model in sensitivity analyses. For the same reason of 
achieving balance of covariates, we categorized the variable “age” into three classes 
(≤65, 66-80, >80) and dichotomized the variable “hospital stay duration (days)” to less or 
more than 9 days”. Before estimating treatment effects, we further assessed the balance 
or the distribution of covariates across treated and control groups by measuring the 
standardized differences between compared groups. We measured the average effect of 
the treatment on the patients who received the treatment (i.e., the average treatment 
effects on the treated group (ATT)). In addition to ATT estimation, we reported the 
respective standard errors, coefficients, confidence intervals and p-values. 
2.3.2. Instrumental variable analysis 
Propensity scores balance for measured covariates but not necessarily for unmeasured 
covariates [16]. Conversely, the instrumental variables approach takes into account 
unmeasured variables that are associated with the treatment but not directly with the 
outcome.  As an instrumental variable, we used the prevalence of statin prescription at 
discharge in our cohort in participating hospitals, denoted F. The endogenous explanatory 
variable was the statin treatment, denoted X. The outcome was all-cause mortality, 
denoted Y. We, therefore, tested the following hypothesis: 
- F is correlated with X, conditional on other covariates  
- F has no direct effect on Y but only via X.    
Using a two-stage least squares method, we regressed the instrumental variable, the 
prevalence of statin treatment in the participating hospitals (dichotomized as above or 
below the median of 47%), on other covariates previously used for the propensity score 
analysis. We verified the null hypotheses that our instrument is weak and/or that the 
variables are exogenous (test of endogeneity).  
 
2.3.3. Kaplan-Meier survival curves and Cox proportional-hazards model 
For survival analyses, we declared our data to be time to event. Our event of interest was 
all-cause mortality while the time of follow-up was set up at 1 year and censored 
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afterwards. We plotted Kaplan-Meier survivor curves by statin treatment once unadjusted 
and adjusted on the other time for the same covariates used in the propensity score 
analysis.  
We used a log-rank test to determine the equality of survivor functions, used a stratified 
log-rank test (on propensity scores), and the stratified Wilcoxon (Breslow) test to compare 
survival curves. To illustrate the increased rate of having an event, we regressed all-
cause mortality (the outcome) on independent variables - previously adjusted for in 
Kaplan-Meier survivor curves - in a multivariable Cox proportional-hazard model with 
Breslow methods for ties. We verified the proportional-hazards assumption by a global 
test for all covariates included in the model and based on Schoenfeld residuals for all 
covariates individually. 
  
3. Results 
3.1. Participants, socio-demographic, medical history, and clinical characteristics   
As shown in Figure 1, we analyzed 2,032 subjects out of 2,254 included in the cohort. 
Those treated with statins (Treated group (45%)) were compared to those not treated with 
statins (Control group (55%)). The number of deaths in our sample was 539. Of those, 
195 (21%) occurred in the treated group versus 344 (31%) in the control group. 
Table 1 shows comparisons of demographic, clinical and therapeutic characteristics 
between the group treated with statins and the control group. Statin-group patients were 
younger, more often male, and smokers; they had less severe heart failure (HF), but more 
often angina or history of acute coronary syndrome, dyslipidemia, or diabetes. However, 
they had less often arrhythmia or atrial fibrillation related events. In addition, statin-group 
patients were more often treated with beta-blockers, angiotensin-converting enzyme 
inhibitors, and were more exposed to statins before hospitalization, but less often treated 
with spironolactone. The test of normality for the selected variables, including the Shapiro-
Wilk and Shapiro-Francia statistics, confirmed our hypothesis of normality assumption.  
 
9 
 
3.2. Propensity score matching  
Once the propensity scores calculated, we assessed the overlap of the propensity scores 
between the treated and control groups that appeared subjectively satisfying (Figure 2). 
After that, we matched the treated group to the control group and estimated the average 
treatment effects on the treated (ATT). The matched sample had 1,197 patients (60%), 
excluding 835 observations with missing values in the following covariates: LVEF, BMI, 
hospital stay duration, and hemoglobin level. We described the characteristics of 
unmatched compared to matched patients in Table 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 .2 .4 .6 .8 1
Propensity Score
Untreated Treated
Figure 2: Distribution and degree of overlap of the propensity score 
between statin-treated and control groups in the included HF patients. 
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After propensity score matching, t-tests showed that the distribution of covariates were 
balanced between treated and control groups, except for the variable hypertension that 
showed imbalance in one block. In addition, the lack of differences between the statin 
and control groups was confirmed by the standardized differences (18.2% for unmatched 
sample versus 5.3% for matched sample). In the matching step, the number of matches 
per observation that had the best distribution of covariates among compared groups was 
three (max. four) and the caliper used was 0.2 times the standard deviation of the logit of 
the propensity scores. As a result, the estimated satin-treatment effects (the average 
treatment effects on the treated, ATT) for all-cause mortality in HF showed no evidence 
of significant reduction [Coefficient: - 0.055, AI robust standard errors: 0.032, Z: -1.73; 
95% CI: (-0.11 to 0.007), p-value: 0.083]. The re-entry of the variable “atrial fibrillation” 
into the propensity score model caused unsatisfied balance in one block but the estimated 
ATT were still insignificant: [Coefficient: -0.056, AI robust standard errors: 0.029 Z: -1.89; 
95% CI: (-0.11 to 0.002), p-value: 0.058] 
 
3.3. Instrumental variable analysis  
Our instrumental variable, designated as the prevalence of statin prescription (denoted 
F) in participating hospitals, was associated with the treatment (denoted X) conditional on 
other covariates (P-value: 0.019). In addition, F showed no direct association with the 
outcome, all-cause mortality (denoted Y). The test of endogeneity (Durbin (score) and 
Wu-Hausman) failed to reject our null hypothesis that the variables are exogenous (p-
value = 0.3). With the two-stage least squares treatment estimation, the instrumental 
variable regression did not show a significant decrease of death in the statin group versus 
the control group [Coefficient: -0.43, standard errors: 0.46, Z: -0.95; 95% CI: (-1.34 to 
0.46), p-value: 0.34].  
3.4. Kaplan-Meier curves and cox-proportional hazards model 
As mentioned before, the number of deaths in our study was 539. Of those, 195 (%) 
occurred in the treated group versus 344 (%) in the control group. Unadjusted Kaplan-
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Meier survivor curves (Figure 3) and the log-rank test showed significant result (p-value 
< 0.001). However, the adjusted Kaplan-Meier survivor curves and the stratified log-rank 
test failed to show a significant difference between the statin and control groups (p-value: 
0.317) (Figure 4). We had similar results when we used a stratified log-rank test on 
propensity scores (P-value: 1.00). Moreover, the multivariable Cox proportional-hazard 
model showed that statins use was not significantly associated with the rate of death 
[Hazard ratio (HR): 0.85, (95% CI 0.66 to 1.11), p-value: 0.26] and [(HR): 0.86, (95% CI 
0.66 to 1.13), p-value: 0.3] when adjusted for the aforementioned independent variables 
or the propensity scores respectively. The test of proportional-hazard assumption was 
globally satisfied (p-value: 0.21) but it appeared that the variable “hospital stay duration” 
was not, when checked individually. Consequently, we re-ran the Cox model without this 
variable but the output stayed almost similar for statins treatment (p-value: 0.20) and the 
global test of proportional-hazard assumption was satisfied again (p-value: 0.69). 
 
4. Discussion 
Statins are not solely recommended in HF but are still widely prescribed in current practice 
[17] and, in contrast, observational studies had often reported mortality benefits [6, 18]. 
Our analysis from the cohort EPICAL2 failed to show an impact of statins on all-cause 
mortality in HF. These results are in accordance with those found in previous clinical trials 
and a meta-analysis of randomized clinical trials [2-4]. Patients who received statins were 
younger, more often men, obese, and had comorbidities (diabetes, kidney disease) but 
less severe HF, less often arrhythmia or atrial fibrillation, more often treated with beta-
blockers and angiotensin converting enzyme inhibitors, and previously more exposed to 
statins.  
Our study used propensity score matching to estimate treatment effects. This method is 
believed to reduce inherent biases like allocation or selection bias. We verified covariate 
balance by measuring standardized differences before and after matching. A balance of 
covariates is satisfied if it resulted into a standardized difference of <21.2% [19-21]. We 
estimated the ATT (i.e. an estimation on the average) because it is an interesting 
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summary of individual causal effects [22]. An Instrumental variable is often difficult to 
identify and it has to be strongly related to the treatment and indirectly to the outcome. 
An instrument is potentially bad if it is correlated with omitted variables or the error term 
[23]. Our instrument “prevalence of statin prescription by participating hospital” appeared 
potentially strong, and we were able to estimate the treatment by statins using a two-
stage least square regression. The similar results from instrumental variable approach 
and propensity score analyses might be of interest [24].  
We acknowledge several limitations. First, we adjusted for selected variables that we 
believe are related to both the treatment assignment and the outcome. Even if the 
assumption of treatment assignment ignorability is satisfied, because of selection of  
observable covariates, a selection bias still potentially exists [25]. Second, we ignored the 
fact that we could have included in our models only those variables with significant p-
values but this might have been a source of bias of not including a relevant variable that 
might affect the outcome. Third, statin treatment is considered among the cholesterol 
lowering drugs, our analysis did not include any cholesterol level measurement at 
baseline nor at follow-up. Fourth, the variables (LVEF, BMI, hospital stay duration, and 
hemoglobin level), used in the propensity score model, had missing values and the way 
to deal with this missingness involved other methods [26, 27] to be considered in further 
research and this might lead to a lack of power in our results. Fifth, Kaplan-Meier curves 
did not have censored patients other than those who survived beyond one-year follow-up 
(potential performance bias). Those who left the study before the end or lost to follow-up 
at some time during the study 1-year follow-up were deleted at pre-analysis level (Figure 
1) instead of being censored. This is due to our primary analysis method that involved 
propensity score analyses. Moreover, only all-cause mortality was recorded, not the more 
specific HF related mortality. Sixth, our study did not follow patient’s drug prescriptions by 
a family physician, for instance, after hospital discharge, nor the observance and real 
intake of statins. Finally, our study provides evidence consistent with large-scale 
randomized clinical trials and recent systematic reviews and current ESC guidelines [2-
4, 28], though it should be interpreted with caution in light of the aforementioned 
limitations.  
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In conclusion, statins prescription was not associated with a decrease in all-cause 
mortality in the statin-treated group in heart failure patients after one-year hospital 
discharge compared to those not treated with statins. Within limitations, our study adds 
an evidence to the current literature because our results are based on real-world data. 
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Figure 1. Flow chart for heart failure patients from EPICAL2 to 
evaluate statin effectiveness on all-cause mortality.  
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Selected variables  Statins 
(N=919) 
- n(%) 
No statins  
(N= 1,113)  
- n(%) 
P-value Standardized 
differences for 
unmatched 
sample (%) 
Standardized 
differences for 
matched 
sample  
Demographic 
characteristics 
     
Mean (SD) age (years) 
≤ 65 
≥ 66 - ≤ 80 
> 80  
 
74.92 (11.06) 
186 (20.24%) 
400 (43.53%) 
333 (36.24%) 
 
79.15 (SD 
11.57) 
155 (13.93%) 
329 (29.56%) 
629 (56.51 ) 
 
<0.001 
 
-30.8 
 
1.8 
Female  383 (41.68%) 536 (58.85%) <0.001 -35.9 -0.5 
      
Clinical characteristics      
Hypertension 716 (77.91%) 841 (75.56%) 0.213 2.3 -3.1 
Mean (SD) BMI (kg/m2)  
<25 (underweight or 
normal) 
≥25 - <30 (overweight) 
≥30  (Obese)  
 
28.91 (6.4) 
207 (27.20%) 
255 (33.51%) 
299 (39.29%) 
28.17 (6.7) 
310 (35.59%) 
264 (30.31%) 
297 (34.10%) 
%)0.0247 16.9 -3.0 
LVEF (%)  
< 40  
≥ 40  
 
317 (43.66%) 
409 (56.34%) 
 
311 (39.82%) 
470 (60.18%) 
0.039 11.7 -8.5 
NYHA class III or IV (%)  
(severe HF) 
734 (79.96%) 927 (83.59%) 0.034 -17.6 -3.9 
Increased BNP  or NT pro-
BNP (pg/mL)*  
580 (63.11%) 680 (61.10%) 0.351 2.4 7.1 
Hemoglobin  
< 10 g/dL 
 
97 (10.90%) 
 
121 (11.27%) 
 
0.796 
-6.7 -2.7 
      
Medical history       
Alcohol abuse  80 (8.71%) 113 (10.15%) 0.268 -3.7 4.7 
Smoking  396 (43.09%) 340 (30.55%) <0.001 29.3 2.9 
Previous history of HF  507 (55.17%) 641 (57.59%) 0.273 *  
Mean (SD) hospital stay 
duration (days) 
11.89 (10.83) 12.31(10.86) 0.3830 -3.6 5.0 
Previous angina 139 (15.13%) 95 (8.54%) <0.001 16.2 -2.7 
Previous stroke/TIA  131 (14.25%) 129 (11.59%) 0.074 5.0 3.3 
Previous or precipitating 
arrhythmias  
450 (48.97%) 700 (62.89%) <0.001 -34.2 -0.3 
Dyslipidemia  533 (58%) 299 (26.86%) <0.001 61.2 -5.9 
      
HF etiology       
Acute coronary syndrome 
(ACS) (%) 
204 (22.20%) 61 (5.48%) 
 
 
<0.001 50.3 8.3 
Comorbidities      
Table 1: Characteristics of included heart failure patients according to treatment with statins 
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COPD/asthma  216 (23.50%) 241(21.65%) 0.320 6.5 5.0 
Diabetes  378 (41.13%) 355 (31.90%) <0.001 18.3 -6.0 
Chronic renal failure 210 (22.85%) 268 (24.08%) 0.516 -9.3 -0.4 
Leukemia or any cancer  145 (15.78%) 188 (16.89%) 0.500 -7.0 -2.0 
Atrial fibrillation  266 (28.94%) 515 (46.27%) <0.001   
      
Treatments      
Beta-blocker (%) 552 (60.07%) 531 (47.71%) <0.001 19.0 3.9 
ACE-i (%) 563 (61.26%) 535 (48.07%) <0.001   
ARB (%) 151 (16.43%) 204 (8.33%) 0.262   
Spironolactone (%) 86 (9.36%) 145 (13.03%) 0.009   
Amiodarone (%) 225 (24.48%) 267 (23.99%) 0.796   
Previous exposure to 
statins  
675 (77.68%) 83 (8.01%) <0.001   
BNP >400 pg/ml or NT-proBNP>450 pg/ml in patients < 50 years, NT-proBNP > 900 pg/ml in patients (50-75 
years), NT-proBNP > 1800 pg/ml in patients >75 years [7, 9]  
SD: standard deviation; TIA: transient ischaemic attack; COPD: chronic obstructive pulmonary disease; LVEF: left 
ventricular ejection fraction; HF: heart failure.    
*deleted in models for collinearity  
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Abstract
Background and Objectives
Sudden cardiac death (SCD) is a severe burden of modern medicine. Aldosterone antago-
nist is publicized as effective in reducing mortality in patients with heart failure (HF) or post
myocardial infarction (MI). Our study aimed to assess the efficacy of AAs on mortality
including SCD, hospitalization admission and several common adverse effects.
Methods
We searched Embase, PubMed, Web of Science, Cochrane library and clinicaltrial.gov for
randomized controlled trials (RCTs) assigning AAs in patients with HF or post MI through
May 2015. The comparator included standard medication or placebo, or both. Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were fol-
lowed. Event rates were compared using a random effects model. Prospective RCTs of
AAs with durations of at least 8 weeks were selected if they included at least one of the
following outcomes: SCD, all-cause/cardiovascular mortality, all-cause/cardiovascular
hospitalization and common side effects (hyperkalemia, renal function degradation and
gynecomastia).
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Results
Data from 19,333 patients enrolled in 25 trials were included. In patients with HF, this treat-
ment significantly reduced the risk of SCD by 19% (RR 0.81; 95%CI, 0.67–0.98; p = 0.03);
all-cause mortality by 19% (RR 0.81; 95% CI, 0.74–0.88, p<0.00001) and cardiovascular
death by 21% (RR 0.79; 95%CI, 0.70–0.89, p<0.00001). In patients with post-MI, the match-
ing reduced risks were 20% (RR 0.80; 95% CI, 0.66–0.98; p = 0.03), 15% (RR 0.85; 95%CI,
0.76–0.95, p = 0.003) and 17% (RR 0.83; 95% CI, 0.74–0.94, p = 0.003), respectively. Con-
cerning both subgroups, the relative risks respectively decreased by 19% (RR 0.81; 95% CI,
0.71–0.92; p = 0.002) for SCD, 18% (RR 0.82; 95% CI, 0.77–0.88, p < 0.0001) for all-cause
mortality and 20% (RR 0.80; 95% CI, 0.74–0.87, p < 0.0001) for cardiovascular mortality in
patients treated with AAs. As well, hospitalizations were significantly reduced, while common
adverse effects were significantly increased.
Conclusion
Aldosterone antagonists appear to be effective in reducing SCD and other mortality events,
compared with placebo or standard medication in patients with HF and/or after a MI.
Introduction
Sudden cardiac death (SCD) is defined as unexpected natural death from a cardiac cause within
a short time period, generally within one hour from the onset of symptoms, in a person without
any prior condition that would appear fatal [1][2]. Patients with previous myocardial infarc-
tions (MI) or cardiac arrest or congestive heart failure (HF) were much more likely to have
inducible arrhythmias, considered as a common cause of SCD [3].
The renin-angiotensin aldosterone hormone system’s (RAAS) main function is to maintain
the homeostasis of arterial pressure and of extracellular fluids [4]. Dysregulation of this system
leads to cardiovascular (CV) disorders including left ventricular remodeling, vasoconstriction/
hypertension, and ventricular hypertrophy which may eventually result in SCD [5]. The hor-
monal cascade is initially induced by a decrease in blood volume which enhances renin secre-
tion into the blood stream, resulting in the production of angiotensin II that is responsible for
blood pressure increase via blood vessel constriction and the stimulation of the aldosterone
hormone production. Aldosterone in its turn promotes the reabsorption of sodium and water,
also leading to an increase in blood pressure [4].
Aldosterone antagonist (AA) inhibits sodium reabsorption and slightly increases water
excretion [6]. This group of drugs, including spironolactone, eplerenone, and canrenone
among others, is often used in managing chronic and congestive HF [7][8]. Officially, AA treat-
ment is recommended in clinical practice at a low-dose in all patients with a left ventricular
ejection fraction (LVEF)< 35% and severe symptomatic HF, i.e. currently New York Heath
Association (NYHA) functional class III or IV, in absence of hyperkalemia and significant
renal dysfunction, unless contraindicated or not tolerated. It is also recommended in patients
suffering acute myocardial infarction (AMI) with LVEF 40% and developing HF symptoms
or having a history of diabetes mellitus, unless contraindicated [9][10].
The benefits of AA in reducing the negative effects of aldosterone hence decreasing death
and hospitalization in HF or AMI patients have been demonstrated in four major trials, includ-
ing RALES (Randomized Aldactone Evaluation Study) [11], EMPHASIS-HF (Eplerenone in
Aldosterone Antagonists and Sudden Death in High Risk Patients
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Mild Patients Hospitalization and Survival Study in Heart Failure) [12], EPHESUS (Eplere-
none Post-AMI Heart Failure Efficacy and Survival Study) [13] and most currently TOPCAT
(Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist)
[14].
Our study aimed to assess the efficacy of AA on SCD, hospitalization admission and several
common adverse events in patients with HF or post MI.
Methods
Inclusion and exclusion criteria
We included randomized controlled trials (RCTs) comparing spironolactone or eplerenone or
canrenoate potassium to placebo or standard treatment. Studies were included if they recruited
patients with left ventricular dysfunction HF (NYHA class I to IV) and/or post AMI with Killip
scores between I and IV and indicated at least one assessment criteria. Our meta-analysis clas-
sified these patients into two corresponding sub-categories: HF and post-MI. The included
studies had to report at least one of the following outcomes: SCD, all-cause/CV mortality, all-
cause/CV hospitalization and common side effects (hyperkalemia, renal function degradation
and gynecomastia).
We excluded studies with a follow-up period< 8 weeks. Trials with inestimable treatment
effect (no event in both arms for all criteria) and small sample size (<40 patients/arm) were
excluded. The lack of double-blind and/or intention-to-treat analysis of AA efficacy was not an
exclusion criterion but was re-examined by sensibility test afterwards.
Search strategy
The research was conducted systematically from Embase, Medline (Pubmed), Cochrane
Library, Web of science and clinicaltrials.gov from 1966 to 31/05/2015 (details of search strat-
egy in S1 App). We searched for studies involving human subjects, clinical trials, RCTs and/or
meta-analyses and/or systematic reviews. No language restriction was applied. Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [15] were
followed (S2 App).
Study screening and analyzing through titles and abstracts was performed independently by
several investigators in different periods (HHL, MM, CK, TA, FG), according to the pre-speci-
fied selection criteria. Data were extracted independently and compared afterwards. The latest
screening and data extraction (through May 2015) were conducted independently by two
investigators (HHL &MM) with kappa statistics (S3 App). Cochrane bias criteria [16] were
used to evaluate the overall quality of the articles. An included trial was considered as of high
quality if all its risks of bias were low. Disagreements were discussed and decisions were made
through consensus. A third party (FG) was involved when necessary. The following informa-
tion was extracted from the studies: the first author or study name, year of publication, baseline
patient characteristics, intervention and related outcomes. Besides database searching, refer-
ence lists of all included studies, meta-analyses and reviews were manually searched for further
potential trials and/or information validation.
Outcomes assessment
The primary endpoints were SCD, total mortality and CV mortality at the end of the follow-up
duration. Secondary outcomes were hospitalization (from all causes and CV causes) and
adverse reaction events (hyperkalemia, renal function degradation and gynecomastia) by AAs.
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Statistical analysis
Kappa statistic was calculated for agreement ratio between two latest reviewers (HHL &MM)
(S3 App). We extracted aggregate data, number of events and number of patients in each sub-
group from included studies, using fixed-effect and random-effect models to pool the data.
Results were reported as relative risk (RR) at 95% confidence intervals (CI) using the Mantel
and Haenszel method for the fixed-effect model [17] or the DerSimonian and Laird method
for the random-effect model [18]. When similar outcomes were obtained by both methods, we
only reported the random-effect results to cover possible heterogeneity as several pharmaco-
logic drugs and different patients were included.
Heterogeneity across studies was estimated using I2 test [18]. I2 values of 25%, 50%, and
75% correspond to low, moderate, and high levels of heterogeneity [19]. Meta-analysis results
were considered only if the I2 value was below 75%. Potential existence of publication bias was
assessed in both subgroups at each criterion of outcome by funnel plots and verified by the
Egger tests [20] using odds ratio (OR) since firm guidance for RR is not yet available [21]. Sen-
sitivity analysis was carried out for each outcome measure to evaluate the contribution of each
study to the pooled estimate by excluding important trials/ lack of blinding trials/ lack of inten-
tion-to-treat analysis trials at one time and recalculating the combined RR for the remaining
studies. Statistical testing was two-tailed, with statistical significance declared at 5%. All analy-
ses were performed using RevMan (version 5.3) and R (version 3.2.2) softwares.
Results
Search results
Our search through Embase, Medline (Pubmed), Cochrane Library, Web of science, clinical-
trials.gov and other sources (www.clinicaltrialsregister.eu & www.trialdetails.com) returned a
total of 3653 studies. After elimination of duplicates, 3143 studies were retained for evaluation.
Through screening of titles and abstracts, 2644 and 320 irrelevant studies were respectively
excluded, respectively. Following full manuscript review of the remaining 80 studies, 54 addi-
tional ones were excluded: full-text not available (n = 10) (correspondences to authors were
made but we have not received positive responses), study period<8 weeks (n = 8), review,
editorial commentary or study design (n = 8), sub-study (n = 3), not RCT (n = 5), and out-
comes of interest not available (n = 21). Finally, 25 studies satisfying all selection criteria were
included in this meta-analysis (Fig 1). The kappa statistic indicated a subtidal agreement good
at 0.75 (IC 95% CI, 0.49–1.02; p = 0.0005) (S3 App).
The quality of evidence of included studies was relatively high: 100% of low risk for selec-
tion, attrition and reporting biases, 70% of low risk for performance bias and>85% of low risk
for detection bias (S1 Fig).
Study characteristics
In total, 25 RCTs [11],[13–14],[22–32],[33–43] were selected in this meta-analysis, which
enrolled a total of 19333 patients (9750 for AA arm and 9583 for control/placebo arm). The
mean follow-up duration was 12.42 months (1.04 year). All trials were placebo controlled
except three trials [22][23][24] which applied routine treatment. Nine trials [25][26][27][28]
[13][29][30][31][24] assessed the effect of AAs in post-AMI patients with left ventricular dys-
function; while the other trials recruited HF patients. Duration of follow-up varied from 3 to
44 months. Spironolactone was the most commonly used AAs (15 studies), followed by eplere-
none (7 studies) and canrenone (3 studies) (Table 1). The risk of bias of included trials was pre-
sented in S1 Table and S1 Fig.
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Baseline patient characteristics
Most trials included elderly people with mean age ranged from 50–80 years (Table 1). Most of
studies consisted dominantly male participants, except two trials [26][23] where more women
were recruited and the trial of Edelmann et al. [32] which had a relatively equal sex ratio.
All trials were restricted to patients without renal dysfunction (kalemia<5.5 mmol/l and
creatinine< 2.5 mg/dL) (Table 2).
Primary outcomes
Sudden cardiac death. In the 25 included articles, six accounting for 8301 subjects (4132
used AAs and 4169 received placebo/control) reported SCD events in patients with HF. In the
Fig 1. Study flowchart for the selection process of the final included trials.
doi:10.1371/journal.pone.0145958.g001
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Table 1. Main characteristics of included studies.
Studies,
(abbreviation
name), year of
publication
Patients;
duration
(follow-up);
countries
Comparison Study
design,
intention to
treat
analysis
(ITTA)
Number of
randomized
patients
(excluded
during follow-
up)
Mean age
(SD)
Male
sex
(%)
Ischemic
etiology
(%)
Ejection
fraction (%)
Boccanelli et al.
2009 (AREA-in-HF)
[35]
HF; 12 months;
Italy
Canrenone 25 mg
(titrated to 50 mg/
day) vs. Placebo
DB; without
ITTA
231(43)/ 236(42) 62.3(9.5)/
62.7(9.5)
82/85 51.1/ 52.1 39.9(8.6)/
39.7(8.6)
Chan et al. 2007
[56]
HF; 12 months;
China
Spironolactone 25
mg/day
+ candesartan vs.
Placebo
+ candesartan
DB; with
ITTA
23(0)/25(0) 61.4(12.3)/
65(0.6)
87/80 47.8/ 64.0 26(2)/28(2)
Cicoira et al. 2002
[22]
HF; 12 months;
Italy
Spironolactone 25
mg (titrated to 50
mg/day) vs. Routine
treatment
Open label,
without ITTA
54(7)/52(6) 62.5(7.9)/
61.7(9.8)
85/88 65/63 33(7)/34(7)
Deswal et al. 2011
(RAAM-PEF) [36]
HF; 6 months;
USA
Eplerenone 25 mg
(titrated to 50 mg/
day) vs. Placebo
DB; without
ITTA
23(2)*/23(0)* 72.2(9.8)*/
68.7(9.1)*
95*/
91*
NR/NR 62.1(5)*/
62.5(7.5)*
Di Pasquale et al.
2005 [25]
MI; 6 months;
Italy
Canrenoate IV 1
mg/h then 25 mg
PO/day + Captopril
vs. Placebo
+ Captopril
DB; without
ITTA
341(33)/ 346(30) 62.6(6)/ 62.8
(5)
71/71 100/100 NR/NR
Edelmann et al.
2013 (Aldo-DHF)
[32]
HFPEF; 12
months;
Germany
&Austria
Spironolactone 25
mg/day vs. Placebo
DB; with
ITTA
213(0)/209(0) 67(8)/67(8) 48/47 NR/NR 67(8)/68(7)
Gao et al. 2007 [57] HF; 6 months;
China
Spironolactone 20
mg/day vs. Placebo
DB, with
ITTA
58(0)/58(0) 55(13)/54(12) 64/66 50/52 42(11)/43
(10)
Kayrak et al. 2010
[26]
AMI; 6 months;
Turkey
Spironolactone 25
mg/day vs. Routine
treatment
Open label,
without ITTA
71(16)/71(16) 55.3(10)*/
57.2(11)*
18*/
26*
100/100 50.5(8.3)*/
49.5(8)*
Mak et al. 2009 [23] DHF; 12 months;
Ireland
Eplerenone 25 mg
(titrated to 50 mg/
day) vs. Routine
treatment
Open label,
without ITTA
24(1)/20(3) 80(7.7)/ 79
(7.9)
38/55 NR/NR 63(9.0)/64
(9.6)
Modena et al. 2001
[27]
MI; 12 months;
Italy
Potassium
canrenoate 50 mg/
day vs. Placebo
NR, with
ITTA
24(0)/22(0) 59(10)/62(13) 71/77 100/100 47(6)/46(5)
Montalescot et al.
2014 (REMINDER)
[28]
MI; 10.5 months;
International (11
countries)
Eplerenone 25 mg
(titrated to 50 mg/
day) vs. Placebo
DB; with
ITTA
506(82)/506(79) 58.5(10.8)/
57.8(11.0)
83/80 100/100 NR/NR
Pitt et al. 2014
(TOPCAT) [14]
HF; 3.3 years;
International (6
countries)
Spironolactone (15
to 45 mg/day) vs.
Placebo
DB; with
ITTA
1722(0)/ 1723(0) 68.7(median)
range 61.0–
76.4/ 68.7
(median)
range 60.7–
75.5
NR/
NR
NR/NR 56(median)
range 51–
61/ 56
(median)
range 51–62
Pitt et al. 2003
(EPHESUS) [13]
LVD after MI; 16
months (range
0–33);
International (37
countries)
Eplerenone 25 mg
(titrated to 50 mg/
day) vs. Placebo
DB; with
ITTA
3319(0)/ 3313(0) 64(11)/64(12) 72/70 100/100 33(6)/33(6)
(Continued)
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follow-up duration, the SCD rate in HF patients was 4.89% (n = 202/4132) in those treated
with AAs, compared with 6.09% (n = 254/4169) in those treated with placebo/control. In post-
MI patients, SCD was reported only in the EPHESUS trial [13] at the rates of 4.88% (n = 162/
3319) and of 6.07% (n = 201/3313) in groups receiving AAs and placebo, respectively.
Table 1. (Continued)
Studies,
(abbreviation
name), year of
publication
Patients;
duration
(follow-up);
countries
Comparison Study
design,
intention to
treat
analysis
(ITTA)
Number of
randomized
patients
(excluded
during follow-
up)
Mean age
(SD)
Male
sex
(%)
Ischemic
etiology
(%)
Ejection
fraction (%)
Pitt et al. 1999
(RALES) [11]
HF; 24 months;
International (15
countries)
Spironolactone 25
mg (titrated to 50
mg/day) vs. Placebo
DB; with
ITTA
822(0)/841(0) 65(12)/65(12) 73/73 55/54 25.6(6.7)/
25.2(6.8)
Taheri et al. 2012
[37]
CHF; 6 months;
Iran
Spironolactone 25
mg/day vs. Placebo
DB; without
ITTA
9(2)/9(3) 50.7(17.4)/
57.2(13.1)
55/55 NR or 0/
NR or 0
26.6(8.3)/
31.1(10.5)
Taheri et al. 2009
[38]
HF; 6 months;
Iran
Spironolactone 25
mg/day vs. Placebo
DB; without
ITTA
8(3)/8(2) 59.5(6.5)/
56.8(9.3)
63/75 NR or 0/
NR or 0
31.3(8.7)/
33.8(9.2)
The RALES
Investigators [58]
HF; 3 months;
International
Spironolactone 12.5,
25, 50, 75 mg/day (4
groups) vs. Placebo
DB; with
ITTA
174(0)/40(0) 63/61(12) 79/83 NR/NR NR/NR
Udelson et al. 2010
[39]
HF; 9 months;
USA
(multicenter)
Eplerenone 25 mg
(titrated to 50 mg/
day) vs. Placebo
DB; without
ITTA
117(13)/109(20) 63.3(12.2)/
62.0(12.9)
84/84 60/61 26.2(0.6)/
27.0(0.6)
Uzunhasan et al.
2009 [29]
AMI; 6 months;
Turkey
Spironolactone 50
mg/day vs. Placebo
DB; with
ITTA
41(0)/41(0) 52(10)/52(10) 79/71 NR/NR 47/44
Vatankulu et al.
2013 [30]
AMI; 6 months;
Turkey
Spironolactone 12.5
& 25 mg/day (2
groups) vs. Routine
treatment
Open label;
with ITTA
104(0)/56(0) 56/57(11) 84/80 100/100 NR/NR
Vizzardi et al. 2013
[34]
CHF; 44 ± 16
months; Italy
Spironolactone 25
mg (titrated to 100
mg/day) vs. Placebo
SB; without
ITTA
65(5)/65(1) 61(14.7)/ 65
(17.4)
NR/
NR
NR/NR 34.5(6.8)/
37.7(11)
Vizzardi et al. 2010
[59]
HF; 6 months;
Italy
Spironolactone 25
mg (titrated to 100
mg/day) vs. Placebo
SB; with
ITTA
79(0)/79(0) 61(13)/58(13) 84/82 NR/NR 35.2(0.7)/
35.4(1.0)
Weir et al. 2009
[31]
MI; 5.5 months;
UK
Eplerenone 25 mg
(titrated to 50 mg/
day) vs. Placebo
DB; without
ITTA
50(4)/50(3) 61.0 12.0)*/
56.8(12.0)*
74*/
80*
100/100 35.2(3.9)*/
32.3(4.8)*
Wu et al. 2013 [24] AMI; 12 months;
China
Spironolactone 20
mg/day vs. Routine
treatment
Open label;
without ITTA
308(46)/308(42) 59.8(11.7)*/
59.9(10.3)*
74*/
72*
100/100 NR/NR
Zannad et al. 2011
(EMPHASIS-HF)
[33]
HF; 21 months;
International
Eplerenone 25 mg
(titrated to 50 mg/
day) vs. Placebo
DB; with
ITTA
1364(0)/ 1373(0) 68.7(7.7)/
68.6(7.6)
77/78 70/68 26.2(4.6)/
26.1(4.7)
The results are shown according to the mean (SD), except for additional explanation in exceptional cases. BD: double blind; ITTA: intention to treat
analysis; HF: Heart failure; DHF: Diastolic heart failure; CHF: congestive heart failure; HFPRE: Heart failure with preserved ejection fraction; MI:
Myocardial infarction; LVD: Left Ventricular Dysfunction; IV: Intra-venous; DB: Double blind; SB: Single blind; NR: not reported; AREA-in-HF: Aldosterone
Receptor Antagonists improve outcome in severe Heart Failure; RAAM-PEF: Randomized Aldosterone Antagonism in Heart Failure with Preserved
Ejection Fraction; Aldo-DHF: Aldosterone Receptor Blockade in Diastolic Heart Failure; TOPCAT: Treatment of Preserved Cardiac Function Heart Failure
With an Aldosterone Antagonist; EPHESUS: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efﬁcacy and Survival Study; RALES: Randomized
Aldactone Evaluation Study; EMPHASIS-HF: Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure.
(*) For only the patients included in ﬁnal analyses.
doi:10.1371/journal.pone.0145958.t001
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There was a significant reduction of SCD rate with AAs in patients with HF (19% SCD
reduction; RR 0.81; 95% CI, 0.67–0.98; p = 0.03) or with post-MI left ventricular dysfunction
(20% SCD reduction; RR 0.80; 95% CI, 0.66–0.98; p = 0.03). In total, the SCD rate was 4.88%
(n = 364/7451) in those treated with AAs compared with 6.08% (n = 455/7482) in those treated
with placebo/control (19% SCD reduction; RR 0.81, 95% CI, 0.71–0.92; p = 0.002) without any
evidence of statistical heterogeneity (I2 = 0%) (Fig 2A).
All-cause mortality. All-cause mortality rate in patients with HF were 16.21% (n = 729/
4496) in those treated with AAs and 19.96% (n = 903/4523) in those assigned to placebo/con-
trol (RR 0.81, 95% CI, 0.74–0.88, p<0.00001) through the follow-up duration. The correspond-
ing numbers in the sub-group of MI were 11.64% (n = 519/4460) and 13.71% (n = 611/4457),
respectively, with 15% reduction (RR 0.85; 95% CI, 0.76–0.95, p = 0.003). Altogether, there
were 1248/8956 (13.93%) and 1514/8980 (16.86%) deaths from all causes, respectively,
observed in treatment and placebo arms with a general reduction rate of 18% (RR 0.82; 95%
CI, 0.77–0.88, p<0.00001). Heterogeneity was not found in each sub-group (consisting 10 and
8 trials, respectively) and in the whole population (all I2 = 0%) (Fig 2B).
Table 2. Main criteria for patients’ eligibility in the included studies.
Studies NYHA
class
Killip
class
Creatinine (mg/dL or other
units)
Serum potassium (mmol/
L)
Ejection fraction
(%)
Boccanelli et al. 2009 (AREA-in-HF)
[35]
II NR 2.5 5.0 45
Chan et al. 2007 [56] II to III NR 200 μmol/l 5.0 <40
Cicoira et al. 2002 [22] NR NR 150 μmol/l 5.0 45
Deswal et al. 2011(RAAM-PEF) [36] II to III NR 2.5 5.0 50
Di Pasquale et al. 2005 [25] NR I to II <2.0 <5.0 NR
Edelmann et al. 2013 [32] II to III NR NR <5.1 50
Gao et al. 2007 [57] II to IV NR <2.5 <5.5 <45
Kayrak et al. 2010 [26] NR I to II 2.0 5.0 40
Mak et al. 2009 [23] IV NR 200 μmol/l NR 45
Modena et al. 2001 [27] NR I to III 2.5 NR NR
Montalescot et al. 2014 (REMINDER)
[28]
NR NR 2.5 NR 40
Pitt et al. 2014 (TOPCAT) [14] I to IV NR <2.5 5.0 45
Pitt et al. 2003 (EPHESUS) [13] I to IV NR 2.5 5.0 40
Pitt et al. 1999(RALES) [11] III to IV NR 2.5 5.0 35
Taheri et al. 2012 [37] III to IV NR NR <5.5 45
Taheri et al. 2009 [38] III to IV NR NR 5.5 45
The RALES Investigators [58] III to IV NR 2.0 <5.5 35
Udelson et al. 2010 [39] II to III NR NR 5.5 35
Uzunhasan 2009 [29] NR I to II <2.5 5.0 NR
Vatankulu et al. 2013 [30] NR I to II 2.0 <5.5 40
Vizzardi et al. 2013 [34] I to II NR NR 5.0 <40
Vizzardi et al. 2010 [59] I to II NR 2.5 5.0 40
Weir et al. 2009 [31] NR I to II 2.5 5.0 <40
Wu et al. 2013 [24] NR I to III 2.5 5.0 NR
Zannad et al. 2011 (EMPHASIS-HF)
[33]
II NR NR 5.0 35
NYHA: New York Heath Association; ND: Not Deﬁned; NR: Not Reported; 221 μmol/l ~ 2.5 mg/dL.
doi:10.1371/journal.pone.0145958.t002
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Fig 2. Efficacy of aldosterone antagonist compared with control for the prevention of (A) Sudden death, (B) All-causemortality, and (C)
Cardiovascular death in patients with heart failure or myocardial infarction.
doi:10.1371/journal.pone.0145958.g002
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Cardiovascular mortality. In the follow-up duration, CVmortality rate was 17.03% (n =
541/4205) in those treated with AAs and 22.54% (n = 697/4234) in those received placebo in the
HF subgroup, resulting in a reduction rate of 21% (RR 0.79; 95% CI, 0.70–0.89, p<0.00001). In
the MI subgroup, the efficacy of AAs was demonstrated by a reduction of 17% (RR 0.83; 95% CI,
0.74–0.94, p = 0.003) of CVmortality in treated patients compared with those receiving placebo
(431/4166 vs 517/4165 deaths, respectively). AAs contributed a general reduction of 20% for the
two categories of patients (RR 0.80; 95% CI, 0.74–0.87, p<0.00001) (Fig 2C).
Generally, there were likely no heterogeneity found in SCD, all-cause mortality and CV
mortality (all I2 = 0%), regarding both categories of patients.
Secondary outcomes
All-cause hospitalization. Relative risk reductions in all-cause hospitalization rate by
AAs compared with placebo/control were 9% in HF patients (RR 0.91; 95% CI, 0.86–0.96;
p = 0.0008) and 37% in post-MI patients (RR 0.63; 95% CI, 0.19–2.05; p = 0.44). In overall anal-
ysis, the results showed a significant decrease of 7% of all–cause hospitalization in patients
receiving AAs compared with those taking placebo/control (RR 0.93; 95% CI, 0.88–0.98;
p = 0.008) (Fig 3A). However, heterogeneity was likely considerable (I2 = 17%, 29% and 35%
respectively).
Cardiovascular hospitalization. In patients with HF, a significant relative risk reduction
of 21% for CV hospitalization was observed in those assigned to AAs, compared with pla-
cebo/control (RR 0.79; 95% CI, 0.68–0.91; p = 0.002). In patients with MI, the corresponding
value was 20% but not significant (RR 0.80; 95% CI, 0.47–1.35; p = 0.44). An analysis for
both subgroups showed a relative risk reduction of 18% (RR 0.82, 95% CI, 0.72–0.92;
p = 0.001) (Fig 3B). However, heterogeneity detected was moderate (I2 = 49%, 31% and 51%
respectively).
Adverse reactions
Hyperkalemia, worsening renal function and gynecomastia were the main observed side effects
of AAs in the 25 included studies, as compared to placebo or control. In general, the incidence
of all considered adverse events significantly doubled in patients treated with AAs, compared
to those receiving placebo or reference therapy. Corresponding RRs were 1.88 (Cl 95%, 1.68–
2.12, p<0.00001) for hyperkalemia; 1.45 (CI 95%,1.08–1.93, p = 0.01) for degradation of renal
function; 3.88 (CI 95%, 1.69–8.91, p = 0.001) for gynecomastia and 1.99 (95% CI, 1.64–2.41;
p<0.00001) for all considered side-effects in general, with remarkably various heterogeneities
found among the subgroups (0%, 23%, 70% and 46% respectively) (Fig 4). Exceptions appeared
for the two big RALES and EMPHASIS-HF trials [11][33], where interestingly enough, patients
in the placebo groups had slightly higher rate of gynecomastia (RALES and EMPHASIS-HF)
and of renal function degradation (EMPHASIS-HF).
Publication bias
Visual analysis of funnel plots suggested the possibility of publication biases in SCD, CV mor-
tality, total/CV hospitalization analyses, with some asymmetries (Figs 5A, 5C and 6A, 6B); this
bias was unlikely in two cases: total mortality (Fig 5B) and side effects (Fig 7).
Statistically, potential existence of publication bias was tested by Egger approach, using OR
instead of RR for the reason explained in the Method session. For clinical outcome with low
incidence (SCD, total/CV mortality, side effects), these two indicators were similar. For exam-
ple, the SCD prevention effect of AAs estimated by RR was 0.81 (95% CI, 0.71–0.92, p = 0.002)
and by OR was 0.80 (95% CI, 0.69–0.92, p = 0.002), both using random effect model. However,
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Fig 3. Efficacy of aldosterone antagonist compared to control for the prevention of (A) All-cause hospitalization and (B) Cardiovascular
hospitalization in patients with heart failure or myocardial infarction.
doi:10.1371/journal.pone.0145958.g003
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the higher the incidence was, the more different these estimators were. For example, for total
hospitalization criteria which had the highest incidence (over 40%), intervention effect mea-
sured by RR was 0.93 (95% CI, 0.88–0.98, p = 0.008) but by OR was 0.84 (95% CI, 0.72–0.97,
p = 0.018), both using random effect model.
Fig 4. Incidences of adverse effects (hyperkalemia, degradation of renal function and gynecomastia) under aldosterone antagonist treatment,
compared with control/placebo group, in patients with heart failure or myocardial infarction.
doi:10.1371/journal.pone.0145958.g004
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Most clinical outcomes in this meta-analysis included at least 10 trials, thus satisfied the rec-
ommendations on testing for funnel plot asymmetry, except the primary outcome (SCD). The
p-values of Egger tests were 0.21 for SCD, 0.79 for total mortality, 0.17 for CV mortality, 0.13
for total hospitalization, 0.08 for CV hospitalization, 0.23 for hyperkalemia, 0.94 for renal func-
tion degradation and 0.29 for gynecomastia, none supporting evidence for publication bias. Of
Fig 5. Funnel plot of standard error (log odds ratio) by odds ratio to evaluate publication bias for
effect of aldosterone antagonist treatment in preventing (A) Sudden death, (B) All-causemortality,
and (C) Cardiovascular mortality in patients with heart failure or myocardial infarction.
doi:10.1371/journal.pone.0145958.g005
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note, regarding both funnel plots & Egger tests, publication biases were not formally assessable
for SCD outcome due to the few number of trials included (n = 6).
Sensitivity analysis
Sensitivity analyses were tested for the biggest trial in each subgroup (among the greatest ones
REMINDER [28], TOPCAT [14], EPHESUS [13], RALES [11], EMPHASIS-HF [33]) which
had the greatest weight percentages, for eight open label/single blind/not reported design trials
if applicable (Cicoira et al. [22], Kayrak et al. [26], Mak et al. [23], Modena et al. [27],
Fig 6. Funnel plot of standard error (log odds ratio) by odds ratio to evaluate publication bias for
effect of aldosterone antagonist treatment in preventing (A) All-cause hospitalization and (B)
Cardiovascular hospitalization in patients with heart failure or myocardial infarction.
doi:10.1371/journal.pone.0145958.g006
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Vatankulu et al. [30], Vizzardi et al. 2013 [34], Vizzardi et al. 2010 40], Wu et al. [24]) and for
11 trials which had no intention to treat analysis (ITTA) if applicable (Boccanelli et al. [35],
Cicoira et al. [22], Deswal et al. [36], Di Pasquale et al. [25], Kayrak et al. [26], Mak et al. [23],
Taheri et al. 2012 [37], Taheri et al. 2009 [38], Udelson et al. [39], Vizzardi et al. 2013 [24],
Weir et al. [31]) (Table 1). As well, we conducted these analyses only for primary outcome, i.e
the preventive effect of AAs on mortality (SCD, total and CV death) in patients with HF or
post-MI.
Among all included trials in considering both subgroups, EPHESUS trial [13] contributed
the largest weight with relative overall weights of 44.1% for SCD, 34.6% for all-cause mortality
and 39.0% for CV mortality analyses. However, when performing a sensitivity test by excluding
this trial, no significant differences of RRs were detected for three cases: from (0.81, 95% CI
0.71–0.92, p = 0.002) to (0.81, 95% CI 0.67–0.98, p = 0.03), from (0.82, 95% CI 0.77–0.88,
p<0.00001) to (0.80, 95% CI 0.74–0.87, p<0.00001) and from (0.80, 95% CI 0.74–0.87,
p<0.00001) to (0.78, 95% CI 0.71–0.86, p<0.00001), respectively.
For patients with HF, the RALES trial [11] had the largest relative weights of 24.6%, 30.8%
and 29.4% for these three criteria, respectively. Excluding this trial resulted in no significant
difference of estimate effect for SCD analysis: RR (0.81; 95% CI, 0.67–0.98; p = 0.03) changed
to (0.82, 95% CI, 0.59–1.14) but the effective estimator turned out non-significant (p = 0.24).
The RRs for all-cause and CV mortality changed moderately from (0.81, 95% CI, 0.74–0.88,
p<0.00001) to (0.87, 95% CI, 0.77–0.98, p = 0.02) and from (0.79, 95% CI, 0.70–0.89,
p = 0.0001) to (0.83, 95% CI, 0.71–0.97, p = 0.02) respectively, with the results remained
significant.
In these patients, removing two trials which had no intention-to-treat analysis (ITTA) (Boc-
canelli et al. [35], Taheri et al. 2012 [37]) gave no remarkable influence on the AAs’ effect in
Fig 7. Funnel plot of standard error (log odds ratio) by odds ratio to evaluate publication bias for
effect of aldosterone antagonist treatment in inducing common side effects (hyperkalemia,
degradation of renal function, gynecomastia) in comparison with placebo/control, in patients with
heart failure or myocardial infarction.
doi:10.1371/journal.pone.0145958.g007
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preventing SCD: RR changed from (0.81; 95% CI, 0.67–0.98; p = 0.03) to (0.83; 95% CI, 0.69–
0.99; p = 0.04). The same attempt for three trials (Boccanelli et al. [35], Taheri et al. 2012 [37],
Taheri et al. 2009 [38]) resulted in slight changes: RR changed from (0.81, 95% CI, 0.74–0.88,
p<0.00001) to (0.81, 95% CI, 0.75–0.88, p<0.00001) and from (0.79, 95% CI, 0.70–0.89,
p = 0.0001) to (0.79, 95% CI, 0.70–0.90, p = 0.0004) in case of total/CV mortality, respectively.
Open or single blind trials in HF subgroup were also excluded for sensitivity analyses (appli-
cable for total and CV mortality analyses). Removing the three trials Cicoira et al. [22], Mak
et al. [23], Vizzardi et al. 2013 [34] for total mortality and removing the trial of Vizzardi et al.
2013 [34] for CV mortality resulted in slight changes: RR changed from (0.81, 95% CI, 0.74–
0.88, p<0.00001) to (0.81, 95% CI, 0.73–0.91, p = 0.0004) and from (0.79, 95% CI, 0.70–0.89,
p = 0.0001) to (0.83, 95% CI, 0.74–0.94, p = 0.003), respectively.
In those with MI, the EPHESUS trial [13] was the only for SCD prevention analysis. This
trial occupied the greatest relative overall weights of 34.6% and 39.0% in case of total and CV
mortality, respectively. Removing this trial returned significant changes of RRs from (0.85,
95% CI, 0.76–0.95, p = 0.003) to (0.71, 95% CI 0.48–1.05, p = 0.09) and from (0.83, 95% CI,
0.74–0.94, p = 0.003) to (0.71, 95% CI 0.43–1.18, p = 0.19), respectively.
For total mortality analysis, there was only one trial without ITTA (Weir et al. [31]) pre-
sented in the MI subgroup and removing this trial had likely no impact on RR: from (0.85, 95%
CI, 0.76–0.95, p = 0.003) to (0.85, 95% CI, 0.76–0.94, p = 0.003). Similarly, when three open
design trials (Kayrak et al. [26], Modena et al. [27], Wu et al. [24]) were removed, only slight
influences on the final effect were observed: RR changed from (0.85, 95% CI, 0.76–0.95,
p = 0.003) to (0.83, 95% CI 0.77–0.88, p = 0.006). No trial without ITTA or with single-blind/
open design involved MI patients was included for CV mortality analysis.
For SCD, all the included trials concerned HF patients with reduced LVEF, except TOPCAT
trial [14] which recruited HF patients with preserved LVEF. Removing this trial resulted in
slight change for treatment effect: RR from (0.81, 95% CI, 0.71–0.92, p = 0.002) to (0.78, 95%
CI 0.67–0.90, p = 0.0006 and the heterogeneity remained likely absent (both I2 = 0%).
Discussion
In our meta-analysis, we evaluated the efficacy of AAs in reducing mortality (SCD, overall/CV
death) and hospitalization rate, as well as their toxicity via the common side effects in 19,333
patients with HF or post-MI from 25 trials. Our findings demonstrated the effectiveness of
AAs in preventing SCD, all-cause mortality and CVmortality, yet a double rate of three studied
adverse effects in these patients.
The cardio-protective effect of AAs is quite well proven in literature for CV protection [40].
Some of the proposed mechanisms of action in HF of AAs include (i) inhibition of myocardial
and vascular remodeling, (ii) blood pressure reduction, (iii) decreased collagen deposition, (iv)
decreased myocardial stiffness, (v) prevention of hypokalemia and arrhythmia, (vi) modulation
of nitric oxide synthesis, and (vii) immunomodulation [41]. For instance, the meta-analysis of
Li et al. [42] demonstrated beneficial effects of AAs on the reversal of cardiac remodeling and
improvement of left ventricular function. Another quantified AAs’ positive effect on ejection
fraction (EF) and functional capacity improvement in different HF functional classes [43].
The RALES trial [11], published in 1999 was the first big study concerning AAs’ effect that
recommended this treatment which significantly decreased mortality rate (SCD, all cause and
CV death) as well as CV hospitalization rate in patients with severe chronic HF (NYHA III to
IV). Next, in 2003, the EPHESUS trial [13] re-confirmed the role of AAs for the same outcomes
in patients with AMI complicated by left ventricular dysfunction. This therapy was thus limited
to patients with severe HF or those with HF following MI until the publication of EMPHASIS-
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HF trial [12] in 2011, which reported additional beneficial evidence for AAs use in mild-to-
moderate HF (NYHA II), regarding the same clinical criteria. However, the current TOPCAT
trial [14] finished in 2014 showed only a significant lower incidence of cardiac hospitalization
in those treated by spironolactone vs. placebo, but not for total deaths and all-cause hospitaliza-
tion, in patients with HF and preserved EF. Sensitivity analysis with this trial suggested that the
treatment effect of AAs was likely similar in HF patients with reduced or preserved EF for SCD
prevention.
The work of Ezekowitz et al. [44] evaluated the effect of aldosterone blockade on left ven-
tricular dysfunction in HF and post-MI participants and reported a significant reduction in
overall mortality of 20% (RR 0.80, 95% CI, 0.74–0.87, p<0.00001). That of Hu et al. [45],
which showed a 21% (RR 0.79, 95% CI 0.66–0.95, p = 0.65) decrease for overall mortality and a
38% (RR 0.62, 95%, CI 0.52–0.74, p = 0.54) decrease for cardiac re-hospitalization by the use of
AAs in patients with mild to moderate chronic HF (NYHA I to II). Another current meta-anal-
ysis of Bapoje et al. [46] that included 8 RCTs, concluded a 23% reduction (OR 0.77; 95% CI,
0.66–0.89; p = 0.001) of SCD in patients with a left ventricular systolic dysfunction of 45%,
treated with AAs. On the contrary, the most recent meta-analysis of Chen et al. [47] in 2015
did not observe any all-cause mortality benefit, yet a reduced CV hospitalization rate (RR 0.83;
95% CI; 0.70 to 0.98), in patients with either HF or MI and preserved EF by AA treatment.
Our meta-analysis, included MI/ HF patients with both preserved and primarily reduced EF,
approved the positive effect of AAs in preventing all considered outcomes: SCD (RR 0.81; 95%
CI, 0.71–0.92; p = 0.002), all-cause mortality (RR 0.82; 95% CI, 0.77–0.88, p< 0.0001), CV
mortality (RR 0.80; 95% CI, 0.74–0.87, p<0.0001), all–cause hospitalization (RR 0.93; 95%
CI, 0.88–0.98; p = 0.008) and CV hospitalization (RR 0.82, 95% CI, 0.72–0.92; p = 0.001) in
patients with HF or post MI.
In terms of security, our work demonstrated a doubled rate of common adverse reactions
(hyperkalemia, worsening renal function and gynecomastia) in those receiving AAs vs. control
or placebo (RR 1.99, 95% CI, 1.64–2.41; p<0.00001). These findings agreed with the results of
currently conducted analyses by Clark et al. [48] for renal function insufficiency, or by Ros-
signol et al. [49] for hyperkalemia and renal function degradation.
In 2013, a systematic study [50] of conventional HF therapies, including angiotensin-con-
verting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), direct renin inhibitor
(DRI), and AA compared their effects (on prevention of total death, CV death, non-fatal MI,
HF hospitalization and composite of CV death or HF hospitalization) and their safety (on
hyperkalemia, hypotension, renal failure). By risk-benefit ratio comparison, this review favored
the administration of AA over ARB or DRI, despite its 110% generated increase in hyperkale-
mia. Likewise, higher proportion of developed hyperkalemia and higher rate of hospitalization
for hyperkalemia by AAs in HF patients were recorded in RALES trial, especially in combined
use of AAs with either ACEIs or ARBs [51]. Moreover, the benefit of AAs on morbi-mortality
prevention seems to overweigh its side-effects, i.e. the reduction in mortality associated with
the use of AA was significantly greater than its use complications. Our work estimated num-
bers of 83, 27 and 18 HF patients need to be treated with AAs to prevent one SCD, one all-
cause death and one CV death in one year, respectively. For patients with MI, the correspond-
ing numbers needed to treat (NNT) were 84, 48 and 48, respectively. Considering both patient
groups, the estimated NNTs were 83, 34 and 35, respectively. As well, the number needed to
harm i.e the number of patients treated on average to have one who suffers at least one of the
three common side effects studied, was 77.
Noticeably, focusing on SCD prevention, while AAs help to reduce CV risk factors thus pre-
vent CV accidents including SCD, paradoxically, their side effects of hyperkalemia may induce
this accident from cardiac arrhythmia [52]. By this point, a study [53] proved that AAs were
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independently associated with increased rates of total mortality (hazard ratio HR 1.4; 95% CI
1.1–1.8; P = 0.005), of CV mortality (HR 1.4; 95% CI 1.1–1.9; P = 0.009) and a doubled inci-
dence of SCD (HR 2.0; 95% CI 1.3, 3.0; P = 0.001) in patients with atrial fibrillation and HF.
This implied a careful examination of risk/benefit ratio for each individual patient before the
prescription of this treatment.
Based on our comprehensive and meticulous search strategy, we believe that we have identi-
fied all existing studies that met our inclusion criteria, hence yielding robust results. However,
certain limitations should be considered when interpreting these outcomes. For instance, publi-
cation bias was not reliably assessed (though seemly negative) for the most important outcome
(SCD) when less than 10 studies were included for pooled analyses by funnel plot (Fig 5A) or
Egger test.
In summary, to gain the maximum benefit from AAs and reduce possible complications, it
is legitimate to individualize and closely monitor their use. For examples, risk-benefit balance
should be carefully considered before using AAs in patients with severe renal insufficiency.
Also, other factors such as time of treatment initiation [54] and cost difference between AA
agents [55] should be taken into account to optimize this therapy.
Conclusion
Our meta-analysis demonstrates that AA treatment may provide beneficial effects on the pre-
vention of SCD, as well as all-cause and CVmortality, for selected patients with HF with
altered left ventricular function or after a MI. Nevertheless, careful consideration before pre-
scribing should be given simultaneously to the therapeutic benefit and the overall safety profile
of this medication.
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A sudden death risk score specifically for hypertension:
based on 25648 individual patient data from six
randomized controlled trials
Hai-Ha Lea, Fabien Subtila, Marc Ceroua, Ivanny Marchantb, Muaamar Al-Gobaric, Mor Falla,d,
Yanis Mimounia,e, Behrouz Kassaı¨a,f, Lars Lindholmg, Lutgarde Thijsh, and Franc¸ois Gueyffiera,i
Objective: To construct a sudden death risk score
specifically for hypertension (HYSUD) patients with or
without cardiovascular history.
Methods: Data were collected from six randomized
controlled trials of antihypertensive treatments with 8044
women and 17604 men differing in age ranges and blood
pressure eligibility criteria. In total, 345 sudden deaths
(1.35%) occurred during a mean follow-up of 5.16 years.
Risk factors of sudden death were examined using a
multivariable Cox proportional hazards model adjusted on
trials. The model was transformed to an integer system,
with points added for each factor according to its
association with sudden death risk.
Results: Antihypertensive treatment was not associated
with a reduction of the sudden death risk and had no
interaction with other factors, allowing model
development on both treatment and placebo groups. A
risk score of sudden death in 5 years was built with seven
significant risk factors: age, sex, SBP, serum total
cholesterol, cigarette smoking, diabetes, and history of
myocardial infarction. In terms of discrimination
performance, HYSUD model was adequate with areas
under the receiver operating characteristic curve of
77.74% (confidence interval 95%, 77.86–81.35) for the
derivation set, of 77.46% (77.70–80.83) for the validation
set, and of 79.17% (79.48–82.40) for the whole
population.
Conclusion: Our work provides a simple risk-scoring
system for sudden death prediction in hypertension, using
individual data from six randomized controlled trials of
antihypertensive treatments. HYSUD score could help
assessing a hypertensive individual’s risk of sudden death
and optimizing preventive therapeutic strategies for these
patients.
Keywords: cardiovascular diseases, cardiovascular risk
factor, diabetes, hypertension, risk score, sudden death
Abbreviations: ARIC, Atherosclerosis Risk in
Communities; AUROC, area under the receiver operating
characteristic curve; CAST, Cardiac Arrhythmia Suppression
Trial; CHADS2-VASC, updated score for atrial fibrillation
stroke risk; CHS, Cardiovascular Health Study; CI,
confidence interval; Duke SCD, Duke Sudden Cardiac
Death Risk Score for Patients With Angiographic(>75%
Narrowing) Coronary Artery Disease; EWPHE, European
Working Party on Hypertension in the Elderly; MRFIT,
Multiple Risk Factor Intervention Trial; RCT, randomized
controlled trial; ROC, receiver operating characteristic;
SCORE, Systemic Coronary Risk Estimation; SHEP, Systolic
Hypertension in the Elderly Program; STOP, Swedish Trial in
Old Patients; SYSTEUR, Systolic Hypertension in Europe
INTRODUCTION
S
udden death, a major cardiovascular event which
occurs only within 1 h (or 24 h according to other
definition) after the first onset of symptoms [1,2], is
responsible for approximately 360 000 deaths (half of all
cardiovascular deaths) annually in the United States [3]. In
France, the annual incidence of sudden death was esti-
mated as 50–70/100 000, thus about 40 000 deaths/year,
occur mainly in men (69%), with a mean age of 65 years and
at home (75%) [4]. Such event is important to be prevented
but unfortunately remains underestimated in public health
[5]. Hypertension is considered as a worldwide epidemiol-
ogy, a well known risk factor for several diseases, and the
leading cause for morbidity andmortality, including sudden
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death, accounting for 7.0% (95% confidence interval (CI)
6.2–7.7) of global disability-adjusted life years and 9.4 (CI
8.6–10.1) million deaths in 2010 [6].
To better protect patients with hypertension regarding
sudden death occurrence, a risk score is needed to stratify
their risks and to adapt therapy. Up to now, two sudden
death risk predictors were developed. One is Duke
Sudden Cardiac Death Risk Score for Patients With
Angiographic(>75% Narrowing) Coronary Artery Disease
(Duke SCD) [7], designed specifically for patients with
high coronary risk thus concerns secondary prevention
patients. The second one was recently built from two
prospective cohorts and for the general population in the
United States [3].
We aimed to build here a quantitative and discrimina-
tive 5-year sudden death risk predictor from six rando-
mized controlled trials (RCTs) of 25 648 patientswith raised
blood pressure (BP), treated or not by antihypertensive
agents.
METHODS
Participants
The INdividual Data ANalysis of Antihypertensive interven-
tion trials (INDANA) database includes most of major RCTs
of antihypertensive drugs vs. placebo or control during the
period of 1985–1995, which characteristics detailed else-
where [8]. We assessed here data from six trials of this
database having unbiased information regarding sudden
death with 25 648 participants [9–14]. Causes of death were
adjudicated in each trial by experts’ committee.
Statistical analysis
We used the Cox proportional hazards regression (semi-
parametric time-to-event) model to establish our sudden
death risk score for hypertension. The population was
divided randomly into two subpopulations: derivation
and validation sets (ratio 2 : 1) to ensure their similar base-
line characteristics. Covariable selection was done in two
steps. First, we conducted univariable analyses with 29
covariables to evaluate their associations with the sudden
death outcome, adjusted on trials (by adding the covariable
trial). Second, multivariable analyses were operated, where
all covariables were offered simultaneously, but separately
for SBP and DBP on one hand, mean BP and pulse BP on
the other hand. Similarly, we did not assess serum crea-
tinine in the multivariable testing, considering that glomer-
ular filtration rate did reflect more accurately renal function.
We used concurrently ‘backward’ and ‘forward elimination’
(stepwise screening) strategies, always adjusted on trials
until obtaining the final model (where all the covariables
were significant). All these uni and multivariable analyses
were done using data of the derivation set.
Tests on time dependence or the linearity of the effect of
continuous covariables on log hazard scale were performed
using martingale residuals plots, and in comparing the
model assuming a linear effect to a model assuming a
quadratic effect. We also investigated possible biological
interactions among them, particularly interactions with trial
and antihypertensive treatment covariables. As well, we
explored the impact of the trial covariable on sudden death
risk, alone (univariable analysis) or adjusted on other risk
factors (multivariable analysis).
The discrimination performance of the final predictive
model was assessed by the areas under the receiver oper-
ating characteristic curve (AUROC) of the derivation set, the
validation set, the whole population, and of each separated
trial, with 95% CI [15]. For model calibration and external
validation, we used the (k1) approach: the final 7-risk
factor model was rebuilt on five trials and tested on the
remaining for six times.
We converted this final model predictor into an integer
score using the method of Sullivan et al. [16]. Briefly, the
score was directly related to an individual’s probability of
sudden death within 5 years. The zero score (risk of
reference) was assigned for an adult at the lowest/most
optimal risk represented in the application population.
Having grouped each factor into convenient intervals, such
as every 10mmHg for SBP, an individual’s score increases
by an integer amount for each risk factor level above the
reference risk category. Each integer amount is a rounding
of the exact figure obtained from the proportional hazards
model, thus the risk score is a simple addition of whole
points.
All statistical tests were two-sided with a type I error of
0.05. All the analyses were performed with ‘survival’,
‘riskset receiver operating characteristic (ROC)’, and ‘time-
ROC’ packages on R software, version 3.2.5.
RESULTS
Among 25 648 participants from six RCTs, 345 sudden death
occurred during a mean of 5.16 years of follow-up [9–14]
(Appendix 1, http://links.lww.com/HJH/A803). All the
trials were double blind, except Coope et al. [9] which
was an open-label trial. The biggest one is Multiple Risk
Factor Intervention Trial (MRFIT) [10], which recruited
12 866 patients and the smallest one was EuropeanWorking
Party on Hypertension in the Elderly (EWPHE) [11] with 840
participants. Characteristics of the derivation and validation
sets are shown in the Table 1.
In univariable analyses, the following parameters were
linked significantly with the incidence of sudden death:
age, male sex, SBP and pulse BP, smoking status, serum
creatinine, glomerular filtration rate, history of myocardial
infarction (MI), history of angina pectoris, and baseline
diabetes but not antihypertensive treatment (Table 2).
No significant interaction was detected between studied
covariables, or between any covariable with antihyperten-
sive treatment and trial ones. As antihypertensive treatment
seemed to have no effect on reducing the risk of sudden
death in univariable analysis (Table 2) and had no inter-
actionwith other covariables, we developed the final model
on both treatment and placebo groups in the derivation set.
Using multivariable method, we identified seven signifi-
cant risk factors of sudden death including age, sex (male),
smoking status, serum cholesterol, SBP, baseline of type 2
diabetes, and history of MI, among which serum cholesterol
was not statistically significant in univariable analyses
(Table 2).
Impact of the trial covariable was tested, indicating a
significantly lower sudden death risk (nearly one-third) in
Le et al.
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MRFIT trial [10], compared with that of Coope et al. [9] trial
in univariable analysis. However, this significance dis-
appeared in multivariable analysis (the final model),
suggesting the difference of sudden death incidence was
explained by the adjustment (Appendix 2, http://links.lww.
com/HJH/A803).
The discrimination performance of the final model was
quantified by AUROC for the derivation set, validation set,
and for each individual trial (Table 3). Overall, our model’s
performance was good with AUROC at 78, 77, and 79% for
the derivation set, validation set, and the whole population,
respectively. However, separate assessment for each trial
varied considerably from 60% for Systolic Hypertension in
the Elderly Program (SHEP) trial [12] to 75% for EWPHE trial
[11].
The final model is then converted to an integer score [16].
We took a woman, nonsmoker, aged 37, nondiabetic, total
serum cholesterol at 3.5mmol/l, SBP at 115mmHg, and
without history of MI as the reference profile. The scoring
system is presented in the Appendix 3, http://links.
lww.com/HJH/A803, allowing to assess the effect of each
risk factor on the overall risk of sudden death (the total
point). In our sudden death risk score specifically for
hypertension (HYSUD) score, one increased year in age
was corresponding with one point plus for sudden death
risk. In terms of sudden-risk attribution, male sex and
history of MI contributed in the same way by 10 points
added, followed by smoking (nine points) and baseline
diabetes (seven points). For any individual, points scored
for each risk factor were cumulated together to estimate
their total risk scores.
The model calibration was assessed in comparing the
incidence of sudden death predicted vs. observed for each
trial in each tertile of predicted risk. Model seemed to work
best for EWPHE [11] and Systolic Hypertension in Europe
(SYSTEUR) [13] trials for all categories, for Swedish Trial in
Old Patients (STOP) [14] except an overestimate in high-risk
category; noticeably underestimate for Coope et al. [9] and
SHEP [12] trials; and largely overestimate for MRFIT [10] trial
(Appendix 4, http://links.lww.com/HJH/A803).
Appendix 5, http://links.lww.com/HJH/A803 presents
the similarity in predicted 5-year sudden death risks by
the scoring system, compared with those obtained by the
final Cox proportional hazards model equation. The former
was converted from the latter.
Appendix 6, http://links.lww.com/HJH/A803 shows the
exponential relation between the risk score and the prob-
ability of dying from sudden death in 5 years for men and
women of the whole population. Figure 1 presents the
distribution of 5-year sudden death risk according to
scenarios of sex and age, illustrating higher risks for men
comparing with women at the same age categories. Of note,
in our database, women accounted for nearly one-third of
the population and were older than men (range age 60–98,
mean age 72 vs. 35–95, and 53 years old).
DISCUSSION
Our study brings a simple and user-friendly predictor for
sudden death risk, specifically for patients of hypertension.
HYSUD risk score included seven risk factors: age, male
sex, history of MI, smoking status, high BP, high blood
cholesterol, and baseline diabetes, ordered by their signifi-
cant impacts. These factors were well known for cardio-
vascular events in general [17] and for sudden death in
particular [18]. Similarly, according to a recent meta-analysis
of 330 376 patients from 47 lipid-modifying trials [19], base-
line diabetes is a significant predictor of cardiovascular
outcomes including sudden death. The score was built
on the point system for an easy assessment of a hyper-
tensive individual’s risk of sudden death in 5 years.
Up to now, two sudden death risk predictors were
developed: one is Duke SCD [7], designed specifically for
secondary coronary prevention and recently, another one
TABLE 1. Baseline characteristics of derivation and validation
sets
Covariables
Derivation
set
Validation
set
Number of patients 17094 8554
Number of sudden death events (%) 329 (1.6) 170 (1.7)
Trials (n, weight % vs. the whole set)
Coope 589 (3.4) 295 (3.4)
EWPHE 559 (3.3) 281 (3.3)
MRFIT 8577 (50.2) 4289 (50.1)
SHEP 3156 (18.5) 1580 (18.5)
STOP 1084 (6.3) 543 (6.3)
SYSTEUR 3129 (18.3) 1566 (18.3)
Sudden death incidence (n, %)
Coope 14 (2.4) 4 (1.4)
EWPHE 9 (1.6) 4 (1.4)
MRFIT 98 (1.1) 55 (1.3)
SHEP 53 (1.7) 38 (2.4)
STOP 11 (1.0) 5 (0.9)
SYSTEUR 35 (1.1) 19 (1.2)
Treated (%) 50.0 50.0
Male (%) 68.3 69.3
Mean (SD) age (years) 58.9 (14.0) 58.9 (14.1)
Smoker (%) 35.0 35.2
Mean (SD) height (cm) 169.6 (10.3) 169.6 (10.3)
Mean (SD) weight (kg) 79.1 (14.8) 79.0 (14.5)
Mean (SD) BMI (kg/m2) 27.4 (4.1) 27.4 (4.0)
Mean (SD) SBP (mmHg) 156.4 (25.9) 156.3 (26.0)
Mean (SD) DBP (mmHg) 88.4 (11.3) 88.5 (11.3)
Mean (SD) arterial/mean BP (mmHg) 111.1 (12.4) 111.1 (12.4)
Mean (SD) pulse BP (mmHg) 67.9 (26.4) 67.8 (26.4)
Mean (SD) serum creatinine (mmol/l) 95.1 (17.6) 95.0 (17.4)
Mean (SD) fasting blood glucose (mmol/l) 5.5 (1.2) 5.5 (1.2)
Mean (SD) serum total cholesterol (mmol/l) 6.4 (1.1) 6.4 (1.1)
Mean (SD) serum uric acid (mmol/l) 376.5 (88.7) 376.4 (88.5)
Mean glomerular filtration rate (ml/min) 84.9 (29.0) 84.8 (28.9)
Proteinuria (%) 4.4 4.5
Mean (SD) serum potassium (mmol/l) 4.4 (0.5) 4.4 (0.5)
Mean (SD) heart rate (beats/min) 76.0 (11.7) 76.0 (11.8)
History of angina pectoris (%) 1.6 1.4
History of atrial fibrillation (%) 0.15 0.09
History of leg intermittent claudication (%) 0.4 0.4
Positive dilated fundus examination (%) 27.6 27.3
Baseline of diabetes (%) 5.9 6.1
History of myocardial infarction (%) 4.6 5.0
History of stroke (%) 1.3 1.1
History of antihypertensive treatment (%) 23.5 23.5
History of high BP (%) 72.7 73.4
Baseline characteristics of the 25648 randomized participants, according to the
derivation/validation sets. Values are numbers (percentages) of patients unless stated
otherwise.
BP, blood pressure; EWPHE, European Working Party on Hypertension in the Elderly;
MRFIT, Multiple Risk Factor Intervention Trial; SHEP, Systolic Hypertension in the Elderly
Program; STOP, Swedish Trial in Old Patients; SYSTEUR, Systolic Hypertension in Europe.
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for the general population [3]. The work of Deo et al. [3]
was derived from 17 884 individual data free of baseline
cardiovascular diseases (some patients had hypertension)
from two cohorts in the United States (Atherosclerosis Risk
in Communities and Cardiovascular Health Study). Our
score included 25 648 patients with hypertension with or
without other cardiovascular diseases or histories (diabetes,
previous stroke/MI/angina, and so on) from six RCTs and of
a wider geographic zone (Europe and the United States).
The score of Deo et al. [3] contained more significant risk
factors than ours (12 vs. 7). However, our HYSUD was
transformed into an easy and friendly pointing system, as
proposed by the work of Pocock et al. [20] for cardiovas-
cular death prediction. A table comparing these two scores
is displayed in Appendix 7, http://links.lww.com/HJH/
A803.
The internal validation of HYSUD risk score indicated a
good routine performance for this prognostic prediction
type, with AUROC reaching almost 80%. However, model
performances differed largely among trials, as was noted in
a recent meta-analysis exploring the applicability of the
updated score for atrial fibrillation stroke risk score pre-
dicting stroke risk in atrial fibrillation patients [21]. These
differences could be partially explained by trial heterogen-
eity regarding: different sudden death definitions: an un-
expected death occurring in a time interval of 1 h in SHEP
[12] and STOP [14], prolonged to 24 h in MRFIT [10] and
SYSTEUR [13], and not given in other trials (details in
Appendix 1, http://links.lww.com/HJH/A803); different
eligibility criteria for age, BP, etc.; different baseline
cardiovascular disease severities that could result in various
event rates of cardiovascular death including sudden death
[22]; different antihypertensive treatments, geographic
zones, periods, follow-up durations; and so on. Nonethe-
less, pooling data from several studies as we did increases
the power of analyses, and allows exploring heterogeneity
of information between trials. We also explored the hetero-
geneity of the links between individual characteristics and
sudden death occurrence between trials, as well as its
interactions with other covariables on sudden death risk:
none was significant. In addition, apparent poor model
calibration may come from low incidence of sudden death
in our database (only 1.35% during trials’ follow-up
durations).
Our HYSUD score was built from a database collected in
the period of 1970–1990, similarly to classical scores such as
Framingham [17] or Systemic Coronary Risk Estimation [23]
and hence, should be calibrated before application for
nowadays patients, to limit possible bias coming from
change in covariable hazards ratio over time or other
TABLE 2. Univariable analyses and multivariable analysis (final model) for sudden death prediction
Univariable analyses Multivariable analysis (final model)
Covariables Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Age (by 5-year increase) 1.33 (1.20–1.48) <0.001 1.37 (1.23–1.53) <0.001
Male sex 1.83 (1.47–2.19) <0.001 2.06 (1.40–3.03) <0.001
SBP (by 10-mmHg increase) 1.15 (1.05–1.26) 0.002 1.14 (1.04–1.25) 0.006
Pulse BP (by 10-mmHg increase) 1.17 (1.06–1.29) 0.002
Smoking status 1.55 (1.24–1.87) 0.007 1.81 (1.31–2.51) <0.001
Serum creatinine (by 10-mmol/l increase) 1.10 (1.02–1.19) 0.01
Glomerular filtration rate (by 10-ml/min increase) 0.92 (0.85–0.99) 0.02
History of myocardial infarction 1.74 (1.23–2.25) 0.03 1.71 (1.02–2.85) 0.041
History of angina pectoris 2.51 (1.07–5.90) 0.04
Baseline diabetes 1.61 (1.13–2.09) 0.05 1.65 (1.02–2.67) 0.040
Mean BP (by 10-mmHg increase) 1.14 (0.99–1.32) 0.08
Weight (10 kg) 0.93 (1.03–0.84) 0.16
Heart rate (by 10-beats/min increase) 1.09 (0.96–1.24) 0.17
BMI (by kg/m2 increase) 0.98 (0.94–1.01) 0.18
Serum total cholesterol (by 1-mmol/l increase) 1.08 (0.95–1.20) 0.24 1.17 (1.04–1.33) 0.011
Treatment 0.89 (0.62–1.15) 0.34
Height (by 10-cm increase) 0.94 (0.80–1.11) 0.49
Serum potassium (by 1-mmol/l increase) 1.13 (0.78–1.48) 0.49
History of stroke 0.72 (0.68–2.12) 0.65
DBP (by 10-mmHg increase) 1.03 (0.89–1.19) 0.72
All the univariable analyses were adjusted on trials. Univariable analyses of nine risk factors with frequently lacking data, including fasting blood glucose, serum uric acid, proteinuria,
positive dilated fundus examination, history of high BP, history of antihypertensive treatment, history of atrial fibrillation, and history of leg intermittent claudication, gave nonsignificant
associations and are not presented in this table. Multivariable analysis was adjusted on trials and treatments. All the analyses were performed on 17094 individual patient data of the
derivation set.
BP, blood pressure; CI, confidence interval.
TABLE 3. Performance and validation of a sudden death risk
score specifically for hypertension risk score using
areas under the receiver operating characteristic curve
Subset/trial Number of patients AUROC (95% CI)
Derivation set 17 094 77.74 (77.86–81.35)
Validation set 8554 77.46 (77.70–80.83)
Coope 884 60.99 (48.55–73.43)
EWPHE 840 75.40 (59.26–91.53)
MRFIT 12 866 65.91 (60.76–71.07)
SHEP 4736 60.12 (53.24–66.99)
STOP 1627 74.07 (60.70–87.45)
SYSTEUR 4695 61.68 (51.72–71.65)
Whole population 25 648 79.17 (79.48–82.40)
AUROC, area under the receiver operating characteristic curve; CI, confidence interval;
EWPHE, European Working Party on Hypertension in the Elderly; MRFIT, Multiple Risk
Factor Intervention Trial; SHEP, Systolic Hypertension in the Elderly Program; STOP,
Swedish Trial in Old Patients; SYSTEUR, Systolic Hypertension in Europe.
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reasons. Concerning this point, the risk score of Deo et al.
[3] which used more updated data (1985–2016, details in
appendix 7, http://links.lww.com/HJH/A803) and Duke
SCD score [7] which is built from 37 258 patients undergoing
coronary angiography in the period of 1 January 1985 to 31
May 2005, could give more accurate estimates.
Another limitation is that our tool was developed in the
RCT setting, where individuals have clinical characteristics
that are usually different of observational populations and
routine practice clinical settings. For example, individuals
in the RCT used generally had SBP higher than 160mmHg
and with a lower proportion of men, except MRFIT trial
[10]. This latter one [10] recruited only middle-aged men
(35–58 years old) and provided approximately half of the
studied population (12 866/total of 25 648), one additional
reason for caution in potential extrapolation to other
individuals. Last but not least, trial-based outcomes are
more accurate but they are also limited by a shorter duration
of follow-up.
All these elements call for external validations and
calibrations of HYSUD score in nowadays hypertensive
patients with various cardiovascular risk levels in different
countries, before being locally applied. This type of work
has been performed for other classical scores by several
studies [24,25], strongly suggesting to adapt model predic-
tors for each specific population. Anyway, our HYSUD
score could help clinicians estimating individual risk and
stratifying patients with regard to their sudden death risks.
As SBP, hypercholesterolemia, and baseline diabetes
were significant risk factors, this suggests logically that
the use of BP/lipid and glucose-lowering drugs may reduce
sudden death risk in these study participants. Paradoxically,
FIGURE 1 Distribution of risk scores by sex and age groups.
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our study, collecting data from six RCTs of antihypertensive
drugs, observed no treatment effect on sudden death risk,
in agreement with a meta-analysis of 39 908 patients with
hypertension [26]. Furthermore, as history of MI was a
significant indicator of sudden death risk, the use of anti-
arrhythmic drugs could appear logical to prevent this event.
However, the Cardiac Arrhythmia Suppression Trial (CAST)
[27] clearly demonstrated that these drugs significantly
increased sudden death and total mortality incidence.
These examples illustrate how such risk score must not
be used to justify preventive drug prescription, which has to
rely on clinical trials’ results only. Of note, till now, the
prevention of sudden death by pharmacological measures
appears effective by b-blockers [28] and antialdosterones
[29] for patients with heart failure but again, not by anti-
hypertensive agents for hypertension [26]. Another meta-
analysis only showed a modest sudden death risk reduction
(one in 10) by statin in populations at risk [30].
Our HYSUD score was built on 17 094 individual data
(derivation set) and validated on the remainder 8554 ones
(validation set) as well as on each separated trial and on the
whole population. This approach integrated the internal
and external validations, and illustrated its transportability.
To summarize, sudden death is a major cardiovascular
event but remains unfortunately underestimated in public
health. This event is associated with considerable loss in
terms of health and economy. Our work provides a good-
performance, user-friendly predictor to assess 5-year indi-
vidual sudden death risk in hypertension. This HYSUD risk
score could help to stratify patients and thus optimize
preventive therapeutic strategies in this population. Local
validation process appears important to check that the
score was appropriately calibrated.
ACKNOWLEDGEMENTS
Franc¸ois Pillon has done the first draft analyses. H.H.L.
would like to thank Professor Herve´ Maisonneuve for his
advice and his training on scientific writing. We thank the
investigators who provided the individual trial data used in
our analyses: John Coope (Coope), Eleanor Schron (SHEP),
L. L. (STOP), Robert Fagard (EWPHE), Jeffrey Cutler
(MRFIT), and Jan Staessen (EWPHE and SYSTEUR).
The whole article was submitted at BMJ but not accepted
(January 2017).
Part of the work has been presented as oral/poster
communications in the following congresses:
H.H.L., F.S., M.C., M.A., M.F., E. He´nin, P. Janiaud, A.
Berrima, M. Girard, S. Erpeldinger, B.K., P. Chevalier, F.G.
The first risk score for sudden death prediction in primary
prevention patients. Oral presentation at the 35th SFHTA
Conference, Paris December 2015 (French Society of Hy-
pertension). Ann Cardiol Angeiol (Paris). December
2015;64 Suppl 1:S5. doi: 10.1016/S0003–3928(16)30005–1.
H.H.L., F.S., M.C., M.A., M.F., I.M., B.K., P. Chevalier,
F.G. The first risk scoring system for sudden death predic-
tion in primary prevention patients. Poster presentation at
the 26th European Meeting on Hypertension and Cardio-
vascular Prevention, Paris June 2016 (European Society of
Hypertension).
H.H.L., M.F., and M.A. are currently receiving scholar-
ships of the French Ministry of Higher Education and
Research, The Academic Agency of La Francophonie
(West Africa Regional Office), and The Federal Department
of Economic Affairs, Education, and Research (EAER)
Switzerland, respectively. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
F.G. proposed the idea of the study. F.S., L.T. made
substantial contributions to study conception and design.
H.H.L. and M.C. performed the analyses. H.H.L. wrote the
article. F.S., M.C., M.A., I.M., L.L., L.T., and F.G. have been
involved in revising the manuscript critically for important
intellectual content. All authors read and approved the
final manuscript.
Conflicts of interest
There are no conflicts of interest.
REFERENCES
1. Fishman GI, Chugh SS, Dimarco JP, Albert CM, Anderson ME, Bonow
RO, et al. Sudden cardiac death prediction and prevention: report from
a National Heart, Lung, and Blood Institute and Heart Rhythm Society
Workshop. Circulation 2010; 122:2335–2348.
2. Papadakis M, Sharma S. Sudden cardiac death. Medicine (Baltimore)
2010; 38:502–506.
3. Deo R, Norby FL, Katz R, Sotoodehnia N, Adabag S, DeFilippi CR, et al.
Development and validation of a sudden cardiac death prediction
model for the general population. Circulation 2016; 134:806–816.
4. Jouven X, Bougouin W, Karam N, Marijon E. [Epidemiology of sudden
cardiac death: data from the Paris sudden death expertise center
registry]. Rev Prat 2015; 65:916–918.
5. Marijon E, Bougouin W, Lamhaut L, Deye N, Jost D, Jouven X. [Sudden
death of the adult: do not forget the hidden part of the iceberg!]. Rev
Med Interne 2012; 33:543–545.
6. Rahimi K, Emdin CA, MacMahon S. The epidemiology of blood
pressure and its worldwide management. Circ Res 2015; 116:925–936.
7. Atwater BD, Thompson VP, Vest RN, Shaw LK, Mazzei WR, Al-Khatib
SM, et al. Usefulness of the Duke sudden cardiac death risk score for
predicting sudden cardiac death in patients with angiographic (>75%
narrowing) coronary artery disease. Am J Cardiol 2009; 104:1624–
1630.
8. Gueyffier F, Boutitie F, Boissel JP, Coope J, Cutler J, Ekbom T, et al.
INDANA: a meta-analysis on individual patient data in hypertension.
Protocol and preliminary results. The´rapie 1995; 50:353–362.
9. Coope J, Warrender TS. Randomised trial of treatment of hypertension
in elderly patients in primary care. Br Med J (Clin Res Ed) 1986;
293:1145–1151.
10. Multiple Risk Factor Intervention Trial Research Group. Multiple risk
factor intervention trial: Risk factor changes andmortality results. JAMA
1982; 248:1465–1477.
11. Amery A, Birkenha¨gerW, Brixko P, Bulpitt C, Clement D, DeruyttereM,
et al.Mortality and morbidity results from the European working party
on high blood pressure in the Elderly trial. Lancet 1985; 1:1349–1354.
12. Prevention of stroke by antihypertensive drug treatment in older
persons with isolated systolic hypertension: final results of the systolic
hypertension in the elderly program (SHEP) SHEP. JAMA 1991;
265:3255–3264; doi: 10.1001/jama.1991.03460240051027.
13. Amery A, Birkenha¨ger W, Bulpitt CJ, Cle´ment D, De Leeuw P, Dollery
CT, et al. Syst-Eur. A multicentre trial on the treatment of isolated
systolic hypertension in the elderly: objectives, protocol, and organ-
ization. Aging (Milano) 1991; 3:287–302.
14. Dahlo¨f B, Lindholm LH, Hansson L, Scherste´n B, Ekbom T, Wester PO.
Morbidity and mortality in the Swedish trial in old patients with
hypertension (STOP-hypertension). Lancet 1991; 338:1281–1285.
15. Blanche P, Dartigues JF, Jacqmin-Gadda H. Review and comparison of
ROC curve estimators for a time-dependent outcome with marker-
dependent censoring. Biom J 2013; 55:687–704.
Le et al.
6 www.jhypertension.com Volume 35  Number 1  Month 2017
CE: Swati; JH-D-17-00152; Total nos of Pages: 7;
JH-D-17-00152
16. Sullivan LM, Massaro JM, D’Agostino RB. Presentation of multivariate
data for clinical use: the Framingham study risk score functions. Stat
Med 2004; 23:1631–1660.
17. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular
disease risk profiles. Am Heart J 1991; 121:293–298.
18. Deo R, Albert CM. Epidemiology and genetics of sudden cardiac death.
Circulation 2012; 125:620–637.
19. Hermans MP, Bouenizabila E, Amoussou-guenou DK, Ahn SA,
Rousseau MF. Baseline diabetes as a way to predict CV outcomes in
a lipid-modifying trial: a meta-analysis of 330 376 patients from 47
landmark studies. Cardiovasc Diabetol 2015; 14:60.
20. Pocock SJ, McCormack V, Gueyffier F, Boutitie F, Fagard RH,
Boissel JP. A score for predicting risk of death from cardiovascular
disease in adults with raised blood pressure, based on indivi-
dual patient data from randomised controlled trials. BMJ 2001;
323:75–81.
21. Quinn GR, Severdija ON, Chang Y, Singer DE. Wide variation in
reported rates of stroke across cohorts of patients with atrial fibrillation.
Circulation 2017; 135:208–219.
22. Zambon A, Arfe` A, Corrao G, Zanchetti A. Relationships of different
types of event to cardiovascular death in trials of antihypertensive
treatment: an aid to definition of total cardiovascular disease risk in
hypertension. J Hypertens 2014; 32:495–508.
23. Conroy RM, Pyo¨ra¨la¨ K, Fitzgerald AP, Sans S, Menotti A, Backer GD,
et al., SCORE project group. Estimation of ten-year risk of fatal
cardiovascular disease in Europe: the SCORE project. Eur Heart J
2003; 24:987–1003.
24. Marchant I, Boissel JP, Kassaı¨ B, Bejan T, Massol J, Vidal C, et al. SCORE
should be preferred to Framingham to predict cardiovascular death in
French population. Eur J Cardiovasc Prev Rehabil 2009; 16:609–615;
doi: 10.1097/HJR.0b013e32832da006.
25. Coleman RL, Stevens RJ, Retnakaran R, Holman RR. Framingham,
SCORE, and DECODE risk equations do not provide reliable cardiovas-
cular risk estimates in type2diabetes.DiabetesCare2007; 30:1292–1293.
26. Taverny G, Mimouni Y, LeDigarcher A, Chevalier P, Thijs L, Wright JM,
et al. Antihypertensive pharmacotherapy for prevention of sudden
cardiac death in hypertensive individuals. Cochrane Database Syst Rev
2016; 3:CD011745.
27. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker
AH, et al. Mortality and morbidity in patients receiving encainide,
flecainide, or placebo. N Engl J Med 1991; 324:781–788.
28. Al-Gobari M, El Khatib C, Pillon F, Gueyffier F. b-blockers for the
prevention of sudden cardiac death in heart failure patients: a meta-
analysis of randomized controlled trials. BMC Cardiovasc Disord 2013;
13:52; doi: 10.1186/1471-2261-13-52.
29. Le HH, El-Khatib C, MombledM, Guitarian F, Al-Gobari M, Fall M, et al.
Impact of aldosterone antagonists on sudden cardiac death prevention
in heart failure and post-myocardial infarction patients: a systematic
review and meta-analysis of randomized controlled trials. PloS One
2016; 11:e0145958.
30. Rahimi K, Majoni W, Merhi A, Emberson J. Effect of statins on ven-
tricular tachyarrhythmia, cardiac arrest, and sudden cardiac death: a
meta-analysis of published and unpublished evidence from random-
ized trials. Eur Heart J 2012; 33:1571–1581.
Reviewers’ Summary Evaluations
Reviewer 1
Among strengths, good performance of the tool, and the
potential educational use of this score (sudden death is
quite an impressive outcome, even for older people).
Among limitations are the dependence on age and use
of data from the 1980s.
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Beta-blockers for the prevention of sudden
cardiac death in heart failure patients: a
meta-analysis of randomized controlled trials
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Abstract
Background: In many studies, beta-blockers have been shown to decrease sudden cardiac death (SCD) in heart
failure patients; other studies reported mixed results. Recently, several large randomized control trials of beta
blockers have been carried out. It became necessary to conduct a systematic review to provide an up-to-date
synthesis of available data.
Methods: We conducted a meta-analysis of all randomized controlled trials examining the use of beta-blockers vs.
placebo/control for the prevention of SCD in heart failure patients. We identified 30 trials, which randomized 24,779
patients to beta-blocker or placebo/control. Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines were followed. Eligible studies had to be randomized controlled trials and provide information
on the incidence of sudden cardiac death in heart failure patients. Additional inclusion criteria included: treatment
for >30 days and follow-up ≥ 3 months. Studies of patients <18 years, randomization to beta-blocker vs. an
angiotensin converting enzyme (without placebo) and/or beta-blocker in both arms were excluded from the
analysis. Pre-specified outcomes of interest included SCD, cardiovascular death (CVD), and all-cause mortality and
were analyzed according to intention-to-treat.
Results: We found that beta-blockers are effective in the prevention of SCD [OR 0.69; 95% CI, 0.62–0.77, P < 0.00001],
cardiovascular death (CVD) [OR 0.71; 95% CI, 0.64–0.79, P < 0.00001], and all-cause mortality [OR 0.67; 95% CI, 0.59–0.76,
P < 0.00001]. Based on the study analysis, 43 patients must be treated with a beta-blocker to prevent one SCD, 26
patients to prevent one CVD and 21 patients to prevent all-cause mortality in one year.
Conclusion: Beta-blockers reduce the risk of sudden cardiac death (SCD) by 31%, cardiovascular death (CVD) by 29%
and all-cause mortality by 33%. These results confirm the mortality benefits of these drugs and they should be
recommended to all patients similar to those included in the trials.
Keywords: Beta, Blocker, Sudden cardiac death, Heart failure, Meta, Analysis
Background
Sudden cardiac death is defined as a non-violent death
that cannot be explained, occurring less than 24 hours
from the onset of symptoms [1]. Sudden cardiac death
accounts for 300 000 to 400 000 deaths annually in the
United States, depending on the definition used [2,3].
When restricted to death <2 hours from the onset of
symptoms, 12% of all natural deaths were classified as
sudden in one study, and 88% of those were due to
cardiac disease [2,3]. Sudden cardiac death is the most
common and often the first manifestation of coronary
heart disease and is responsible for ≈50% of the mortal-
ity from cardiovascular disease in the United States and
other developed countries [4]. The risk of sudden cardiac
death (SCD) is most pronounced among patients with
heart failure, in whom the 1 year absolute risk of SCD is
between 4 and 13% [5]. It is worth mentioning that BEST
[6], a randomized trial of the beta-blocker bucindolol in
patients with advanced chronic heart failure, reported that
it did not reduce sudden cardiac death and/or all-cause
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mortality. However, BEST included demographically di-
verse groups and severe heart failure patients [7]. In this
study, we intended to quantify the effect of beta-blockers
in the risk reduction of sudden cardiac death in patients
with heart failure by using pooled analysis techniques.
Recently, several large randomized control trials of beta-
blockers have been carried out. Therefore, a systematic
review is required to provide an up-to-date synthesis of
available data.
Methods
Study search
We searched the Cochrane Central Register of Controlled
Trials (Central) in the Cochrane Library (Version 2012)
and MEDLINE (1966 to March 2012). The bibliographies
of identified studies were checked. The Medline query
was limited to studies involving human subjects, rando-
mized controlled trials and/or meta-analyses. No language
restrictions were applied.
Selection criteria and data abstraction
A systematic review of the literature with meta-analysis
was needed to identify all clinical trials evaluating beta-
blockers for heart failure and reporting all-cause morta-
lity. Eligible studies had to be placebo-controlled trials
and provide information on the incidence of sudden
cardiac death. Additional inclusion criteria included:
treatment for >30 days and follow-up ≥3 months. Studies
of patients <18 years, randomization to beta-blocker vs.
an angiotensin converting enzyme (without placebo),
and/or beta-blockers in both arms were excluded from
the analysis.
Abstracted data included eligibility criteria, baseline
characteristics, study design (including treatment and
control arms), follow-up, and outcomes. Pre-specified
outcomes of interest included SCD, cardiovascular death
(CVD), and all-cause mortality. Outcomes were analyzed
according to intention-to-treat. Study quality was for-
mally evaluated using the Jadad score [8] for the quality
assessment of randomized controlled trials. For the pur-
pose of this analysis, studies which had a score of 3/5 or
more were considered high quality. The study selection
process (according to the PRISMA guidelines) is shown
in Figure 1.
Statistical analysis
The patient was chosen as the individual unit of analysis
(as opposed to person years). The effects of beta-
blockers on SCD, CVD, and all-cause mortality were de-
termined using fixed-effect and random-effect modeling.
Medline and Cochrane Library: 
Search for ‘‘Beta-blocker AND heart 
failure AND sudden death’’ 
(n = 441) 
Sc
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en
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cl
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ed
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tif
ic
at
io
n
Additional records identified through 
other sources  
(n = 23) 
Records after duplicates removed 
(n = 383)
Records screened 
(n = 441) 
Records excluded 
(n = 360) 
Full-text articles assessed for 
eligibility 
(n = 81)
Full-text articles excluded 
(n = 51): 
- No placebo or control 
(n=9)
- Publication of same 
study (n=16)
- Outcome of no 
interest (n=15)
- Absence of  beta 
blocker arm (n=10 )
- Use of beta blocker 
in both the arms 
(n=1)
Studies included in 
qualitative synthesis  
(n = 30) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n =30)
Figure 1 PRISMA flow diagram for the meta-analysis. Study selection process according to Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines.
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Fixed-effect modeling was performed using the Mantel
and Haenszel method. Random-effect modeling was
conducted using the DerSimonian and Laird method [9].
The results were similar with both methods, so we only
reported the random-effect results. Treatment effect was
measured using odds ratios (ORs) with 95% confidence
intervals (CIs).
Heterogeneity across the studies was estimated using
I-square test [9]. I-square values of 25%, 50%, and 75%
correspond to low, moderate, and high levels of hetero-
geneity [10]. Meta-analysis results were reported only if
the I-square value was under 75%. Sensitivity analyses
were performed for each outcome measure to assess the
contribution of each study to the pooled estimate by
excluding individual trials one at a time and recalculat-
ing the combined OR for the remaining studies. Statis-
tical testing was two-tailed, and statistical significance
was declared with α = 0.05. All analyses were conducted
using RevMan software (Version 5.1).
Results
Search results
After searching Medline and the Cochrane Library, we
identified 441 abstracts which were reviewed for inclusion
and exclusion criteria (Figure 1). Out of these, 361 were
excluded for the following reasons: non-randomized study
(including observational studies, pharmacokinetic and
pharmacodynamic studies, substudies, editorials, etc.;
Table 1 Randomized trials of beta blockers for the prevention of sudden cardiac death
Trial (Reference) Year Number of
patients
Name of drug Comparator Daily maintenance
dose (mg)
Follow-up
(months)
Jadad
scoring
Anderson et al.12 1985 50 Metoprolol Control 61 19 3
ANZ16 1997 415 Carvedilol Placebo 12.5 19 4
BEST6 2001 2708 Bucindolol Placebo 152 24 5
BHAT39 1986 3837 Propranolol Placebo 180/240 25 5
Bristow et al.17 1994 139 Bucindolol Placebo 12.5/50/200 3 5
Bristow et al.18 1996 345 Carvedilol Placebo 12.5/25/50 6 5
Capricorn19 2001 1959 Carvedilol Placebo 50 15.6 5
CIBIS II21 1999 2647 Bisoprolol Placebo 10 15 5
CIBIS20 1994 641 Bisoprolol Placebo 5 23 5
CILICARD33 2000 124 Celiprolol Placebo 100 12 5
Colucci et al.22 1996 366 Carvedilol Placebo 100 15 5
COPERNICUS8 2002 2289 Carvedilol Placebo 50 10.4 5
De Milliano et al.34 2002 59 Metoprolol Placebo 150 6 5
ELANDD35 2011 116 Nebivelol Placebo 5/10 6 5
Engleimeir et al.23 1985 25 Metoprolol Placebo 92 12 4
Fisher et al.24 1994 50 Metoprolol Placebo 87 6 5
Hansteen V. et al.25 1982 560 Propranolol Placebo 160 12 5
Krum et al.26 1995 49 Carvedilol Placebo 50 4 5
MDC27 1993 383 Metoprolol Placebo 108/115 18 3
MERIT-HF28 1999 3991 Metoprolol Placebo 159/170 12 5
Metra et al.29 1994 40 Carvedilol Placebo 50 4 4
Olsen et al.30 1995 60 Carvedilol Placebo 81 4 5
Packer et al.31 1996 1094 Carvedilol Placebo 60 6 5
Pollock et al.32 1990 19 Bucindolol Placebo 200 3 4
RESOLVD36 2000 426 Metoprolol Placebo 156 6 5
SENIORS14 2005 2128 Nebivelol Placebo 7.7 21 5
Sturm37 2000 100 Atenolol Placebo 89 24 5
UHLIR et al.38a 1997 91 Nebivelol Placebo 2.5/5 3.5 5
Wisenbaugh et al.15 1993 24 Nebivelol placebo 5 3 5
Woodley et al.13 1991 50 Bucindolol Placebo 175 3 5
ANZ: Australian/New Zealand Heart Failure Research Collaborative Group; BEST: Beta-blocker Bucindolol in patients with advanced chronic heart failure; CAPRICORN:
Effect of carvedilol on outcome after myocardial infarction inpatients; COPRINCUS: Effect of Carvedilol on the Morbidity of Patients with Severe chronic Heart
Failure; MDC: Metoprolol in Dilated Cardiomyopathy Trial study; Merit-HF: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure; SENIORS:
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure.
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n=349), absence of placebo or inactive control arm
(n=11), and inclusion of subjects < 18 years (n=1).
The full manuscripts of the remaining 81 studies were
retrieved for detailed review. Following full manuscript
review, an additional 51 studies were excluded: no placebo
or control (n= 9), duplicate report or substudy (n= 16),
absence of a beta-blocker arm (n=10), outcome of no inter-
est (n=15) and use of beta-blockers in both arms (n= 1).
Trial characteristics and study quality
As shown in Table 1, we identified 30 randomized
controlled trials of beta-blocker for inclusion in this meta-
analysis, which enrolled a total of 24,779 patients
[6,11-39]. The mean follow-up duration was 11.51 months
(0.96 year) and all trials are placebo controlled except the
trial of Anderson et al. [11] which used standard therapy.
Using the Jadad score [8], all studies were estimated with
score of 3–5 and qualified as high quality. All trials were
analyzed according to the intention-to treat paradigm.
Baseline patient characteristics
Baseline patient characteristics (Table 2) were remark-
ably similar in age and gender in all trials except for
Woodley et al. [12] which included younger patients and
the SENIORS [13] which included elderly patients.
Therefore, the mean age ranged from 28–76 and all
trials enrolled mostly men except for Wisenbaugh et al.
[14] and ELANDD [35] which enrolled 50% and 65%
women respectively. Copernicus [22] and RESOLVD
[36] were not evaluated for cardiovascular death
Table 2 Patient characteristics in randomized trials of beta blockers for the prevention of sudden cardiac death
Trial (Reference) Mean age (Years) Male (%) Inclusion criteria Population
(Ischaemic or non-ischaemic)
Mean EF (%) NYHA
Anderson et al. 50 66 IDC Non-ischaemic 29 II-IV
ANZ13 67 80 chronic heart failure Ischaemic 29 II-III
BEST6 60 78 NYHA III-IV, EF ≤ 35% Both 23 III-IV
BHAT39 55 NR MI, HF NR NR NR
Bristow et al.14 55 61 IDC and ISCD Both 24 I-IV
Bristow et al.15 60 76 Mild, moderate, chronic heart failure Both 23 II-IV
CAPRICORN16 63 74 Acute MI, EF ≤ 40% Ischaemic 32 NR
CELICARD33 57 89.5 NYHA II- IV, LVEF<40% Both 26 II-III
CIBIS II18 61 80 NYHA III or IV, EF ≤ 35% Both 28 III-IV
CIBIS17 60 83 IDC, NYHA III-IV, ≤ 40% Both 25 III-IV
Colucci et al.19 54 85 Mildly symptomatic heart failure Both 23 II-III
COPERNICUS20 63.3 79.5 HF and EF ≤ 25% 67% ischaemic 20 NR
De Milliano et al.34 65 60 HF,, LVEF<35%, Both 25 II-III
ELANDD35 66 35 HF, age>40 years, LVEF>45% Non-ischaemic 62 II-III
Engleimeir et al.21 50 64 IDC Both 17 II-III
Fisher et al22 63 96 HF and CAD NR 23 II-IV
Hansteen V. et al.23 58 84.5 Acute MI NR NR NR
Krum et al.24 55 78 Advanced heart failure Both 16 II-IV
MDC25 49 73 DCM and EF<40% Non-ischaemic 22 I-III
MERIT-HF26 64 77 NYHA II-IV,EF ≤ 40% Both 28 II-IV
Metra et al.27 51 90 NYHA II-III, IDC Non-ischaemic 20 II-III
Olsen et al.28 52 94 NYHA II-III, IDC/CAD Both 20 II-IV
Packer et al.29 58 77 Chronic heart failure Both 23 II-IV
Pollock et al.30 54 79 CHF Both 21 II-IV
RESOLVD36 62 82 CHF(NYHA II- IV), LVEF<35% Both 28.5 I-IV
SENIORS11 76 63 HF,EF ≤ 35% NR 35 I-IV
Sturm et al.37 62 88 Age(18-75), LVEF≤25% Both 17 II-IV
UHLIR et al.38 56 89 Age(18-75), NYHA II- III, LVEF<40% Ischaemic NR II-III
Wisenbaugh et al.12 50 50 NYHA II-III, IDC/ISCD Both 24 II-III
Woodley et al.10 52 72 NYHA II- III, IDC/CAD Both 22 II-III
CAD Coronary artery disease, CHF congestive heart failure, DCM dilated cardiomyopathy, ISCD ischemic dilated cardiomyopathy, EF ejection fraction, HF Heart
failure, IDC ischemic dilated cardiomyopathy, MDC Metoprolol in Dilated Cardiomyopathy, MI myocardial infarction, NR not reported, NYHA 'Classification of' New
York Heart Association.
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Figure 2 Efficacy of beta blockers compared with control for the (A) Prevention of sudden death. (B) Cardiovascular death, and (C) all-cause
mortality in patients with heart failure.
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outcome due to missing data. Four trials were restricted
to patients with non-ischaemic cardiomyopathy, three to
ischaemic patients, three not reported, and the remain-
der enrolled patients with ischaemic and non-ischaemic
cardiomyopathy. Mean left ventricular ejection fraction
ranged from 16-62%.
Efficacy of beta-blockers
A total of 3,764 deaths occurred in the 24,779 patients
included in this analysis, including 1,597 SCDs. The SCD
rate was 5.27% (n= 673/12768) in those treated with beta-
blockers compared with 7.69% (n = 924/12011) in those
treated with placebo/control [OR 0.69; 95% CI, 0.62–0.77,
P < 0.00001] as shown in Figure 2(A). Cardiovascular
mortality rate was 10.84% (n = 1236 /11398) in those
treated with beta-blockers and 14.86% (n =1585/10666) in
those assigned to placebo/control [OR 0.71; 95% CI, 0.64–
0.79, P < 0.00001] see Figure 2(B). All-cause mortality rate
was 12.82% (n = 1626 /12678) in those treated with beta-
blockers and 17.80% (n =2138/12011) in those assigned to
placebo/control [OR 0.67; 95% CI, 0.59–0.76, P < 0.00001]
as shown in Figure 2(C).
Based on these data, 43 patients need to be treated
(NNT) with beta-blockers to prevent one SCD, 26
patients to prevent one CVD, and 21 patients to prevent
all-cause mortality in one year. The forest plot compari-
son of beta-blockers vs. placebo for SCD and all-cause
mortality is shown in Figure 3 and Figure 4 respectively.
The I-square test of heterogeneity was relatively low in
SCD, CVD, and all-cause mortality with I2 =0%, 20%,
and 43% respectively.
Sensitivity analysis
The BEST trial had the largest relative overall weight of
23.2%, 17.5%, and 11.8% in SCD, CVD and all-cause
mortality respectively. Therefore, we conducted a sensi-
tivity analysis to assess the impact of this trial on the
results. When excluding the BEST trial from the random-
effect estimates, there was no significant difference: OR
for SCD [0.64 (95% CI 0.57 -0 .72), p = 0.00001], OR
for CVD [0.69 (95% CI 0.62 -0 .77), p = 0.00001] and
OR for all-cause mortality [0.65 (95% CI 0.58 -0 .73),
p = 0.00001]. I2 = 0%, 7%, and 25% respectively. The
Capricorn [18] and Hansteen et al. [25] and BHAT [39]
studies included patients with acute myocardial infarc-
tion. But when they were excluded from the analysis,
no significant difference was found: OR for SCD [0.69
(95% CI 0.61 -0 .78), p = 0.00001], OR for CVD [0.70
(95% CI 0.60 -0 .82), p = 0.00001] and OR for all-cause
mortality [0.65 (95% CI 0.55 -0 .77), p = 0.00001]. I2 = 0%,
26%, and 47% respectively. Also, the trial of ELANDD [35]
had included patients with LVEF>45%. The sensitivity
analysis showed no significant difference: OR for SCD
[0.69 (95% CI 0.62 - 0 .77), p = 0.00001], OR for CVD
[0.71 (95% CI 0.67–0.79), p = 0.00001] and OR for all-
cause mortality [0.67 (95% CI 0.59 - 0 .76), p = 0.00001].
I2 = 0%, 20%, and 43% respectively.
Publication bias
To assess a potential existence of publication bias in the
effect of beta-blockers in sudden cardiac death and all-
cause mortality, a funnel plot as shown in Figure 3 and
Figure 4 indicates large symmetry and therefore a publi-
cation bias is likely excluded.
Discussion
There exist several meta-analyses which evaluated the
mortality benefits of beta-blockers among chronic heart
failure patients [40-44]. One of the eldest is the study of
Heidenreich et al. [40] that reported significant reduc-
tion in all-cause mortality but had not concluded for
sudden cardiac death. This is apparently due to lack of
power and sudden death missing data in the studied
clinical trials. Also, the meta-analysis of McAllister et al.
Figure 3 Funnel plot of SE (log odds ratio) by odds ratio to
evaluate publication bias for effect of treatment in sudden
cardiac death (SCD).
Figure 4 Funnel plot of SE (log odds ratio) by odds ratio to
evaluate publication bias for effect of treatment for
all-cause mortality.
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[41] showed 24% risk reduction of mortality related to
the magnitude of heart rate reduction but not to dosing
of beta-blockers. A recent meta-analysis by Chatterjee
et al. [42] included 21 trials using beta-blockers in
patients with heart failure and reduced ejection fraction
showing a 31% reduction in overall mortality with no
difference among the different agents used. However,
this study, like many others, had not evaluated the
overall reduction of beta-blockers in the prevention of
sudden cardiac death. Another study, Fauchier et al.
[44], found similar beneficial effects of beta-blockers in
ischemic and non-ischemic cardiomyopathy. Though,
the number of clinical trials that classified such patients
accounts for <22% in our meta-analysis. Similarly, study
of Bonet et al. [43] reported no difference in mortality
benefits among ischemic and non-ischemic heart disease
and proposed greater benefit of vasodilating beta-
blockers compared with the non-vasodilating agents
particularly in patients with non-ischemic cardiomyo-
pathy and attributed mortality benefits to significant
reduction of pump failure and sudden death. Briefly,
previous studies whether had not evaluated overall
reduction of beta-blockers in the prevention of sudden
cardiac death or need to be updated such as the studies
of Bonet et al. [43] and Heidenreich et al. [40] as several
recent and large randomized clinical trials have been
carried out.
In this meta-analysis of 24,779 randomized patients, we
found that beta-blockers are effective in the prevention of
SCD with [OR 0.69; 95% CI, 0.62–0.77, P < 0.00001],
CVD [OR 0.71; 95% CI, 0.64–0.79, P < 0.00001], and all-
cause mortality [OR 0.67; 95% CI, 0.59–0.76, P < 0.00001].
Ventricular arrhythmias (including non-sustained ventri-
cular tachycardia) have been documented in up to 85% of
patients with severe congestive heart failure [45]. As anti-
arrhythmic agents, beta-blockers have been shown to
reduce morbidity and mortality in patients with chronic
heart failure in randomized controlled trials, and consis-
tently reduce the risk of SCD by 40–55% [20,28]. How-
ever, our meta-analysis showed a 32% reduction of SCD
risk. As indicated earlier, the 1-year absolute risk of SCD
in heart failure patients is 4-13% [5]. In our study, the 1-
year absolute risk of SCD in the beta-blocker group and
placebo/control group is 5.5% and 8.10% respectively.
Mortality rates increase the higher the New York Heart
Association (NYHA) class, but the proportion of patients
dying suddenly (rather than from progressive pump
failure) is highest among those with less severe heart
failure (NYHA class II or III) [28]. The evaluation of
clinical benefits for patients at different stages of heart
failure by subgroup analysis merits further investigation.
Our study included two clinical trials with acute myocar-
dial infarction patients. When they were excluded from
the meta-analysis, no significant differences were found in
a sensitivity analysis of the remaining trials. Our study
provides a high level of evidence given the large number
of randomized patients included.
Clinical implications
American College of Cardiology (ACC), American Heart
Association (AHA), and European Society of Cardiology
(ESC) guidelines recommend the use of beta-blockers to
reduce sudden death and especially in patients with
heart failure [46,47]. Our results support such recom-
mendations with a high level of argument.
Conclusion
Out of all antiarrhythmic agents, only beta-blockers have
been shown to be effective at reducing the risk of SCD.
Beta-blockers reduce the risk of SCD by 31%, CVD by
29%, and all-cause mortality by 33% and therefore, this
meta-analysis study confirms beta-blockers’ clinical
benefits and should be recommended to all patients
similar to those included in the trials.
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